A product of growth arrest-specific gene 6 modulates scavenger receptor expression in human vascular
Gas6系统研究进展
通信作者:吴俊 Email:wujunpostbox@Gas6(growth arrest specific gene 6)是人类发现的一类新的生长因子,它作用于细胞受体,它的受体属于受体酪氨酸激酶家族,它们包括Sky (Tyro3)、Axl 、Mer ,也统称TAMreceptor (Tyro3,Axl ,Mer )。
随着研究的深入,人们发现,Gas6系统具有广泛的生物学作用。
1 Gas6及其受体结构,细胞表达情况(图1)Gas6属维生素K 依赖的蛋白质,广泛表达于各类细胞。
它和protein S 具有42%同源性[1]。
Axl 普遍表达于各类细胞,Tyro3主要表达于中枢神经系统,而Mer 在单核转化的巨噬细胞较丰富。
Axl 、Mer 、Tyro3可以在金属蛋白酶作用下切割,成为可溶性受体(soluble Axl ,sAxl ;soluble Mer ,sMer ;soluble T yro3,sT yro3),血浆中可检测到游离受体。
2 Gas6与细胞凋亡Gas6是一种细胞因子,与细胞生长相关。
Gas6系统研究进展吴俊(北京大学人民医院 检验科,北京 100037)Gas6具有抗血管内皮细胞、平滑肌细胞凋亡的作用,通过Gas6-Axl-PI3K-Akt 起抗凋亡作用。
它可介导凋亡细胞吞噬。
目前已知,Gas6对于凋亡细胞的吞噬主要是通过受体Mer 来实现的[2],Mer 表达于巨噬细胞和树突状细胞[2],凋亡细胞表达磷脂酰丝氨酸,Gas6或protein S 通过维生素K 依赖的Gla domain 结合凋亡细胞表面磷脂酰丝氨酸[3],通过吞噬细胞表面的Mer 受体,介导吞噬作用。
Gas6调节巨噬细胞的成熟、转移[4],促进内皮细胞生长并抗凋亡[5]。
Mer 受体缺陷导致视网膜色素上皮细胞清除障碍[6,7],可导致色素性视网膜炎甚至失明。
精子细胞的成熟和凋亡也需要通过Gas6系统的调控[8]。
脂肪细胞的基础知识
脂肪细胞的基础知识脂肪细胞的生长全过程及其形态变化脂肪母细胞,是指能向脂肪细胞分化的ADSCs在激素、生物活性因子、寒冷等因素刺激下均能逐渐分化成为单能干细胞。
它可保持着干细胞增殖活跃的特性,脂肪母细胞再进一步分化为前脂肪细胞,即通常人们所说的脂肪细胞前体。
前脂肪细胞再经历细胞融合、接触抑制和克隆扩增等步骤启动向成熟脂肪细胞分化,并在胰岛素、地塞米松等诱导剂作用下完成向成熟脂肪细胞的分化。
全过程可以表示为:多能干细胞——脂肪母细胞——前脂肪细胞——不成熟脂肪细胞——成熟脂肪细胞。
生长期前脂肪细胞的形态与成纤维细胞相似,经诱导分化,其细胞骨架和细胞外基质发生变化,开始进入不成熟细胞向成熟细胞转变。
细胞形态由成纤维细胞样逐渐趋于类圆或圆形,胞体逐渐增大,胞质中开始出现小脂滴,脂质开始累积,以后小脂滴增多并融合为较大的脂滴,可经油红“O”染色等方法于显微镜下显色,从而获得成熟脂肪细胞的形态特征。
此时的细胞无分裂增殖能力,为脂肪细胞分化的终末阶段。
张高娜,梁正翠.动物脂肪细胞的研究进展[J].饲料工业,2009,30(2):42-44.脂肪细胞由起源于中胚层的间充质干细胞逐步分化形成,按间充质干细胞→脂肪母细胞→前脂肪细胞→不成熟脂肪细胞→成熟脂肪细胞的过程发展。
前脂肪细胞在多种转录因子调控下,激活脂肪组织相关基因,并在这些基因的顺序性调控下,经一系列复杂的步骤分化为成熟脂肪细胞。
张艳.脂肪细胞分化过程中的分子事件[J].儿科药学杂志,2008,14(1):56-57.间充质干细胞概念:不同文献中,分别命名为抽脂处理细胞(processed lipoaspirate cells, PLA),脂肪基质微管碎片细胞(stromal vascularfraction cells, SVF),脂肪组织源基质细胞(adipose-tissue derived stromal cells, ATSCs),脂肪源中胚层干细胞(adipose-derived mesodermal stem cells, ADMSCs)等。
冠心病伴2型糖尿病患者血清中Gas6水平检测及意义
冠心病伴2型糖尿病患者血清中Gas6水平检测及意义陈馨;陈杰;蒋冰;徐升强【摘要】目的:探讨生长停滞特异性基因产物6(Gas 6)与冠心病伴2型糖尿病患者血清中的变化及其临床意义。
方法选择心血管内科120例冠心病患者(CHD)作为冠心病组,120例冠心病伴2型糖尿病患者(CHD+T2DM)组,同时选择健康体检者80例作为对照组。
ELISA 法对三组血清进行 Gas 6的浓度检测,并检测其空腹血糖(FBG)、糖化血红蛋白(HbAlc)、甘油三酯(TG)、高密度脂蛋白(HDL)、低密度脂蛋白(LDL)、hs-CRP、同型半胱氨酸(Hcy)含量,并对结果数据进行统计学分析。
结果 ELISE 法检测健康对照组 Gas 6的含量为227.61±7.28 pg/ml,冠心病患者组血清中 Gas 6含量为278.57±6.61 pg/ml,冠心病伴2型糖尿病患者血清中 Gas 6含量为285.66±6.37 pg/ml。
冠心病患者组和冠心病伴2型糖尿病患者组较健康对照组明显升高,冠心病伴2型糖尿病患者组明显高于冠心病患者组,差异有统计学意义(P <0.05)。
冠脉狭窄支数越多,血清 Gas 6水平越高(P <0.05)。
结论生长停滞特异性基因产物6(Gas 6)在冠心病伴2型糖尿病患者血清中浓度明显升高,且随冠脉狭窄支数增多而增高,提示 Gas 6参与冠心病伴2型糖尿病的发生发展。
%Objective To study the change of growth arrest-specific gene 6 (Gas 6)in serum of coronary heart dis-ease combined with type 2 diabetes mellitus,and clinical significance.Methods We have selected 120 cases of patients with coronary heartdisease(CHD)out of the in-part patients in cardiovascular department as the coronary heart disease group,and 120 cases of patients with coronary heart disease combined with type 2 diabetes mellitus(CHD+T2DM)as coronary heart disease combinedwith type 2 diabetes mellitus group,80 healthy people were selected as controls.Serum levels of Gas6 were determined by an enzyme-linked immunosorbent assay (ELISA)kit,FBG,HbAlc,triglyceride (TG),high density lipoprotein (HDL),low density lipoprotein (LDL),hs-CRP,homocysteine (Hcy)were detected and the data were statistically analyzed.Results ELISA adopted to detect the content of Gas 6 in the healthy group was227.61±3.28 pg/ml,in CHD group was 278.57±1.61 pg/ml and inCHD+T2DM group was 285.66±2.37 pg/ml, in CHD group and CHD+T2DM group are significantly higher than the control group,CHD+T2DM group are signifi-cantly higher than the CHD group,and the data has statistically significant (P <0.05).The more the amount of coro-nary stenosis is,the higher level of Gas 6 is(P <0.05).Conclusion The concentraction of growth arrest-specific gene 6 (Gas 6)in serum of coronary heart disease combined with type 2 diabetes mellitus increased evidently and rise with the increase in the number of coronary stenosis,Gas 6 reaction was closely associated with coronary heart disease combined with type 2 diabetes mellitus.【期刊名称】《中国实验诊断学》【年(卷),期】2015(000)006【总页数】4页(P896-899)【关键词】生长停滞特异性基因产物 6;冠心病;2 型糖尿病;炎症因子【作者】陈馨;陈杰;蒋冰;徐升强【作者单位】武汉市第一医院检验科,湖北武汉 430022;武汉市第一医院检验科,湖北武汉 430022;武汉市第一医院检验科,湖北武汉 430022;武汉市第一医院检验科,湖北武汉 430022【正文语种】中文【中图分类】R541.4;R587.1冠状动脉粥样硬化性心脏病(冠心病,CHD)是一种严重威胁中老年人的心血管疾病,近年来认为冠心病是一种炎症反应性疾病[1,2]。
化学品安全技术说明书英文缩写是
Chemical Safety Data Sheet Abbreviation (CSDSAbb)IntroductionChemical Safety Data Sheet (CSDS) is a crucial document that provides information about the safe handling, storage, and disposal of hazardous chemicals. It is designed to ensure the safety of workers, the environment, and the general public. In this technical document, we will delve into the abbreviations commonly used in CSDS.CSDSAbb - Chemical Safety Data Sheet AbbreviationHazard Identification (HI)•CAS: Chemical Abstracts Service number. A unique identifier assigned to each chemical substance.•GHS: Globally Harmonized System of Classification and Labelling of Chemicals.•HMIS: Hazardous Materials Identification System. It provides a numerical rating that indicates the health, flammability, and reactivity hazards of a chemical product.•WHMIS: Workplace Hazardous Materials Information System. It is a Canadian system for hazard communication through labels and safety datasheets.Composition/Information on Ingredients (COI)•MSDS: Material Safety Data Sheet. The old term for the precursor to the modern CSDS.•VOC: Volatile Organic Compound. Organic chemicals that have a high vapor pressure at room temperature, posing potential health andenvironmental risks.•PEL: Permissible Exposure Limit. The maximum concentration of a substance that a worker can be exposed to during a specific time period.•TLV: Threshold Limit Value. Similar to PEL, it is the airborne concentration of a substance to which workers may be exposed repeatedlywithout adverse effects.First Aid Measures (FAM)•CPR: Cardiopulmonary Resuscitation. An emergency lifesaving procedure performed to manually restore the heartbeat and breathing of aperson who is in cardiac arrest.•PPE: Personal Protective Equipment. Equipment worn to minimize exposure to hazards that may cause injuries or illnesses.•SDS: Safety Data Sheet. Similar to CSDS, it provides comprehensive information about a substance or mixture regarding its physical and chemical properties, health hazards, and safety precautions.Firefighting Measures (FM)•MSDS: Material Safety Data Sheet (old term for CSDS, mentioned previously).•LEL: Lower Explosive Limit. The lowest concentration of a flammable substance that can ignite in the presence of an ignition source.•UEL: Upper Explosive Limit. The highest concentration of a flammable substance that can ignite in the presence of an ignition source.Accidental Release Measures (ARM)•VOC: Volatile Organic Compound (mentioned previously).•EHS: Environment, Health, and Safety. Refers to the management and protection of the environment and the health and safety of individuals within an organization.•RCRA: Resource Conservation and Recovery Act. A US federal law that provides guidelines for the proper management and disposal of hazardous waste.Handling and Storage (HS)•OSHA: Occupational Safety and Health Administration. A US federal agency that sets and enforces workplace safety standards.•DOT: Department of Transportation. A US federal agency responsible for regulating and ensuring the safe transportation of hazardous materials.•HAZMAT: Hazardous Materials. Refers to substances or materials that pose risks to health, safety, or property during transportation.Personal Protection (PP)•PEL: Permissible Exposure Limit (mentioned previously).•TLV: Threshold Limit Value (mentioned previously).•SCBA: Self-Contained Breathing Apparatus. A device worn by rescue workers, firefighters, and others to provide breathable air in areas that are immediately dangerous to life and health.Physical and Chemical Properties (PCP)•VOC: Volatile Organic Compound (mentioned previously).•UV: Ultraviolet. Electromagnetic radiation with a wavelength shorter than that of visible light.•MSDS: Material Safety Data Sheet (mentioned previously).Stability and Reactivity (SR)•OSHA: Occupational Safety and Health Administration (mentioned previously).•DOT: Department of Transportation (mentioned previously).•VOC: Volatile Organic Compound (mentioned previously).Toxicological Information (TI)•LD50: Lethal Dose 50. The amount of a substance that, when administered to a group of test animals, kills 50% of them.•LOAEL: Lowest Observable Adverse Effect Level. The lowest concentration or amount of a substance that produces detectable, adversehealth effects in test animals.•IDLH: Immediately Dangerous to Life or Health. The maximum airborne concentration of a substance that poses a threat to life or can cause irreversible harm.ConclusionUnderstanding the abbreviations used in Chemical Safety Data Sheets (CSDS) is crucial for effectively communicating and comprehending the information provided. This document serves as a reference guide for those involved in handling hazardous chemicals, ensuring their safety and the safety of those around them.。
STAT3 Pathway
STAT3 PathwayRT² Profiler™ PCR ArrayJAK / STAT Signaling Pathway PCR ArrayTh17 for Autoimmunity and Inflammation PCR Array Stem Cell Transcription Factors PCR Array PI3K-AKT Signaling Pathway PCR ArraySureSilencing RNAiJAK / STAT Signaling Pathway Gene RNAiTh17 for Autoimmunity and Inflammation Gene RNAi Stem Cell Transcription Factors Gene RNAi PI3K-AKT Signaling Pathway Gene RNAiCignal™ Reporter AssaysISRE Reporter Assay KitGAS Reporter Assay KitSTAT3 Reporter KitFOXO Reporter KitMulti-A nalyte ELISArray™ KitsTh1 / Th2 / Th17 Cytokines Multi-AnalyteELISArray™ KitsSTATs (Signal Transducers and Activators of Transcription) are a family of cytoplasmic proteins with SH2 (Src Homology-2) domains that act as signal messengers and transcription factors and participate in normal cellular responses to Cytokines and GFs (Growth Factors). STATs are activated via the tyrosine phosphorylation cascade after ligand binding and stimulation of the Cytokine Receptor–Kinase complex and Growth Factor-Receptor complex like the EGF (Epidermal Growth Factor), FGF (Fibroblast Growth Factor), PDGF (Platelet-Derived Growth Factor), GCSF (Granulocyte Colony Stimulating Factor), IL-6(Interleukin-6), CNTF (Ciliary Neurotrophic Factor), OSM (Oncostatin-M), LIF (Leukemia Inhibitory Factor), CSF1R (Colony Stimulating Factor-1 Receptor), c-kit, Insulin receptor, c-Met and GPCRs (G-Protein Coupled Receptors): AgtR2 (Angiotensin-II Receptor). Ligands signaling through the same class of receptor complexes usually activates the same set of STAT factors, e.g. all IL-6-type cytokines activate STAT3 and STAT1 (Ref.1). The activated STATs are subsequently translocated to the nucleus where they bind to specific DNA sites as homo or heterodimers to stimulate transcription of the responsive genes. Among the STAT proteins known to date, STAT3 has been implicated in transduction of the cellular signals that are involved in development of cardiac hypertrophy. The signal-transducing receptor protein GP130 stimulates the JAK (Janus-family tyrosine kinases)-STAT3 pathway and is associated with the regulation of cardiac growth and development (Ref.2).STAT3 induce gene activation in response to Cytokine Receptor stimulation. Following tyrosine phosphorylation, STAT3 proteins dimerize, translocate to the nucleus, and activate specific target genes like the cis element ISRE (IFN-stimulated Response Element) thereby initiating transcription of several IFN-inducible genes. This transcriptional activation by STAT3 proteins requires the recruitment of coactivators such as CBP (CREB-binding Protein)/p300. STAT3 proteins recognize a conserved element in the promoter of p21/WAF1 (Wildtype p53-Activated Fragment-1) and increase the mRNA expression of this cell cycle regulatory gene. Effectively, STAT3 activates several other genes involved in cell cycle progression such as Fos, Cyclin-D, CDC25A, c-Myc or Pim1 and up-regulates antiapoptotic genes such as BCL2 (B-Cell CLL/Lymphoma-2), BCLXL and Beta2-Macroglobulin (Ref.3). Thus, many STAT3 target genes are key components of the regulation of cell cycle progression from G1 to S phase. Accordingly, STAT3 activation is often associated with cell growth or transformation, and disruption of the STAT3 gene causes embryonic lethality. Following IL-6 stimulation, transcriptional cofactor NCOA/SRC1a interacts with STAT3 and potentiates its transcriptional activity through its CBP/p300-interacting domain AD1 (Ref.4). Pathways other than JAK kinases involving mTOR (mammalian Target of Rapamycin) or p70S6 kinase, MAPK (Mitogen Activated Protein Kinase), p38, and MEK (MAPK/ERK Kinase) signaling cascades also lead to phosphorylation and activation of STAT3 (Ref.5).RhoA efficiently modulate STAT3 transcriptional activity by inducing its simultaneous tyrosine and serine phosphorylation via Src Family of Kinases and JAK2. The JNK (c-Jun N-terminal Kinase)/ERK (Extracellular-Signal Regulated Kinase) Pathway mediates serine phosphorylation (Ser727) and cooperation of both tyrosine as well as serine phosphorylation is necessary for full activation of STAT3 (Ref.5). The Type-I Interferon (IFN-Alpha/Beta) promotes the DNA-binding activity of the transcription factors including STAT3, which is involved in the induction of NF-KappaB (Nuclear Factor-KappaB) DNA-binding activity and in the induction of antiviral and antiproliferative activity. STAT3 is also activated in response to the small guanine nucleotide-binding protein Rac1. The Rac functions in growth factor-induced activation of STAT3 in two ways. It apparently helps localize STAT3 to kinase complexes at the cell surface through Ras and also promotes activation of kinases, like MLKs (Mixed-Lineage Kinases), JAK2, TYK2 that phosphorylate STAT3 at Tyr705 (Ref.6). The SOCS (Suppressor of Cytokine Signaling) family of proteinsnegatively regulates the receptor-associated JAK-STAT3 pathway of transcriptionalactivation.STATs have been implicated in programming gene expression in biological events such as embryonic development, programmed cell death, organogenesis, innate immunity, adaptive immunity and cell growth regulation in many organisms. Abnormal activity of certain STAT family members, particularly STAT3 is associated with a wide variety of human malignancies, including lymphomas; leukemias; mycoses fungoides and multiple myeloma (Ref.7). Thus, STAT3 activate either of two gene expression programs, one for growth promotion and one for growth arrest. Recently inhibition of the STAT3 signaling pathway using the JAK-selective inhibitor, AG490, and a dominant negative STAT3 (STAT3-Beta) significantly suppressed the growth of ovarian and breast cancer cell lines. These results suggest that inhibition of STAT3 signaling may provide a potential therapeutic approach for treatingovarian and breast cancers (Ref.8).References:1.Abell K, Watson CJThe Jak/Stat pathway: a novel way to regulate PI3K activity.Cell Cycle. 2005 Jul; 4(7):897-900. Epub 2005 Jul 11.2.Ji JD, Kim HJ, Rho YH, Choi SJ, Lee YH, Cheon HJ, Sohn J, Song GGInhibition of IL-10-induced STAT3 activation by 15-deoxy-Delta12,14-prostaglandinJ2.Rheumatology (Oxford). 2005 Aug; 44(8):983-8. Epub 2005 Apr 19.3.Barre B, Avril S, Coqueret OOpposite Regulation of Myc and p21waf1 Transcription by STAT3 Proteins.J Biol Chem. 2003 Jan 31; 278(5): 2990-6.4.Giraud S, Bienvenu F, Avril S, Gascan H, Heery DM, Coqueret OFunctional interaction of STAT3 transcription factor with the coactivatorNcoA/SRC1a.J Biol Chem. 2002 Mar 8; 277(10): 8004-11.5.Aznar S, Valeron PF, del Rincon SV, Perez LF, Perona R, Lacal JCSimultaneous tyrosine and serine phosphorylation of STAT3 transcription factor is involved in Rho A GTPase oncogenic transformation.Mol Biol Cell. 2001 Oct; 12(10): 3282-94.6.Simon AR, Vikis HG, Stewart S, Fanburg BL, Cochran BH, Guan KLRegulation of STAT3 by direct binding to the Rac1 GTPase.Science. 2000 Oct 6; 290(5489): 144-7.7.Shen Y, Devgan G, Darnell JE Jr, Bromberg JFConstitutively activated Stat3 protects fibroblasts from serum withdrawal and UV-induced apoptosis and antagonizes the proapoptotic effects of activated Stat1.Proc Natl Acad Sci U S A. 2001 Feb 13; 98(4): 1543-8.8.Yu X, Kennedy RH, Liu SJJAK2/STAT3, not ERK1/2 pathway mediates interleukin-6-elicited inducible NOS activation and decrease in contractility in adult ventricular myocytes.J Biol Chem. 2003 Feb 20 [epub ahead of print]。
Gas6系统研究进展
通信作者:吴俊 Email:wujunpostbox@Gas6(growth arrest specific gene 6)是人类发现的一类新的生长因子,它作用于细胞受体,它的受体属于受体酪氨酸激酶家族,它们包括Sky (Tyro3)、Axl 、Mer ,也统称TAMreceptor (Tyro3,Axl ,Mer )。
随着研究的深入,人们发现,Gas6系统具有广泛的生物学作用。
1 Gas6及其受体结构,细胞表达情况(图1)Gas6属维生素K 依赖的蛋白质,广泛表达于各类细胞。
它和protein S 具有42%同源性[1]。
Axl 普遍表达于各类细胞,Tyro3主要表达于中枢神经系统,而Mer 在单核转化的巨噬细胞较丰富。
Axl 、Mer 、Tyro3可以在金属蛋白酶作用下切割,成为可溶性受体(soluble Axl ,sAxl ;soluble Mer ,sMer ;soluble T yro3,sT yro3),血浆中可检测到游离受体。
2 Gas6与细胞凋亡Gas6是一种细胞因子,与细胞生长相关。
Gas6系统研究进展吴俊(北京大学人民医院 检验科,北京 100037)Gas6具有抗血管内皮细胞、平滑肌细胞凋亡的作用,通过Gas6-Axl-PI3K-Akt 起抗凋亡作用。
它可介导凋亡细胞吞噬。
目前已知,Gas6对于凋亡细胞的吞噬主要是通过受体Mer 来实现的[2],Mer 表达于巨噬细胞和树突状细胞[2],凋亡细胞表达磷脂酰丝氨酸,Gas6或protein S 通过维生素K 依赖的Gla domain 结合凋亡细胞表面磷脂酰丝氨酸[3],通过吞噬细胞表面的Mer 受体,介导吞噬作用。
Gas6调节巨噬细胞的成熟、转移[4],促进内皮细胞生长并抗凋亡[5]。
Mer 受体缺陷导致视网膜色素上皮细胞清除障碍[6,7],可导致色素性视网膜炎甚至失明。
精子细胞的成熟和凋亡也需要通过Gas6系统的调控[8]。
LncRNAGAS5与肾脏病发生关系
㊃专题㊃基金项目:河北省科技计划项目(16397733D )通信作者:徐金升,E m a i l :x js 5766@126.c o m L n c R N A G A S 5与肾脏病发生关系高少辉,徐金升(河北医科大学第四医院肾内科,河北石家庄050011) 摘 要:最新研究发现,生长抑制特异性转录本5(g r o w t ha r r e s t -s p e c i f i c t r a n s c r i p t 5,G A S 5)在多种急㊁慢性疾病的发生和发展过程中具有重要调控作用㊂研究显示,G A S 5能够调控细胞增殖㊁凋亡㊁细胞周期等生命过程,与急性心肌梗死㊁缺血性脑卒中㊁高血压等多种疾病发生㊁发展及治疗密切相关,推测其有望成为疾病精准靶向治疗的新靶标㊂本文就G A S 5在肾脏病中的相关研究进展进行综述㊂关键词:肾疾病;肾肿瘤;L n c R N A G A S 5中图分类号:R 692 文献标志码:A 文章编号:1004-583X (2018)10-0846-03d o i :10.3969/j.i s s n .1004-583X.2018.10.004L n c R N AG A S 5a n d c h r o n i c k i d n e y di s e a s e s G a oS h a o h u i ,X u J i n s h e n gD e p a r t m e n t s o f N e p h r o l o g y ,t h eF o u r t h H o s p i t a l o f H e b e iM e d i c a lU n i v e r s i t y ,S h i j i a z h u a n g ,050011,C h i n a C o r r e s p o n d i n g a u t h o r :X uJ i n s h e n g ,E m a i l :x js 5766@126.c o m A B S T R A C T :L a t e s ts t u d i e sh a v er e p o r t e dt h a t g r o w t ha r r e s t -s p e c i f i ct r a n s c r i p t5p l a y sa ni m p o r t a n tr o l ei n m u l t i p l e a c u t ea n dc h r o n i cd i s e a s e s .T h ec u r r e n ts t u d i e sr e po r tt h a tG A S 5,w h i c hi si d e n t i f i e da sa p o t e n t i a ln o v e l t u m o r s u p p r e s s o r g e n e r e g u l a t i n g v i t a l e v e n t s ,s u c h a s c e l l p r o l i f e r a t i o n ,a p o p t o s i s ,a n d c e l l c y c l e ,i s c l o s e l y r e l a t e d t o t h e a c u t em y o c a r d i a l i n f a r c t i o n ,i s c h e m i c s t r o k e ,a n dh y p e r t e n s i o n .I t i s e x p e c t e d t h a tG A S 5c a nb ean e wt a r g e t f o r p r e c i s e t a r g e t i n g t h e r a p y .T h e p a p e r r e v i e w s t h e r e l a t i o n s h i p b e t w e e nG A S 5a n dk i d n e y di s e a s e s .K E Y W O R D S :k i d n e y d i s e a s e s ;k i d n e y n e o pl a s m s ;L n c R N A G A S5 徐金升,男,主任医师㊁教授㊁医学博士㊁博士研究生导师㊂现任职务:河北医科大学第四医院副院长㊁肾内科主任㊂荣誉称号:河北省有突出贡献中青年专家㊂学术兼职:中国研究型医院学会血液净化专业委员会副主任委员,中国医学装备协会血液净化装备技术专业委员会副主任委员㊁中国医师协会肾康复专业委员会副主任委员㊁京津冀血液净化质控联盟副主席㊁中国医院协会血液净化中心管理分会常务委员㊁河北省血液净化专业质量管理与控制中心主任㊁河北省医院协会血液净化中心管理分会主任委员㊁河北省药学会肾病药学专业委员会主任委员㊁河北省医学会肾脏病学分会候任主任委员等㊂学术成就:承担省厅级科研课题11项;发表论著120余篇,其中S C I 收录23篇,主编专著2部;获河北省科学技术奖二等奖2项㊁三等奖2项,河北省医学科技奖一等奖4项㊂ 长链非编码R N A (L o n g n o n c o d i n g RN A s ,L n c R N A )是指转录本长度大于200个核苷酸的功能性R N A 分子,哺乳动物基因组序列中4%~9%的序列产生的转录本是L n c R N A [1-2]㊂L n c R N A 缺乏编码蛋白的能力,位于细胞核和(或)细胞浆内,以R N A 形式在多种层面(如表观遗传学㊁转录调控及转录后调控等)调控基因的转录㊁剪接㊁转运㊁稳定性和翻译等过程,调节基因的表达水平[3-6]㊂近年来,尽管L n c R N A 作为临床医学和分子生物学的重要研究领域取得了快速的进展,但有关L n c R N A 在人类疾病发生中作用的认识尚处于起步阶段㊂特异性转录本5(g r o w t ha r r e s t -s p e c i f i c t r a n s c r i pt 5,G A S 5)[7]是一个新发现的L n c R N A ,因其在生长受抑制的细胞中表达增多而命名㊂研究显示,G A S 5表达于多种组织器官,不仅参与了机体组织器官的发育和多种细胞的生物学功能,也在高血压血管重塑[8]㊁心肌梗死[9]㊁缺血性脑卒中[10]㊁多囊卵巢综合征[11]等发生㊁发展中具有重要的调控作用,并且可能成为疾病诊疗的新靶标㊂本文就G A S 5的结构和生物学功能及其在肾脏病发生中的作用进行如下综述㊂1 G A S 5的结构和生物学功能G A S 5由650个核苷酸组成,基因定位于人类染色体1q21[12],包含12个外显子,编码两种成熟的l n c R N A s :G A S 5a 和G A S 5b ,后者为其主要亚型,它们能够与糖皮质激素应答元件竞争性结合糖皮质激㊃648㊃‘临床荟萃“ 2018年10月5日第33卷第10期 C l i n i c a l F o c u s ,O c t o b e r 5,2018,V o l 33,N o .10Copyright ©博看网. All Rights Reserved.素受体[13];11个内含子能够编码10种含C/D盒的s n o R N A s(s m a l ln u c l e o l a r R N A s)[14],其中U44㊁U74和U78可能是m i R N A的前体㊂G A S5的5ᶄ端起始区域含有一段长度较短的开放阅读框架(o p e n r e a d i n g f r a m e,O R F),其后有多个终止密码子[15];3ᶄ端能够与糖皮质激素应答元件(g l u c o c o r t i c o i d r e s p o n s e e l e m e n t,G R E)竞争性结合糖皮质激素受体(g l u c o c o r t i c o i dr e c e p t o r,G R)[13]㊂由于G A S5起始端含有较多的终止密码子,能激活无义密码子介导的R N A降解,使细胞内G A S5累积量下降,与G R E竞争性结合G R的能力下降,糖皮质激素靶基因转录增加,细胞生长抑制减弱;反之,当发生生长抑制或用雷帕霉素处理细胞时,G A S5翻译活性降低,G A S5在细胞内累积,与G R结合增多,抑制了糖皮质激素靶基因的转录,使依赖糖皮质激素生长的细胞生长受到抑制,凋亡增加㊂2G A S5在肾脏病中的作用2.1 G A S5与缺血性肾脏病据报道住院患者急性肾损伤(A K I)的发生率为2%~7%,与之相关的死亡率则高达10%~20%㊂在I C U住院患者中这一比例则更高㊂肾脏缺血/再灌注损伤是导致A K I的常见病因㊂肾小管凋亡被认为是肾脏缺血/再灌注损伤的重要机制之一㊂研究发现,G A S5参与了肾小管凋亡过程㊂G e n g等[16]证实A K I小鼠肾脏再灌注后24小时G A S5开始表达升高,同时G A S5下游的凋亡相关基因P53㊁c I A P2和T S P-1的表达也增加㊂为了验证G A S5在肾脏缺血/再灌注损伤中的作用, G e n g等采用低氧刺激人肾小管上皮细胞H K-2细胞,随着刺激时间的延长G A S5表达逐渐升高,至24小时达到顶峰㊂接着在给予3小时充足氧供应后, G A S5表达则进一步升高㊂此时,P53和c I A P2表达与G A S5一同升高,而T S P-1则相反㊂T S P-1在细胞和动物实验出现不同结果可能与在缺氧/再通损伤时有其他通路对其进行调节有关㊂另外,G e n g等利用转染技术,通过敲低和过表达H K-2细胞G A S5的表达,进一步证实了G A S5促进肾小管细胞凋亡,而抑制其表达可降低肾小管细胞凋亡,从而为G A S5成为A K I治疗靶点提供了理论依据㊂2.2 G A S5与足细胞损伤足细胞在维持肾小球滤过屏障完整性方面起着重要作用,足细胞损伤可以导致蛋白尿,是多种肾小球疾病的基本病理表现㊂M a r t i n等[17]研究发现,超氧阴离子和H2O2刺激足细胞可以立即增加G A S5和C HO P(C/E B P h o m o l o g yp r o t e i n)m R N A表达,并且长时间持续在高水平状态㊂既往数据表明,G A S5可通过s n o R N A 调节C HO P表达,但M a r t i n等的研究表明过表达C HO P的足细胞G A S5表达下降,推测C HO P和G A S5之间存在负反馈调节机制㊂另外,组织化学证据发现,微小病变㊁局灶节段性肾小球硬化(F S G S)和膜性肾病患者足细胞C HO P表达增加,推测G A S5可能也参与了以上3种肾脏病的发生和发展㊂因此,临床需要进一步的数据支持上述假设㊂2.3G A S5与肾癌许多研究已经证实, m i c r o R N A在调控肾癌的发生㊁发展及预后中发挥着重要作用,但L n c R N A G A S5在肾癌中的研究较少㊂采用实时定量P C R对12例肾细胞癌患者癌组织及其邻近正常组织研究发现,与正常组织相比,12例癌组织G A S5表达量明显减低,但其表达量与临床参数之间并没有明显的联系㊂体外分析发现,与正常人肾小管上皮细胞H K-2相比,肾细胞癌细胞系A498G A S5表达量明显减低㊂以上研究可以证实,在肾细胞癌组织中,G A S5表达量相对减低㊂此外, Q i a o等[18]还通过瞬时转染技术在体外细胞实验中证实,转染G A S5基因后,A498细胞增殖㊁转移及侵袭能力明显减弱,而凋亡能力显著增强,处于G1期细胞显著增多,进而证实G A S5在肾细胞癌中发挥抑癌基因的作用[19]㊂D o n g等[20]研究发现,G A S5-m i R233-h Z I P1轴在调控肾透明细胞癌中发挥着重要作用,其机制为G A S5发挥分子海绵作用竞争性吸附m i R233,从而上调h Z I P1的表达,抑制肾透明细胞癌进展㊂酪氨酸激酶抑制剂索拉菲尼是治疗肾细胞癌的一线用药,但仍有约22%的患者存在耐药[21]㊂L i u等[22]发现,索拉菲尼耐药患者的肿瘤组织较敏感患者G A S5表达明显降低,而体外实验表明过表达G A S5可以增加肾细胞癌细胞对索拉菲尼的敏感性,而抑制G A S5表达则起到相反的作用, G A S5增加索拉菲尼敏感性的机制为G A S5可以竞争性的结合m i R21,从而增加S O X5的表达㊂以上实验表明,G A S5表达下调可能预示着肾细胞癌对索拉菲尼耐药,同时G A S5也可能是改善索拉菲尼治疗肾细胞癌的潜在治疗靶点之一㊂3展望尽管G A S5在肾癌发生㊁发展机制和临床诊治中的作用取得了重要进展,但它在慢性肾脏病方面,尤其是G A S5在膜性肾病㊁微小病变㊁F S G S等常见肾脏疾病发生机制和诊疗价值尚不清楚㊂G A S5作㊃748㊃‘临床荟萃“2018年10月5日第33卷第10期 C l i n i c a l F o c u s,O c t o b e r5,2018,V o l33,N o.10Copyright©博看网. All Rights Reserved.为细胞生长和凋亡的重要调节因子,目前的研究成果仍给了我们信心,G A S5有可能成为慢性肾脏病精准治疗的靶点之一㊂参考文献:[1] K i t a g a w aM,K o t a k eY,O h h a t aT.L o n g n o n-c o d i n g R N A si n v o l v e d i n c a n c e r d e v e l o p m e n t a n d c e l l f a t e d e t e r m i n a t i o n[J].C u r rD r u g T a r g e t s,2012,13(13):1616-1621.[2]S h i X,S u n M,L i u H,e t a l.L o n g n o n-c o d i n g R N A s:an e wf r o n t i e r i nt h es t u d y o fh u m a n d i s e a s e s[J].C a n c e r L e t t,2013,339(2):159-166.[3] Y a n g G,L uX,Y u a nL.L n c R N A:a l i n kb e t w e e nR N Aa n dc a n c e r[J].B i o c h i m B i o p h y s A c t a,2014,1839(11):1097-1109.[4] M a t h i e u E L,B e l h o c i n e M,D a o L T,e ta l.F u n c t i o n s o fl n c R N Ai nd e v e l o p m e n ta n dd i s e a s e s[J].M e dS c i(P a r i s), 2014,30(8-9):790-796.[5] W a n g K C,C h a n g H Y.M o l e c u l a r m e c h a n i s m s o f l o n gn o n c o d i n g R N A s[J].M o l e c u l a rC e l l,2011,43(6):904-914.[6]罗燕鸿,林娟娟,王恺,等.长链非编码R N A与宫颈癌的相关性研究进展[J].肿瘤防治研究,2016,43(1):82-86. [7]S m i t hC M,S t e i t z J A.C l a s s i f i c a t i o no f g a s5a s am u l t i-s m a l l-n u c l e o l a r-R N A(s n o R N A)h o s t g e n ea n dam e m b e ro f t h e5'-t e r m i n a l o l i g o p y r i m i d i n e g e n e f a m i l y r e v e a l s c o mm o n f e a t u r e s o f s n o R N Ah o s t g e n e s[J].M o l C e l l B i o l,1998,18(12):6897-6909.[8] W a n g Y N,S h a n K,Y a o M D,e ta l.L o n g n o n c o d i n g R N A-G A S5:a n o v e lr e g u l a t o r o f h y p e r t e n s i o n-i n d u c e d v a s c u l a rr e m o d e l i n g[J].H y p e r t e n s i o n,2016:68(3):736-48. [9] H a oS,L i u X,S u iX,e ta l.L o n g n o n-c o d i n g R N A G A S5r e d u c e s c a r d i o m y o c y t e a p o p t o s i s i n d u c e d b y M I t h r o u g hs e m a3a[J].I n t JB i o lM a c r o m o l,2018,120(P tA):371-377.[10] C h e nF,Z h a n g L,W a n g E,e t a l.L n c R N A G A S5r e g u l a t e si s c h e m i c s t r o k e a s a c o m p e t i n g e n d o g e n o u sR N Af o rm i R-137t o r e g u l a t e t h e N o t c h1s i g n a l i n g p a t h w a y[J].B i o c h e mB i o p h y sR e sC o mm u n,2018,496(1):184-190.[11] L i nH,X i n g W,L iY,e t a l.D o w n r e g u l a t i o no f s e r u ml o n gn o n c o d i n g R N A G A S5m a y c o n t r i b u t e t o i n s u l i nr e s i s t a n c e i nP C O S p a t i e n t s[J].G y n e c o lE n d o c r i n o l,2018,34(9):784-788.[12] N a m R K,Z h a n g WW,L o b l a w D A,e ta l.A g e n o m e-w i d ea s s o c i a t i o ns c r e e n i d e n t i f i e s r e g i o n s o nc h r o m o s o m e s1q25a n d7p21a sr i s kl o c if o rs p o r a d i c p r o s t a t ec a n c e r[J].P r o s t a t eC a n c e rP r o s t a t i cD i s,2008,11(3):241-246.[13] W i l l i a m sG T,F a r z a n e hF.A r es n o R N A sa n ds n o R N A h o s tg e n e s n e w p l a y e r s i n c a n c e r[J].N a tR e vC a n c e r,2012,12(2):84-88.[14] B r a m e i e rM,H e r w i g A,R e i n h a r d tR,e t a l.H u m a nb o xC/Ds n o R N A sw i t hm i R N Al i k e f u n c t i o n s:e x p a n d i n g t h e r a n g eo f r e g u l a t o r y R N A s[J].N u c l e i cA c i d sR e s,2011,39(2):675-686.[15] Y a c q u b-U s m a n K,P i c k a r d M R,W i l l i a m s G T.R e c i p r o c a lr e g u l a t i o no fG A S5l n c R N Al e v e l s a n dm T O Ri n h i b i t o r a c t i o ni n p r o s t a t e c a n c e r c e l l s[J].P r o s t a t e,2015,75(7):693-705.[16] G e n g X,X uX,F a n g Y,e t a l.T h ee f f e c to f l o n g n o n c o d i n gR N A G A S5o na p o p t o s i s i nr e n a l i s c h e m i a/r e p e r f u s i o n i n j u r y[J].N e p h r o l o g y(C a r l t o n),2018,A u g20.[E p u ba h e a do f p r i n t][17] B e k M F,B a y e rM,M u l l e rB,e t a l.E x p r e s s i o na n d f u n c t i o no f C/E B Ph o m o l o g y p r o t e i n(G A D D153)i n p o d o c y t e s[J].A mJP a t h o l,2006,168(1):20-32.[18] Q i a oH P,G a o W S,H u oJ X,e ta l.L o n g n o n-c o d i n g R N AG A S5f u n c t i o n s a s a t u m o r s u p p r e s s o r i nr e n a l c e l l c a r c i n o m a[J].A s i a nP a c JC a n c e rP r e v,2013,14(2):1077-1082. [19] Z h o u S,W a n g J,Z h a n g Z.A n e m e r g i n g u n d e r s t a n d i n g o f l o n gn o n c o d i n g R N A si n k i d n e y c a n c e r[J].J C a n c e r R e s C l i nO n c o l,2014,140(12):1989-1995.[20] D o n g X,K o n g C,L i uX,e t a l.G A S5f u n c t i o n s a s a c e R N At or e g u l a t eh Z I P1e x p r e s s i o nb y s p o n g i n g m i R-223i nc l e a rc e l l r e n a l c e l l c a r c i n o m a[J].A mJC a n c e rR e s,2018,8(8):1414-1426.[21] H e n g D Y,M a c k e n z i eM J,V a i s h a m p a y a nU N,e t a l.P r i m a r ya n t i-v a s c u l a re n d o t h e l i a l g r o w t h f a c t o r(V E G F)-r e f r a c t o r ym e t a s t a t i cr e n a lc e l lc a r c i n o m a:c l i n i c a lc h a r a c t e r i s t i c s,r i s kf a c t o r s,a n ds u b s e q u e n tt h e r a p y[J].A n n O n c o l,2012,23(6):1549-1555.[22] L i uL,P a n g X,S h a n g W,e t a l.L o n g n o n-c o d i n g R N AG A S5s e n s i t i z e s r e n a l c e l l c a r c i n o m at os o r a f e n i bv i a m i R-21/S O X5 p a t h w a y[J].C e l l C y c l e,2018J u n12.[E p u ba h e a do f p r i n t]收稿日期:2018-10-16编辑:张卫国㊃848㊃‘临床荟萃“2018年10月5日第33卷第10期 C l i n i c a l F o c u s,O c t o b e r5,2018,V o l33,N o.10Copyright©博看网. All Rights Reserved.。
老年下肢深静脉血栓患者血清Gas6、IL-1β、NETs水平与介入治疗效果的关系
作者简介:吴邮电,男,主治医师,主要从事介入治疗研究㊂㊃论 著㊃D O I :10.3969/j.i s s n .1672-9455.2024.04.019老年下肢深静脉血栓患者血清G a s 6㊁I L -1β㊁N E T s 水平与介入治疗效果的关系吴邮电,李 宁许昌医院介入科,河南许昌461000摘 要:目的 探讨老年下肢深静脉血栓(D V T )患者血清生长停滞特异性基因产物6(G a s 6)㊁白细胞介素-1β(I L -1β)㊁中性粒细胞胞外陷阱(N E T s )水平与介入治疗效果的关系㊂方法 选取2021年2月至2023年1月该院收治的120例老年D V T 患者为研究对象,根据治疗7d 后临床疗效分为无效组(22例)和有效组(98例)㊂比较两组治疗前及治疗3㊁7d 后血清G a s 6㊁I L -1β㊁N E T s 水平,分析治疗3㊁7d 后血清G a s 6㊁I L -1β㊁N E T s 水平与治疗效果的关系㊂结果 无效组与有效组G a s 6㊁I L -1β㊁N E T s 水平存在时间与组间的交互效应,差异有统计学意义(F 交互=15.214,P <0.001);两组G a s 6㊁I L -1β㊁N E T s 水平随着治疗时间变长而逐渐降低,差异均有统计学意义(F =12.375㊁12.271㊁13.277,P <0.001);无效组G a s 6㊁I L -1β㊁N E T s 水平明显高于有效组,差异均有统计学意义(F =23.537㊁22.851㊁23.213,P <0.001)㊂治疗3㊁7d 后血清G a s 6㊁I L -1β㊁N E T s 联合检测预测D V T 患者介入治疗无效的曲线下面积明显大于各项指标单独检测(P <0.05)㊂结论 血清G a s 6㊁I L -1β㊁N E T s 水平对预后有明显影响,3项指标联合检测可作为预测D V T 患者介入治疗效果的重要辅助途径㊂关键词:下肢深静脉血栓; 介入治疗; 中性粒细胞胞外陷阱; 白细胞介素-1β; 生长停滞特异性基因产物6中图法分类号:R 459.9文献标志码:A文章编号:1672-9455(2024)04-0515-05C o r r e l a t i o n o f s e r u m G a s 6,I L -1β,N E T s l e v e l s a n d i n t e r v e n t i o n a l t h e r a p y e f f e c t i n e l d e r l y p a t i e n t s w i t h l o w e r e x t r e m i t y d e e p ve n o u s t h r o m b o s i s WU Y o u d i a n ,L I N i n gD e p a r t m e n t o f I n t e r v e n t i o n a l R a d i o l o g y ,X u c h a n g H o s p i t a l ,X u c h a n g ,H e n a n 461000,C h i n a A b s t r a c t :O b je c t i v e T o i n v e s t i g a t e t h e c o r r e l a t i o n s b e t w e e n t h e l e v e l s of s e r u mg r o w th a r r e s t -s p e ci f i c g e n e p r o d u c t 6(G a s 6),i n t e r l e u k i n -1β(I L -1β),n e u t r o p h i l e x t r a c e l l u l a r t r a p (N E T s )a n d i n t e r v e n t i o n a l t h e r a -p y i n e l d e r l y p a t i e n t s w i t h l o w e r e x t r e m i t y d e e p v e i n t h r o m b o s i s (D V T ).M e t h o d s A t o t a l o f 120e l d e r l y pa -t i e n t s w i t h D V T a d m i t t e d t o X u c h a n g H o s p i t a l f r o m F eb r u a r y 2021t o J a n u a r y 2023w e r e d i v i d e d i n t o i n e f f e c -t i v e g r o u p (22c a s e s )a n d e f f e c t i v e g r o u p (98c a s e s )a c c o r d i n g t o t h e c l i n i c a l e f f i c a c y a f t e r 7d a ys o f t r e a t -m e n t .T o c o m p a r e t h e l e v e l s o f s e r u m G a s 6,I L -1βa n d N E T sb e f o r e t r e a t m e n t a n d a f t e r 3a n d 7d o f t r e a t m e n t b e t w e e n t h e t w o g r o u p s ,a n d t o a n a l y z e t h e r e l a t i o n s h i p s b e t w e e n t h e l e v e l s o f s e r u m G a s 6,I L -1β,N E T s a f t e r 3a n d 7d o f t r e a t m e n t a n d t h e t r e a t m e n t e f f e c t .R e s u l t s T h e i n t e r a c t i o n e f f e c t s o f G a s 6,I L -1βa n d N E T s b e -t w e e n t h e i n e f f e c t i v e g r o u p a n d t h e e f f e c t i v e g r o u p w e r e s t a t i s t i c a l l y s i g n i f i c a n t (F i n t e r a c t i o n =15.214,P <0.001).T h e l e v e l s o f G a s 6,I L -1βan d N E T s i n t h e t w o g r o u p s g r a d u a l l y d e c r e a s e d w i t h t h e i n c r e a s e o f t r e a t -m e n t t i m e ,t h e d i f f e r e n c e s w e r e s t a t i s t i c a l l y s i gn i f i c a n t (F =12.375,12.271,13.277,P <0.001).T h e l e v e l s o f G a s 6,I L -1βan d N E T s i n t h e i n e f f e c t i v e g r o u p w e r e s i g n i f i c a n t l y h i g h e r t h a n t h o s e i n t h e e f f e c t i v e g r o u p ,a n d t h e d i f f e r e n c e s w e r e s t a t i s t i c a l l y s i g n i f i c a n t (F =23.537,22.851,23.213,P <0.001).A f t e r 3a n d 7d a ys o f t r e a t m e n t ,t h e c o m b i n e d d e t e c t i o n o f s e r u m G a s 6,I L -1βan d N E T s p r e d i c t e d t h e i n e f f e c t i v e i n t e r v e n t i o n a l t h e r a p y i n D V T p a t i e n t s w i t h t h e a r e a u n d e r t h e c u r v e w a s s i g n i f i c a n t l y gr e a t e r t h a n t h a t o f e a c h i n d e x a l o n e (P <0.05).C o n c l u s i o n S e r u m G a s 6,I L -1βan d N E T s l e v e l s h a v e s i g n i f i c a n t e f f e c t s o n p r o g n o s i s ,a n d c o m -b i n e d d e t e c t i o n o f t h e t h r e e i n d i c a t o r s c a n b e u s e d a s a n i m p o r t a n t a u x i l i a r y w a y to p r e d i c t t h e e f f e c t o f i n t e r -v e n t i o n a l t h e r a p yi n D V T p a t i e n t s .K e y wo r d s :l o w e r e x t r e m i t y d e e p v e i n t h r o m b o s i s ; i n t e r v e n t i o n a l t h e r a p y ; n e u t r o p h i l e x t r a c e l l u l a r t r a p ; i n t e r l e u k i n -1β; g r o w t h a r r e s t -s p e c i f i c g e n e p r o d u c t 6㊃515㊃检验医学与临床2024年2月第21卷第4期 L a b M e d C l i n ,F e b r u a r y 2024,V o l .21,N o .4下肢深静脉血栓(D V T)属于血管外科疾病,可累及全身主干静脉,经皮导管介入溶栓治疗是其常用治疗手段,能够有效纠正血液循环,溶解血栓,但仍有部分患者疗效欠佳[1-2]㊂早期预测D V T患者介入治疗预后情况对调整治疗方案及改善患者预后尤为关键㊂白细胞介素-1β(I L-1β)是一种促炎性细胞因子,可通过激活炎症-免疫细胞,影响血管内皮细胞活性[3]㊂中性粒细胞胞外陷阱(N E T s)在多种炎症及免疫系统中起重要调节作用,已有研究证实,其可加快血小板㊁红细胞凝结,促进纤维蛋白生成[4]㊂生长停滞特异性基因产物6(G a s6)是一种分泌型蛋白,其水平与动脉斑块高度和斑块总面积明显相关,这说明G a s6在动脉粥样硬化形成过程中发挥重要调控作用[5]㊂但有关血清G a s6㊁I L-1β㊁N E T s与D V T患者介入治疗效果关系的研究较少见㊂因此,本研究通过分析G a s6㊁I L-1β㊁N E T s与D V T患者介入治疗效果的关系,以期为疾病诊治提供参考依据,现报道如下㊂1资料与方法1.1一般资料选取2021年2月至2023年1月本院收治的120例老年D V T患者作为研究对象㊂纳入标准:符合D V T相关诊断标准[6],经下肢彩色多普勒超声检查确诊;年龄ȡ60岁;发病在14d内且为单侧下肢血栓㊂排除标准:伴有下肢损伤或下肢血管病变;既往存在下肢骨折;有先天或获得性凝血障碍疾病史;存在精神障碍㊁意识模糊;合并严重肝肾功能不全;对介入治疗不能耐受;近6个月内服用过影响凝血功能㊁血小板功能的药物㊂根据治疗7d后临床疗效将研究对象分为无效组(22例)和有效组(98例)㊂无效组中男15例,女7例;年龄65~75岁,平均(67.87ʃ2.74)岁;体质量指数(B M I)18.7~24.1 k g/m2,平均(22.05ʃ0.75)k g/m2;病因:创伤性关节炎10例,类风湿关节炎5例,膝骨关节炎7例㊂有效组中男61例,女37例;年龄65~77岁,平均(68.01ʃ2.80)岁;B M I18.5~24.0k g/m2,平均(21.95ʃ0.70)k g/m2;病因:创伤性关节炎40例,类风湿关节炎22例,膝骨关节炎36例㊂两组一般资料比较,差异无统计学意义(P>0.05),具有可比性㊂所有研究对象均知情同意本研究,并签署知情同意书,本研究经本院医学伦理委员会审批通过(伦理审批号:20201245)㊂1.2疗效评价标准参考‘深静脉血栓形成的诊断和治疗指南(第三版)“[6]评价疗效:疼痛㊁肿胀消失,超声检查结果显示深静脉通畅,无血栓,血管壁光滑,静脉管径正常为治愈;活动后轻微疼痛,超声检查结果显示深静脉基本通畅,静脉管径正常,血栓明显缩小为显效;超声显示大部分血栓消失,深静脉部分再通,患肢周径缩小ȡ2c m为有效;未达上述标准为无效㊂1.3治疗方法均经导管介入溶栓,患者取平卧位,股静脉穿刺健侧,进行下腔静脉造影检查,明确病变位置后,于下腔静脉处放置滤器,保证滤器顶端距深静脉开口距离为0.5~1.0c m,经浅静脉留置针,选取适宜溶栓导管,置入血栓远心端,使末端与微量泵相连,以每次100000~200000U尿激酶经溶栓导管持续微量泵入,于2h内泵入完毕,间隔6h进行下一次泵入,溶栓12h后,进行静脉造影,随后每间隔24h 静脉造影1次,以便调整导管位置㊂待血栓2d无变化或完全溶解时治疗停止,疗程5~7d㊂1.4检测方法治疗前及治疗3㊁7d后取3m L空腹静脉血,离心处理,离心半径为10c m,离心转速为3000r/m i n,离心时间为10m i n,取上清液备用㊂采用酶联免疫吸附试验检测血清G a s6㊁I L-1β水平, M P O-D N A复合物捕捉酶联免疫吸附试验检测N E T s水平,试剂盒均购自美国R&D S Y S T E M S公司,所有操作严格遵循试剂盒说明书㊂1.5观察指标(1)比较两组治疗前及治疗3㊁7d后血清G a s6㊁I L-1β㊁N E T s水平;(2)分析G a s6㊁I L-1β㊁N E T s与老年D V T患者介入治疗效果关系;(3)血清G a s6㊁I L-1β㊁N E T s联合检测预测D V T患者介入无效的价值㊂1.6统计学处理采用S P S S22.0统计学软件进行数据处理及统计分析㊂符合正态分布的计量资料以xʃs表示,重复测量资料比较采用重复测量方差分析;两独立样本组间比较采用独立样本t检验;计数资料以例数或百分率表示,组间比较采用χ2检验;采用受试者工作特征(R O C)曲线分析血清G a s6㊁I L-1β㊁N E T s联合检测预测D V T患者介入无效的价值;采用多因素L o g i s t i c回归分析介入治疗效果的影响因素㊂以P<0.05为差异有统计学意义㊂2结果2.1两组血清G a s6㊁I L-1β㊁N E T s水平比较无效组与有效组G a s6㊁I L-1β㊁N E T s水平存在时间与组间的交互效应,差异有统计学意义(F交互=15.214,P< 0.001);两组G a s6㊁I L-1β㊁N E T s水平均随着治疗时间变长而逐渐降低,差异有统计学意义(F=12.375㊁12.271㊁13.277,P<0.001);无效组G a s6㊁I L-1β㊁N E T s水平均明显高于有效组,差异有统计学意义(F=23.537㊁22.851㊁23.213,P<0.001)㊂见表1㊂2.2老年D V T患者介入治疗无效的影响因素分析以老年D V T患者介入治疗效果为因变量(有效=0,无效=1),将治疗3㊁7d后血清G a s6㊁I L-1β㊁N E T s水平作为自变量,对自变量进行赋值(以120例研究对象检测结果的平均值为界:ɤ平均值=0,>平㊃615㊃检验医学与临床2024年2月第21卷第4期 L a b M e d C l i n,F e b r u a r y2024,V o l.21,N o.4均值=1)㊂赋值如下,治疗3d 后:G a s 6ɤ12.05n g /m L =0,>12.05n g /m L =1;I L -1βɤ4.84m g /L =0,>4.84m g/L=1;N E T sɤ0.58=0,>0.58=1㊂治疗7d 后:G a s 6ɤ9.86n g/m L =0,>9.86n g /m L=1;I L -1βɤ2.96m g /L=0,>2.96m g/L =1;N E T s ɤ0.32=0,>0.32=1㊂多因素L o -gi s t i c 回归分析结果显示,治疗3d 后血清G a s 6>12.05n g /m L ㊁I L -1β>4.84m g /L ㊁N E T s >0.58,治疗7d 后血清G a s 6>9.86n g /m L ㊁I L -1β>2.96m g /L ㊁N E T s >0.32是老年D V T 患者介入治疗无效的危险因素(P <0.05)㊂见表2㊂2.3 血清G a s 6㊁I L -1β㊁N E T s 联合检测预测D V T 患者介入无效的效能 以治疗无效老年D V T 患者为阳性样本,以治疗有效老年D V T 患者为阴性样本,绘制R O C 曲线㊂结果显示,治疗3d 后血清G a s 6㊁I L -1β㊁N E T s 联合检测预测老年D V T 患者治疗无效的曲线下面积(A U C )为0.904,灵敏度㊁特异度分别为81.82%㊁98.98%,联合检测的A U C 明显大于单独检测(P <0.05);治疗7d 后血清G a s 6㊁I L -1β㊁N E T s 联合检测预测老年D V T 患者治疗无效的A U C 为0.941,灵敏度㊁特异度分别为86.36%㊁87.76%,联合检测的A U C 明显大于单独检测(P <0.05)㊂见表3㊁图1㊁图2㊂图1 治疗3d 后血清G a s 6㊁I L -1β㊁N E T s 预测D V T 患者介入无效的R O C 曲线表1 两组血清G a s 6㊁I L -1β㊁N E T s 水平比较(x ʃs )组别nG a s 6(n g/m L )治疗前治疗3d 后治疗7d 后I L -1β(m g /L )治疗前治疗3d 后治疗7d 后N E T s (A )治疗前治疗3d 后治疗7d 后无效组2216.74ʃ2.8316.35ʃ3.1416.09ʃ3.277.48ʃ2.167.18ʃ2.356.95ʃ2.290.84ʃ0.250.82ʃ0.210.79ʃ0.25有效组9816.59ʃ3.4211.08ʃ2.978.46ʃ2.257.22ʃ2.084.31ʃ1.152.06ʃ0.680.81ʃ0.260.53ʃ0.070.22ʃ0.06注:A 为吸光度值㊂表2 多因素L o gi s t i c 回归分析老年D V T 患者介入治疗无效的影响因素时间自变量βS E W a l d χ2P O R 95%C I 治疗3d 后G a s 62.1110.53315.690<0.058.2563.475~19.628I L -1β1.6150.48411.133<0.055.0281.795~14.081N E T s1.8350.47914.676<0.056.2652.349~16.711治疗7d 后G a s 62.1630.50118.633<0.058.6974.182~18.073I L -1β1.5970.38117.570<0.054.9381.539~15.846N E T s1.8590.42619.051<0.056.4173.654~11.279表3 血清G a s 6㊁I L -1β㊁N E T s 联合检测预测D V T 患者介入无效的效能时间指标A U C95%C Ic u t -o f f 值灵敏度(%)特异度(%)P治疗3d 后G a s 60.7960.713~0.864>15.75n g/m L 68.1888.78<0.001I L -1β0.7090.619~0.788>6.34m g/L 59.0983.67<0.001N E T s0.7180.629~0.796>0.7954.5583.67<0.0013项联合0.9040.837~0.95081.8298.98<0.001治疗7d 后G a s 60.8250.745~0.889>16.46n g /m L 68.1884.69<0.001I L -1β0.7610.674~0.834>6.78m g/L 63.6485.71<0.001N E T s0.8490.772~0.907>0.7177.2778.57<0.0013项联合0.9410.883~0.97686.3687.76<0.001注:为无数据㊂㊃715㊃检验医学与临床2024年2月第21卷第4期 L a b M e d C l i n ,F e b r u a r y 2024,V o l .21,N o .4图2治疗7d后血清G a s6㊁I L-1β㊁N E T s预测D V T患者介入无效的R O C曲线3讨论既往研究报道,炎症反应与D V T形成密切相关,一方面炎症反应可引起凝血因子大量生成,从而加快血液高凝状态形成,另一方面血栓生成又可加剧炎症反应[7-8]㊂I L-1β是一种促炎性细胞因子,广泛参与人体组织破坏㊁水肿形成等多种病理损伤过程,其可通过改变巨噬细胞㊁内皮细胞,以及聚集活化血小板㊁白细胞,加重凝血㊁纤溶系统失衡而促进血栓形成[9-10]㊂G a s6主要在巨噬细胞㊁内皮细胞及血管平滑肌细胞中表达[11],有研究通过分析864例静脉血栓栓塞患者血清G a s6水平,发现老年患者高G a s6水平与静脉血栓栓塞复发㊁大出血和病死风险明显相关[12]㊂严志强等[13]报道,非肿瘤D V T患者治疗前I L-1β水平明显高于健康人群,抗凝治疗后明显下降,但仍明显高于健康人群㊂在此基础上,本研究发现,治疗3㊁7d后无效组血清G a s6㊁I L-1β水平均高于有效组,表明G a s6㊁I L-1β在D V T演变过程中发挥重要作用㊂考虑原因在于以下方面:I L-1β可诱导内皮细胞与血小板发生黏附,同时可促进中性粒细胞迁移并黏附内皮细胞,导致血液纤溶能力下降,从而引起血栓生成;G a s6可通过作用于G PⅡb/Ⅲa,磷酸化A K T和P I3K,启动 自内而外 信号转导机制,激活下游信号分子β3整合素,促进颗粒释放,使纤维蛋白原交连相近血小板,进而形成牢固血小板栓㊂本研究还发现,血清G a s6㊁I L-1β水平升高可影响老年D V T患者介入治疗效果,提示临床可于疾病早期动态监测血清G a s6㊁I L-1β水平变化情况,为评估病情变化㊁预测预后提供有效信息[14-15]㊂N E T s是由中性粒细胞颗粒和细胞外D N A㊁组蛋白组成的复合物,能够杀灭和捕获细胞外病原菌[16-17]㊂T H A K U R等[18]报道,N E T s可激活血小板和凝血级联反应,对诱导血栓生成具有促进作用㊂本研究结果表明,无效组治疗3㊁7d后血清N E T s水平高于有效组,且其水平与治疗效果呈负相关,与张银龙等[19]研究论点相近,说明血清N E T s水平变化不仅与病情变化联系紧密,还能影响预后㊂推测原因, N E T s可通过作用于凝血因子XⅡ㊁血管性血友病因子等分子,促进红细胞㊁血小板聚集及纤维蛋白形成;还可通过与组织因子相结合,激活外源性凝血途径[20]㊂已有相关研究证实,N E T s可裂解㊁氧化血栓调节蛋白和组织因子通道抑制剂,导致体内天然抗凝物质降解失活,加剧凝血反应[21]㊂此外,R O C曲线分析结果证实,血清G a s6㊁I L-1β㊁N E T s对D V T患者介入治疗无效均具有良好预测价值,但可能目前还无法满足临床实际应用,仍有较大提升空间㊂为此,本研究创新性探讨3项指标联合检测的预测价值,结果发现,治疗7d后,血清G a s6㊁I L-1β㊁N E T s联合检测预测D V T患者介入治疗无效的A U C达0.941,较各项血清指标单独检测的A U C明显提高,可为临床提供更为可靠的诊断途径㊂综上所述,血清G a s6㊁I L-1β㊁N E T s水平变化对预后有明显影响,3项指标联合检测可作为预测D V T 患者介入治疗效果的重要辅助途径㊂但本研究不足之处在于纳入样本量偏少,可能造成数据的偏倚,仍需后续扩大样本量进行进一步的验证㊂参考文献[1]杜娜,高玲.集束化护理联合气压治疗在冠心病患者介入术后下肢深静脉血栓中的作用[J].血栓与止血学,2022, 28(2):308-309.[2]王莉莎,任欢,张杰,等.血清炎症细胞因子检测对预警子宫内膜癌术后深静脉血栓的应用分析[J].中国实验诊断学,2022,26(6):820-824.[3]付勇超.动静脉内瘘血栓形成的危险因素及其与血清HMG B1㊁I L-1β㊁I L-10水平的关系[J].药物生物技术, 2021,28(6):611-614.[4]陈塍林,惠曙国,王志远,等.膝关节置换术后深静脉血栓栓塞影响因素及血清N E T s及s V C AM-1水平变化意义[J].中国骨伤,2022,35(11):1053-1059.[5]郭长磊,李雅钗,司澳洋,等.血清G a s6水平联合C HA_2D S_2-V A S c评分对S T E M I患者P C I术后短期发生MA C E的预测价值[J].中国现代医学杂志,2023,33(7): 20-27.[6]李晓强,张福先,王深明,等.深静脉血栓形成的诊断和治疗指南(第三版)[J/C D].中国血管外科杂志(电子版), 2017,9(4):250-257.[7]郑桂莲,耿晓慧,张莎莎,等.中性粒细胞胞外陷阱㊁炎性蛋白水平对全膝关节置换术后下肢深静脉血栓形成预测价值分析[J].安徽医药,2022,26(6):1128-1132.㊃815㊃检验医学与临床2024年2月第21卷第4期 L a b M e d C l i n,F e b r u a r y2024,V o l.21,N o.4[8]胡建华,黄洁,肖莹,等.新型炎症反应标志物对老年股骨转子间骨折术后下肢深静脉血栓的预测价值[J].护理研究,2022,36(21):3792-3798.[9]王喜尧,王育文,齐桂云,等.T L R4㊁T R A F6㊁I L-6和I L-1β在深静脉血栓大鼠模型中的表达和意义[J].现代生物医学进展,2023,23(4):641-645.[10]贺梅婷,程颐,刘凤菊,等.下肢静脉血栓及炎症因子与高龄新型冠状病毒感染患者预后的关系[J].中国医药, 2023,18(10):1466-1469.[11]蒋能美,管鑫娟,杨社珍.生长停滞特异性蛋白6和C1q/肿瘤坏死因子相关蛋白4水平与2型糖尿病患者颈动脉粥样硬化的关联[J].实用临床医药杂志,2023,27(5): 123-127.[12]S C H N E G G-K A U F M A N N A,C A L Z A V A R I N I S,L I M A C-H E R A,e t a l.A h i g h G a s6l e v e l i n p l a s m a p r e d i c t s v e n o u st h r o m b o e m b o l i s m r e c u r r e n c e m a j o r b l e e d i n g a n d m o r t a l i t yi n t h e e l d e r l y a p r o s p e c t i v e m u l t i c e n t e r c o h o r t s t u d y[J].JT h r o m b H a e m o s t,2019,17(2):306-318.[13]严志强,解绪红,冯凌思,等.膝关节置换术后早期外周血I L-1β㊁T N F-α水平对下肢深静脉血栓的预测价值[J].吉林医学,2022,43(3):602-605.[14]派孜拉㊃肉孜买买提,方青波,田广磊,等.白细胞介素-1β及相关标志物在下肢深静脉血栓中的表达变化与作用机制相关性研究[J].国际外科学杂志,2019,46(3): 164-168.[15]李斌,邓修高,李金,等.维持性血液透析患者血浆生长停滞特异性蛋白6水平与动静脉内瘘血栓形成的关系[J].临床肾脏病杂志,2022,22(9):737-741.[16]张超杰,赵辉.深静脉血栓诊断及治疗相关检验学标志物的研究进展[J].山东医药,2022,62(4):112-115. [17]汪倩玲.白细胞介素8介导C X C趋化因子受体1/2促进中性粒细胞胞外诱捕网生成影响转录因子ⅡB相关因子在胃癌疾病进展中的作用[D].合肥:安徽医科大学, 2022.[18]T HA K U R M,J U N HO C V,B E R N HA R D S M,e t a l.N E T s-i n d u c e d t h r o m b o s i s i m p a c t s o n c a r d i o v a s c u l a r a n dc h r o n i c k id ne y d i s e a s e[J].C i r c R e s,2023,132(8):933-949.[19]张银龙,崔玉凤,李树锋,等.中性粒细胞胞外诱捕网水平与全髋关节置换术后下肢深静脉血栓形成相关性[J].齐鲁医学杂志,2017,32(3):311-314.[20]刘瑞鹏,寇俊杰.中性粒细胞胞外诱捕网在动脉粥样硬化及血栓中作用相关研究的进展[J].心血管康复医学杂志,2022,31(5):634-638.[21]张林,刘都,王恒,等.外周血T X B2㊁N E T s㊁6-K-P G F1α水平对创伤骨折患者深静脉血栓形成的评估价值[J].临床和实验医学杂志,2023,22(3):296-300.(收稿日期:2023-07-19修回日期:2023-12-05)(上接第514页)s t r o k e(p o s t h y p e r a c u t e a n d p r e h o s p i t a l d i s c h a r g e):u p-d a te t o2009c o m p r e h e n s i v e n u r s i n g c a r e s c i e n t if i c s t a t e-m e n t:a s c i e n t i f i c s t a t e m e n t f r o m t h e a m e r i c a n h e a r t a s-s o c i a t i o n[J].S t r o k e,2021,52(5):179-197.[2]欧彩虹,董治燕,杨增烨.r t-P A静脉溶栓治疗急性缺血性脑卒中的疗效及对凝血指标的影响[J].血栓与止血学, 2022,28(2):181-183.[3]洪怡瑜,王群,王倩,等.急诊 零通道 模式在提高脑卒中静脉溶栓效率中的效果研究[J].中华神经医学杂志, 2022,21(2):176-179.[4]艾克拜尔㊃加马力,谢克来㊃阿不力肯,艾合买提㊃扎依尔.超时间窗静脉溶栓治疗轻㊁中型急性缺血性脑卒中[J].中国临床神经外科杂志,2022,27(8):688-689. [5]钟丽红,黄秀丽,朱婵燕,等.基于循证的急诊护理流程在急性缺血性脑卒中患者中的应用[J].海南医学,2023,34(2):263-267.[6]中华医学会神经病学分会,中华医学会神经病学分会脑血管病学组.中国急性缺血性脑卒中诊治指南2018[J].中华神经科杂志,2018,51(9):666-682.[7]王微,方传勤,曹磊,等.中性粒细胞/淋巴细胞比值㊁N I H S S评分和侧支循环T a n评分联合预测前循环大血管闭塞性脑卒中患者静脉溶栓转归[J].国际脑血管病杂志,2022,30(2):88-93.[8]刁兆香,谢莉,叶明芳,等.揿针埋针技术对泌尿外科腹腔镜术后患者康复的影响[J].护理研究,2023,37(2):337-339.[9]钟根龙,项琳,陈伟康,等.不同时间窗溶栓治疗急性缺血性脑卒中患者C T灌注成像核心梗死的可逆性研究[J].中华神经科杂志,2020,53(1):31-37.[10]朱琳,夏东,乔林.急诊绿色通道模式下溶栓治疗对轻中型急性缺血性脑卒中影响[J].临床军医杂志,2021,49(6):683-684.[11]解晨.D N T延长的影响因素及急诊绿色通道的优化对急性缺血性脑卒中患者D N T及预后改善的研究[D].兰州:兰州大学,2020.[12]陈莉,钟华.79例A I S患者静脉溶栓D N T延长的影响因素分析[J].重庆医学,2020,49(15):2515-2518. [13]谢婷,杨霞,史秋,等.以控制溶栓时间为基础急诊绿色通道在急性缺血性脑卒中患者急救护理中的应用[J].齐鲁护理杂志,2019,25(24):35-37.(收稿日期:2023-03-06修回日期:2023-11-12)㊃915㊃检验医学与临床2024年2月第21卷第4期 L a b M e d C l i n,F e b r u a r y2024,V o l.21,N o.4。
血红素氧合酶-1抑制介导Gas6通过ERK_STAT3轴增强多发性骨髓瘤对硼替佐..
中图分类号:R551单位代码:10660 UDC:616学号:1210660170375学科专业代码:100201密级:公开贵州医科大学2019届硕士学位论文(科学学位)血红素氧合酶-1抑制介导Gas6通过ERK/STAT3轴增强多发性骨髓瘤对硼替佐米的敏感性Heme oxygenase-1inhibition mediates Gas6to enhance bortezomib-sensitivity in multiple myeloma viaERK/STAT3axis论文作者:张照苑指导教师:王季石教授申请学位:临床医学硕士科学学位培养单位:临床医学院学科专业:内科学(血液病)研究方向:造血干细胞移植研究起止日期:2017年10月至2019年05月论文评阅人:冯永怀副主任医师韦四喜副主任技师答辩委员会主席:龚芳泽教授论文答辩日期:2020年6月2日二〇二〇年六月贵阳医学院学位论文原创性声明本人郑重声明:所呈交的论文是本人在导师的指导下,独立进行研究工作所取得的成果。
除了文中特别加以标注引用的内容外,本论文不包含任何其他个人或集体已经发表或撰写的成果作品。
对本文的研究做出重要贡献的个人和集体,均已在文中以明确方式标明。
除与外单位合作项目将予以明确方式规定外,本研究已发表与未发表成果的知识产权均归属贵阳医学院。
本人完全意识到本声明的法律后果由本人承担。
作者签名(手写):导师签名(手写):____2020____年___6_月__3__日____2020___年___6_月__3__日学位论文版权使用授权书本学位论文作者完全了解学校有关保留、使用学位论文的规定,同意学校保留并向国家有关部门或机构送交论文的复印件和电子版,允许论文被查阅和借阅。
本人授权贵阳医学院可以将本学位论文的全部或部分内容编入有关数据库进行检索,可以采用影印、缩印或扫描等复制手段保存和汇编本学位论文。
本学位论文属于(请在以下相应方框内打“√”):1、保密□,在年解密后适用本授权书。
长链非编码RNA-GAS5的功能与作用机制
长链非编码RNA-GAS5的功能与作用机制朱文彦;李响【期刊名称】《内江科技》【年(卷),期】2017(038)012【总页数】2页(P145-146)【作者】朱文彦;李响【作者单位】陆军军医大学大坪医院肿瘤中心;重庆医科大学第一附属医院心内科【正文语种】中文长链非编码RNA(long noncoding RNA, lncRNA)是近年来新发现的一类长度大于200nt的转录产物。
因其不具备编码功能性蛋白质的能力或者仅编码短的非功能多肽,故最初被认为是不具备生物学功能的转录副产物。
但近年来越来越多的研究表明,lncRNA广泛参与了生理和疾病的过程。
生长阻滞特异转录物5(growth arrest-specific transcript 5,GAS5),作为一种含有5'-TOP (5'-terminal oligopyrimidine tract)的长链非编码RNA,近年来被发现在哺乳动物细胞的生长和凋亡过程中起了关键的调控作用 [1]。
为能够向GAS5功能和作用机制的进一步研究提供线索,我们对GAS5的部分功能和作用机制进行综述。
GAS5最早是在在具有高度增殖活性的小鼠NIH 3T3细胞系中鉴定出来的,且在增殖活跃的NIH 3T3细胞和Friend leukemia细胞中GAS5表达量很低。
但当细胞营养缺乏时,其表达量升高[2],预示GAS5可能与细胞的生长状态有关。
Mourtada-Maarabouni等人 [3]在原代培养的人T淋巴细胞和CEM-C7细胞系中敲低内源性GAS5的表达,发现细胞正常状态下应该出现的生长停滞效应明显减弱,而血清饥饿或者地塞米松处理后的细胞本应受到抑制的克隆形成能力却依然存在。
结果预示,至少在人T细胞系中,正常的生长停滞效应依赖于GAS5的内源性表达。
mTOR是一种丝氨酸/苏氨酸蛋白激酶,被证实是调控细胞生长、分化、翻译、周期进程等多种生理功能的信号汇聚点。
维生素K与糖代谢研究进展
Relationship between Vitamin K and Glucose Metabolism REN Ruijun,TAN Jing* North Sichuan Medical College,Nanchong 637000,China *Corresponding author:TAN Jing,Associate professor;E-mail:79468064@
kuo等38研究了血浆gas6水平与肥胖和胰岛素敏感性之间的关系结果显示女性血浆gas6水平与体质指数腰围腰臀比和homair呈负相关与isi呈正相关提示gas6能对女性肥胖及2型糖尿病起到有益的作用研究者认为这可能与女性中雌激素水平有关有待研究进一步揭示两者之间的关系相关研究结果可能会提供一种新的关于女性肥胖及糖尿病的治疗方案
最近,DIHINGIA 等[11]首次证明,与年龄对照组相比,2 型糖尿病患者血液循环中维生素 K 水平明显降低(仅为对照组的 1/3),并且维生素 K 水 平 与 HOMA-IR 呈 负 相 关。YOSHIDA 等[12] 研 究 了一个大样本(1 247 名男性和 1 472 名女性,26~81 岁)中叶绿醌摄入量与胰岛素敏感性和血糖水平之间 的相关性,用半定量食物频率问卷(FFQ)评估了研 究对象过去 12 个月的叶绿醌摄入量。研究发现在调 整性别、年龄、腰围、生活方式等混杂因素后,测定 口服葡萄糖耐量试验(OGTT)2 h 后胰岛素水平和胰 岛素敏感指数(ISI),提示摄入较高剂量叶绿醌受 试者胰岛素敏感性较摄入低剂量者明显提高,并且前 者血糖状况较后者更为理想。许多临床干预试验证 实在补充维生素 K 后,可明显降低 HOMA-IR,而不 影响空腹血糖水平[13-15]。维生素 K 与空腹血糖、胰 岛素敏感性、HOMA-IR 等指标的关系在其他一些临 床研究也得到论证[16-17]。3 项干预性研究[13,15,18] 分析了补充维生素 K1 对糖代谢的影响,另一项研究[14] 不仅补充维生素 K1,还同时补充维生素 D 以及钙剂, 研究证明维生素 K1 对胰岛素敏感性的作用。另有 3 项研究[14,16-17]分析了补充维生素 K2 对糖代谢的作用, 其中一项研究[16]观察到维生素 K 不影响空腹血糖和 空腹胰岛素水平变化。关于维生素 K 与糖代谢的相 关临床研究简要总结见表 1。 3 可能的机制 3.1 骨 钙 素(osteocalcin,OC) 与 糖 代 谢 OC, 亦 称 λ- 羧 基 谷 氨 酸 蛋 白 或 骨 维 生 素 K 依 赖 性 蛋 白,是骨基质中最丰富的非胶原性蛋白,主要由成 骨细胞分化后期阶段产生[19]。总 OC 包括羧化 OC (carboxylated OC,cOC)和低羧化 OC(uncarboxylated
巨噬细胞胞葬功能在急慢性肝病中的作用机制及其靶向治疗
巨噬细胞胞葬功能在急慢性肝病中的作用机制及其靶向治疗杨焕焕,袁诗雨,唐映梅昆明医科大学第二附属医院消化内科,昆明 650101通信作者:唐映梅,************************.cn(ORCID:0000-0002-0731-4198)摘要:胞葬作用是指吞噬细胞(包括巨噬细胞、树突状细胞等专职吞噬细胞和上皮细胞等非专职吞噬细胞)吞噬并清除凋亡细胞的过程。
肝巨噬细胞是肝脏中具有胞葬功能的主要细胞。
近年来,越来越多的研究表明包括急性肝损伤、酒精性肝病、非酒精性脂肪性肝病、自身免疫性肝病、肝纤维化及肝细胞癌等在内的多种急慢性肝病均与肝巨噬细胞的胞葬作用有关。
本文通过阐述巨噬细胞胞葬相关分子的表达、胞葬过程及其胞葬功能在不同肝病中作用的最新研究进展,旨在为肝病治疗提供新思路。
关键词:肝疾病;巨噬细胞;胞葬基金项目:国家自然科学基金(82360108);云南省医学领军人才项目(L-2019013);云南万人计划名医专项(YNWR-MY-2018-028);云南省科技人才与平台计划(院士专家工作站202305AF150065);昆明医科大学第二附属医院临床研究项目(2020ynlc010, ynIIT2021017)Mechanism of action of macrophage efferocytosis in acute and chronic liver diseases and related targeted therapy YANG Huanhuan,YUAN Shiyu,TANG Yingmei.(Department of Gastroenterology,The Second Affiliated Hospital of Kunming Medical University, Kunming 650101, China)Corresponding author: TANG Yingmei,************************.cn(ORCID: 0000-0002-0731-4198)Abstract:Efferocytosis refers to the process by which apoptotic cells are engulfed and cleared by phagocytes, including professional phagocytes, such as macrophages and dendritic cells, and non-professional phagocytes, such as epithelial cells. Liver macrophages are the main cells with the function of efferocytosis in the liver. In recent years,an increasing number of studies have shown that various acute and chronic liver diseases are associated with the efferocytosis function of liver macrophages,including acute liver injury, alcoholic liver disease, nonalcoholic fatty liver disease, autoimmune liver disease, liver fibrosis, and liver cancer. This article elaborates on the expression of molecules associated with the efferocytosis function of macrophages, the process of efferocytosis, and the role of efferocytosis function in different liver diseases, so as to provide new ideas for the treatment of liver diseases.Key words:Liver Diseases; Macrophages; EfferocytosisResearch funding:National Natural Science Foundation of China (82360108); Medicine Leading Talents of Yunnan Province (L-2019013); The Yunnan Wanren Project (YNWR-MY-2018-028); Yunnan Province Science And Technology Talents and Platform Plan (The Yunan Academician Expert Workstation 202305AF150065); Clinical Research Project of the Second Affiliated Hospital of Kunming Medical University (2020ynlc010, ynIIT2021017)成年人体内约有37.2万亿个细胞,每天死亡的细胞约占0.4%[1]。
PETS-3词汇(含音标)
PETS-3 Aa (an) art.(非特指的)一(个);任何一个;每一(个) AD. [æd] n.公元A.M. [,ei 'em] adv.上午,午前abandon[ə'bændən] v.放弃;抛弃,离弃abdomen['æbdəmən; æb'dəumən] n.腹;腹部abide [ə'baid] v.(by)坚持;遵守;容忍ability[ə'biliti] n.能力,智能;才能,才干;技能able ['eibl] adj.能够,有能力的abolish[ə'bɔliʃ] v.废除,取消about ['əbaut] adv.大约prep.关于;在…周围;在…各处above [ə'bʌv] prep.在…上方;(数量,价格等)大于…abroad[ə'brɔ:d] adv.出国,在国外abrupt[ə'brʌpt] adj.突然的,意外的;陡峭的,险峻的;(举止,言谈等) 不流畅的absence ['æbsəns] n.缺席,不在场;缺乏absent['æbsənt] adj.(from)缺席的,不在场的;漫不经心的absolut e ['æbsəlu:t] adj.绝对的;完全的;专制的absorb[əb'sɔ:b] v.吸收;吸引,使专心abstrac t ['æbstræk t] adj.抽象的;深奥的n.摘要;抽象v.摘要;转移absurd[əb'sə:d] adj.愚蠢的;荒唐的abundan t [ə'bʌndənt] adj.丰富的;充足的abuse [ə'bju:z] v.&n.滥用;谩骂academi c [,ækə'demik] adj.学院的;学术的,教学的acceler ate [æk'selərei t] v.加速;促进accent['æksənt] n.腔调,口音;重音(符号)accept[ək'sept] v.认可,接受access['ækses] n.接近,进入;入口,通路;接近(或进入) 的方法acciden t ['æksidən t] n.事故acciden tal [,æksi'dentl] adj.偶然的,意外的accommo date [ə'kɔmədei t] v.留宿,收容;供应,供给;容纳accommo dation s n.住宿accompa ny [ə'kʌmpəni] v.陪伴,陪同accompl ish [ə'kɔmpliʃ] v.完成,实现accordi ng to [ə,kɔ:diŋtu:]prep.根据account[ə'kaunt] n.账户accumul ate [ə'kju:mjuleit] v.积累,积蓄;堆积accurat e ['ækjurit] adj.精确的,准确的accuse[ə'kju:z] v.(of) 控告,谴责accusto m [ə'kʌstəm] v.(to) 使习惯ache [eik] v.痛;哀怜n.疼痛,酸痛achieve[ə'tʃi:v] v.完成,达到;获得acid ['æsid] n.酸adj.酸的;酸性的acquain t [ə'kweint] v.使认识,使了解acquain tance[ə'kweintəns] n.熟人;相识;熟悉acquire[ə'kwaiə] v.取得,获得;学到acre ['eikə] n.英亩acrobat['ækrəbæt] n.杂技演员across[ə'krɔs] prep.穿过;在另一边,在对面adv.横越act [ækt] v.行动;做action['ækʃən] n.行动,行为;动作,活动;(on) 作用active['æktiv] adj. 活动的,活泼的,活跃的;主动的,积极的;敏捷的;剧烈的activit y [æk'tiviti] n.活动actor ['æktə] n.男演员actress['æktris] n.女演员actual['æktjuəl] adj.实际的,事实上的;真实的ad [æd] (=adverti sement)n.广告adapt [ə'dæpt] v.(to)(使) 适合;改编,改写add [æd] v.加additio n [ə'diʃən] n.加,加法;附加物additio nal [ə'diʃənl] adj.附加的,另外的address[ə'dres] n.地址adequat e ['ædikwit] adj.足够的,充分的;符合要求的adhere[əd'hiə] v.(to) 粘附;坚持,遵循adjecti ve ['ædʒikti v] n.形容词adj.形容词的adjust[ə'dʒʌst] v.调节,校正;(to)(使)适应adminis tratio n [ədminis'treiʃən] n.管理,经营;行政(机关,部门);政府admire[əd'maiə] v.羡慕,赞赏,钦佩admit [əd'mit] v.承认adopt [ə'dɔpt] v.采用,采纳;收养adult [ə'dʌlt, 'ædʌlt] n.成(年)人;adj.成年人的;成熟的advance[əd'vɑ:ns] v.前进;取得进展advance d [əd'vɑ:nst] adj.高级的,先进的advanta ge [əd'vɑ:ntidʒ] n.优点,优势adventu re [əd'ventʃə] v.大胆进行,拿…冒风险n.冒险活动,冒险;奇遇adverti se ['ædvətai z] v.做广告advice[əd'vais] n.忠告;建议advise[əd'vaiz] v.劝告,建议adviser[əd'vaizə] n.(政府,公司等的) 顾问affair[ə'fɛə] n.事,事情,事件affect[ə'fekt] v.影响,传染;感动affecti on [ə'fekʃən] n.爱,慈爱affirm[ə'fɜ:m] v.断言;(法庭上) 陈述affirma tive [ə'fə:mətiv] adj.肯定的n.(指言语) 表示同意的词语afford[ə'fɔ:d] v.买得起,担负得起afraid[ə'freid] adj.恐怕的;担心的;害怕的Africa['æfrikə] n.非洲African['æfrikən] adj.非洲的n.非洲人after ['ɑ:ftə] prep.在…以后conj.在…以后adv.以后afterno on ['ɑ:ftə'nu:n] n.下午afterwa rd ['ɑ:ftəwəd] adv.(-s)后来,以后again [ə'gein] adv.又,再against[ə'genst, ə'geinst] prep.反对;与之成对手,对着;防止;碰age [eidʒ] n.年龄agency['eidʒəns i] n.经办;媒介;代理处agent ['eidʒənt] n.代理人,代表ago [ə'gəu] adv.以前agony ['ægəni] n.苦恼;极大痛苦agree [ə'gri:] v.同意agreeme nt [ə'gri:mənt] n.协议,协定;一致,同意agricul tural[,ægri'kʌltʃərəl] adj. 农业的agricul ture ['ægrikʌl tʃə] n.农业,农学ahead [ə'hed] adv.在前;向前aid [eid] v./n.辅助,援助,救助aim [eim] v.把…瞄准,把…对准air [ɛə] n.空气;天空aircraf t ['eəkrɑ:ft] n.飞机,航空器airline['eəlain] n.航线;航空公司airmail['eəmeil] n.空邮airplan e ['eəplein] n.飞机airport['eəpɔ:t] n.机场alarm [ə'lɑ:m] n.警报;惊恐v.使惊恐,惊动,惊吓;向…报警alcohol['ælkəhɔl] n.酒精,乙醇alert [ə'lə:t] adj.警惕的;机灵的n.警报;警戒状态;警戒期间v.使警觉alike [ə'laik] adj.相同的;相像的adv.相同地,一样地alive [ə'laiv] adj.活着的;存在的;有活力的,活跃的all [ɔ:l] adj.所有的adv.都,全部地pron.所有,全部allied['ælaid] adj.联合的;同盟的;同源的allow [ə'lau] v.允许ally [ə'lai] n.同盟国,同盟者;支持者v.(with) 使结盟,结成同盟almost['ɔ:lməust] adv.几乎alone [ə'ləun] adj.独自一人的ad v.单独;只有,仅仅along [ə'lɔŋ]adv.向前;和…一起,一同prep.沿着,顺着alongsi de [əlɔŋ'said]prep.在…旁边,横靠;adv.并排地,并肩地aloud [ə'laud] adv.出声地,大声地already[ɔ:l'redi] adv.已经also ['ɔ:lsəu] adv.也alter ['ɔ:ltə] v. 改变,变样alterna te [ɔ:l'tə:nit, 'ɔ:ltə:neit] adj.交替的;预备的n.代理人v.交替,轮流althoug h [ɔ:l'ðəu] conj.虽然;尽管;即使altoget her [,ɔ:ltə'geðə] adv.完全,全部地always['ɔ:lweiz] adv.总是,无例外地;永远,始终AM [m, əm, æm] (=A.M.,a.m.) 上午am [m, əm, æm] v.是amaze [ə'meiz] v.认使惊奇,使惊愕,使惊叹ambassa dor [æm'bæsədə] n.大使ambiguo us [æm'bigjuəs] adj.模棱两可的ambitio n [æm'biʃən] n.雄心,野心ambitio us [æm'biʃəs] adj.有雄心的,野心勃勃的ambulan ce ['æmbjuləns] n.救护车;野战医院America[ə'merikə] n.美洲;美国America n [ə'merikən] adj.美国(洲)的n.美国人;美洲人among [ə'mʌŋ]prep.在…之中amount[ə'maunt] n.数量ample ['æmpl] adj.充分的,富裕的;宽敞的,宽大的amuse [ə'mju:z] v.逗…笑,给…以娱乐(消遣) amuseme nt [ə'mju:zmənt] n.娱乐,消遣;娱乐活动analysi s [ə'næləsis] n.分析,分解analyze['ænəlaiz] v.分析;分解;解析 (=analyse) ancient['einʃənt] adj.古代的,古老的and [ənd, ænd] conj.与,和;又;另外angel ['eindʒəl] n.天使anger ['æŋgə] v.使发怒,激怒n.愤怒,气愤angle ['æŋgl]n.角;角度,观点angry ['æŋgri]adj.生气的animal['æniməl] n.动物anniver sary [,æni'və:səri] n.周年(纪念日)adj.周年的announc e [ə'nauns] v.宣告,宣布annoy [ə'nɔi] v.使恼怒,使生气;打扰,干扰annual['ænjuəl] adj.每年的,年度的;一年一次的n.年报,年刊another[ə'nʌðə] adj.另一,再一;别的pron.另一个answer['ɑ:ŋsɚ] n./v.回答;答复n.答案ant [ænt] n.蚂蚁anxiety[æŋ'zaiəti] n.挂念;焦虑;渴望anxious['æŋkʃəs] adj.(about)忧虑的,担心的;渴望的any ['eni] adj.一些;任何的pron.无论哪一个;无论哪些anybody['eni,bɔdi, 'enibədi] prep.(否定、疑问、条件句中)任何人;(肯定句中)随便哪一个人anyhow['enihau] adv.无论如何,不管怎么说anyone['eniwʌn] pron.任何人anythin g ['eni,θiŋ]pron.任何事物anyway['eniwei] adv.无论如何anywher e ['eniweə] adv.任何地方;不论哪里apartme nt [ə'pɑ:tmənt] n.单元房,套房;公寓apologi ze [ə'pɔlədʒa iz] (=apologi se)v.道歉,认错apology[ə'pɔlədʒi] n.道歉,认错apparen t [ə'pærənt] adj.(to)明显的,显而易见的;表面的,貌似的appeal[ə'pi:l] v.呼吁,请求;上诉,申诉;求助于n.呼吁,请求;上诉appear[ə'piə] v.出现appeara nce [ə'piərəns] n.出现,外表appendi x [ə'pendiks] n.附录;附属物appetit e ['æpitait] n.食欲,胃口;欲望,爱好;要求applaud[ə'plɔ:d] v.喝彩,鼓掌;称赞apple ['æpəl] n.苹果applica tion [,æpli'keiʃən] n.请求;申请(书,表);应用,运用apply [ə'plai] v.申请appoint[ə'pɔint] v.任命,委任;约定,指定appoint ment [ə'pɔintmənt] n.约会,预约;任命,选派appreci ate [ə'pri:ʃieit] v.感谢,感激;欣赏,赏识approac h [ə'prəutʃ] v.靠近,接近,临近n.方法,途径;探讨approva l [ə'pru:vəl] n.赞成,同意;认可,批准approve[ə'pru:v] v.(of) 赞成;批准,通过April ['eiprəl] n.四月apt [æpt] adj.恰当的,适宜的;(习性)易于…的,有…倾向的Arabian[ə'reibiən] n.阿拉拍人adj.阿拉伯(人) 的arch [ɑ:tʃ] n.拱门;弓形结构v.拱起;(使) 成弓形archite ct ['ɑ:kitekt] n.建筑师;设计师archite cture['ɑ:kitektʃə] n.建筑(式样,风格);建筑学Arctic['ɑ:ktik] adj.北极的,北极区的n.北极, 北极圈are [ɑ:] v.是area ['eəriə] n.地区argue ['ɑ:gju:] vi.论证,认定;争论,争吵argumen t ['ɑ:gjumənt] n.争论,争吵arise [ə'raiz] vi.出现;呈现arm [ɑ:m] n.胳膊army ['ɑ:mi] n.军队,军;大群,大批around[ə'raund] prep.在…各处,到处;adv.大约,到处arouse[ə'rauz] v. 唤醒;激起arrange[ə'reindʒ] v.整理,排列;安排arrest[ə'rest] v.逮捕;扣留;阻止;吸引n.逮捕;扣留arrival[ə'raivəl] n.到达,到来;到达的人或物arrive[ə'raiv] v.到达arrow ['ærəu] n.箭(状物);箭头符号;箭头art [ɑ:t] n.艺术artific ial [,ɑ:ti'fiʃəl] adj.人工的,人造的;矫揉造作的artist['ɑ:tist] n.美术家;艺术家as [æs] prep.作为adv./conj.像…一样;如同;由于ash [æʃ] n.灰,灰末ashamed[ə'ʃeimd] adj.惭愧的,害臊的ashore[ə'ʃɔ:] adv.在岸上;上岸Asia ['eiʃə] n.亚洲Asian ['eiʃən] adj.亚洲的;亚洲人的n.亚洲人aside [ə'said] adv.在旁边;到旁边ask [ɑ:sk] v.问,询问asleep[ə'sli:p] adj.睡着的aspect['æspekt] n.样子,外表,面貌;(问题等的) 方面assembl e [ə'sembəl] v.集合,集会;装配,组装PETS-3assembl y [ə'sembli] n.集会,会议;装配assert[ə'sə:t] v.断言,宣称;维护assignm ent [ə'sainmən t] n.分配,委派;任务,(课外)作业assist[ə'sist] v.帮助,援助,协助assista nce [ə'sistəns] n.帮助,援助assista nt [ə'sistənt] n.助理,助手associa te [ə'səuʃiei t] v.(with) 使联系;交往,结合 n.合作人,伙伴,同事,同行adj.合伙的;副的associa tion[ə,səusi'eiʃən] n.协会,团体;联合,交往;联想assume[ə'sju:m] v.假装;假定,设想;采取,承担assure[ə'ʃuə] v. 使确信,使放心;保证,担保astonis h [əs'tɔniʃ] v. 使惊讶;使惊恐at [æt] prep.在…(表示时间或地点)Atlanti c [ət'læntik] n.大西洋atmosph ere ['ætməsfiə] n.大气(层);空气;气氛,环境atom ['ætəm] n.原子;微粒attach[ə'tætʃ] v.(to) 缚上,系上,贴上attack[ə'tæk] v.攻击,进攻n.攻击,进攻;(病) 发作attain[ə'tein] v.达到;获得;完成attempt[ə'tempt] v.企图,试图n.努力,尝试;企图attend[ə'tend] v.出席,参加(会议等);护理,侍候;照料,关心;看管attenda nt [ə'tendənt] n.服务员,值班员;护理人员adj.在场的;伴随的attenti on [ə'tenʃən] n.注意,留心attenti ve [ə'tentiv] adj.注意的,留神的attitud e ['ætitju:d] n.(to, towards) 态度,看法;姿势attorne y [ə'tə:ni] n.律师;代理人attract[ə'trækt] v.吸引n.标准,规范attract ive [ə'træktiv] adj.有吸引力的;引起注意的attribu te ['ætribju:t, ə'tribju:t] v.(to) 把…归因于,把…归咎于n.属性,特征audienc e ['ɔ:diəns] n.听众,读者;会见August['ɔ:gʌst] n.八月aunt [ɑ:nt] n.伯母;婶母;姑母;姨母;舅母aural ['ɔ:rəl] adj.听觉的Austral ia [ɔ'streiliə] n.澳大利亚Austral ian [ɔ'streiliən] adj.澳大利亚的,澳洲区的;澳大利亚人的n.澳大利亚人author['ɔ:θə] n.作者;创始人authori ty [ə'θɔriti] n.权力,权威;权威者;有权威性的典籍;(pl.)当局auto ['ɔ:təu] n.(=automob ile)汽车autumn['ɔ:təm] n.秋天availab le [ə'veiləbəl] adj.可用的,可得到的;可以见到的,随时可来的avenue['ævənju:, 'ævinju:] n.林荫道,大街;途径,手段average['ævəridʒ] n.平均数,平均v.均分(利益等),平均adj.平均的;通常的,一般的avoid [ə'vɔid] v.避免;回避,躲开await [ə'weit] v.等候;期待awake [ə'weik] adj.醒着的v.唤醒;醒award [ə'wɔ:d] n.奖(品)v.授予,奖给aware [ə'weə] adj.(of) 知道的,意识到的away [ə'wei] adv.离,远离;变化,消失;不在这里awful ['ɔ:fl] adj.糟糕的;令人恐惧的;可怕的;极坏的awfully['ɔ:fuli] adv.非常,很awkward['ɔ:kwəd] adj.笨拙的,不灵活的;棘手的,尴尬的;使用不便的axe (=ax) n.斧子PETS-3Bbaby ['beibi] n.婴儿,孩子;年龄最小的人back [bæk] n.后部;背面;脊背adj.最后面的adv.向后backgro und ['bækgrau nd] n.背景backwar ds ['bækwədz] adv.&adj.向后地(的), 相反地(的) bacon ['beikən] n.咸猪肉,熏猪肉bad [bæd] adj.不好,坏的,糟糕的badly ['bædli] adv.不好地,坏地,糟糕地badmint on ['bædmintən] n.羽毛球bag [bæg] n.包baggage['bægidʒ] n.(美)行李bake [beik] v.烘,烤bakery['beikəri] n.面包房;面包糕点店balance['bæləns] n.平衡;余额bald [bɔ:ld] adj.秃的;秃头的ball [bɔ:l] n.球balloon[bə'lu:n] n.气球banana[bə'nɑ:nə] n.香蕉band [bænd] n.条,带;乐队;波段;一群,一伙v.认缚,绑扎bandage['bændidʒ] n.绷带v.用绷带扎缚bang [bæŋ]n.砰砰的声音;猛击v.砰地关上;猛撞bank [bæŋk]n.银行,河岸bankrup t ['bæŋkrʌp t] adj.破产的v.使破产n.破产者banner['bænə] n.旗(帜);横幅bar [bɑ:] n.酒吧barber['bɑ:bə] n.理发师,队理发bare [bɛə] adj.光的,秃的barely['beəli] adv.赤裸裸地,无遮蔽地;仅仅,勉强bargain['bɑ:gən] n.协定,契约,合同;交易;特价商品,便宜货v.认讲价还价;达成协议bark [bɑ:k] v.吠叫;咆哮n.吠声,狗叫声barn [bɑ:n] n.谷仓,仓库;草料房barrel['bærəl] n.桶;枪管,炮管base [beis] n.基(础),底(座);基地v.(on) 把…建立在…基础上basebal l ['beisbɔ:l] n.棒(垒)球运动;棒(垒)球basemen t ['beismən t] n.地下室,地窖basic ['beisik] adj.基础的,根本的;主要的,首要的basin ['beisən] n.脸盆,盆;盆地basis ['beisis] n.基础,根据;主干basket['bɑ:skit] n.篮,篓basketb all ['bɑ:skitbɔ:l] n.篮球bat [bæt] n.球拍,球棒;蝙蝠v.用球棒(拍) 打球batch [bætʃ] n.一批,一组,一群bathe [beið] v.洗澡bathroo m ['bɑ:θrum,-ru:m] n.浴室battery['bætəri] n.电池(组);炮兵连,炮组battle['bætl] n.战役;战斗bay [bei] n.海湾,(港)湾BC ['bi:'si:] abbr.公元前(=B.C.)be [bi:] v.是beach [bi:tʃ] n.海滨,海滩beam [bi:m] n.(横) 梁,桁条;(光线的) 束,柱v.微笑;发光bean [bi:n] n.豆,菜豆,蚕豆bear [bɛə]n.熊;v.生子女;忍受;负担beard [biəd] n.(下巴上的)胡须,络腮胡子;vt.公开反对beast [bi:st] n.兽,牲畜;凶残的人,举止粗鲁的人beat [bi:t] n.(心脏等的) 跳动(声);有节奏的敲击(声)v.(连续地) 打,击;打败,战胜beautif ul ['bju:tifəl] adj.美丽的beauty['bju:ti] n.美,美丽;美人;美的东西because[bi'kɔz] conj.因为become[bi'kʌm] v.变成;成为bed [bed] n.床bedroom['bedrum, -ru:m] n.卧室bee [bi:] n.蜜蜂beef [bi:f] n.牛肉v.抱怨;发牢骚beer [biə] n.啤酒before[bi'fɔ:] prep.&conj. 在…之前adv.以前beforeh and [bi'fɔ:hænd] adv.提前地,超前地adj.预先准备好的;提前的beg [beg] v.乞讨,乞求;恳求,请求begin [bi'gin] v.开始beginne r [bi'ginə] n.初学者beginni ng [bi'giniŋ]n.开始,开端,起点behalf[bi'hɑ:f] n.利益behave[bi'heiv] v.举止,表现;运转behavio ur n.行为,举止(=behavio r)behind[bi'haind] prep.在…的背后,在…后面,落后于adv.在背后,向后,落在后面being ['bi:iŋ]n.生命;存在,生存belief[bi'li:f] n.信仰;相信,信念believe[bi'li:v] v.相信,认为bell [bel] n.钟,铃belong[bi'lɔŋ]v.(to)属于beloved[bi'lʌvid] adj.受爱戴的,敬爱的n.爱人,心爱的人below [bi'ləu] prep.在下面,在下方;…以下,低于…belt [belt] n.腰带;长形地带v.系上腰带bench [bentʃ] n.长凳,长椅bend [bend] n.弯曲(处)v.(使)弯曲beneath[bi'ni:θ] prep.在…下边,在…之下adv.在下方,低于benefit['benifit] n.利益,好处;恩惠v.有益于;(from, by) 受益bent [bent] adj.弯曲的;下决心的n.(for)嗜好;倾向beside[bi'said] prep.在…旁边(或附近);和…相比besides[bi'saidz] adv.而且,还有prep.除…之外best [best] adv.&adj.最好(的)bet [bet] v.赌,打赌;相信n.打赌,赌注betray[bi'trei] v.背叛,出卖;暴露,泄露;辜负better['betə] adj.较好的,更好的adv.更好地between[bi'twi:n] prep./adv.在(两者)之间;在…之间beware[bi'wɛə] v.当心,谨防;留神beyond[bi'jɔnd] prep.在(或向)…的那边,远于;超出,超过adv.在更远处Bible ['baibl] n.《圣经》bicycle['baisik(ə)l] n.自行车bid [bid] v.祝愿;命令,吩咐;报价;投标n.出价,投标big [big] adj.大的bill [bil] n.账单billion['biljən] n.(美) 十亿;(英) 万亿bind [baind] v.捆,绑,包扎;束缚;凝固biograp hy [bai'ɔgrəfi] n.传记bird [bə:d] n.鸟birth [bə:θ]n.出生,分娩;起源,根源birthda y ['bə:θdei]n.生日birthpl ace ['bə:θpleis] n.出生地biscuit['biskit] n.饼干bit [bit] n.一点bite [bait] v.&n.咬,叮bitter['bitə] adj.有苦味的;苦的;很冷的black [blæk] adj.黑的,黑色的n.黑色blackbo ard ['blækbɔ:d] n.黑板blame [bleim] v.责备,责怪;(on, onto) 把…归咎于n.责任;责怪,责备blank [blæŋk]adj.空白的;空虚的;失色的,无表情的n.空白blanket['blæŋkit] n.毯子;厚厚一层v.铺上一层blast [blɑ:st] n.一阵(风),一股(气流);爆炸冲击波;管乐器或汽笛声v.爆炸,爆破;摧毁blaze [bleiz] n.火焰;火光;闪光,光亮v.燃烧,冒火焰;照耀,发光bleed [bli:d] v.流血;榨取;渗出bless [bles] v.祝福,保佑;对(上帝) 感恩blind [blaind] adj.瞎的,失明的;盲目的v.使失明block [blɔk] n.街区blood [blʌd] n.血,血液bloody['blʌdi] adj.流血的;血腥的;残忍的bloom [blu:m] n.花(朵);开花(期)v.开花blossom['blɔsəm] n.(某一树丛或树上开的)全部花朵;开花期blouse[blauz] n.女衬衫,童衫blow [bləu] v.刮,吹blue [blu:] adj.蓝色的n.蓝色blush [blʌʃ] v.&n.脸红,羞愧board [bɔ:d] n.木板boast [bəust] v.(of, about) 自夸,夸耀n.自夸的话,大话;夸耀的事boat [bəut] n.船,小船body ['bɔdi] n.身体,躯体,主体;物体;尸体;(一) 群,(一) 批boil [bɔil] v.沸腾boiler['bɔilə] n.锅炉;煮器bold [bəuld] adj.大胆的,勇敢的;冒失的;黑体的,粗体的;醒目的,清晰的bomb [bɔm] n.炸弹v.投弹于,轰炸bond [bɔnd] n.结合(物),黏结(剂),联结;证券,债券;契约;保证书bone [bəun] n.骨,骨骼book [buk] n.书,书本v.预订boot [bu:t] n.(长统) 靴;(汽车后部) 行李箱booth [bu:ð] n.电话亭;货摊border['bɔ:də] n.边界,国界;边(沿)v.交界,接壤born [bɔ:n] adj.出生的,产生的,天生的borrow['bɔrəu] v.借,借人bosom ['buzəm] n.(心)胸;内心boss [bɔs] n.老板both [bəuθ]pron.两者,双方;两人adj.两,双bother['bɔðə] v.打扰,麻烦;使烦恼,使难受n.麻烦,困难bottle['bɔtl] n.瓶子bottom['bɔtəm] n.底,底部bound [baund] v.跳(跃);限制n.跳(跃);界限adj.被束缚的;密切关联的boundar y ['baundər i] n.分界线,边界,国界bow [bau] n.弓;鞠躬;点头;蝴蝶结bowl [bəul] n.碗box [bɔks] n.盒子,箱子boy [bɔi] n.男孩brain [brein] n.脑,脑髓;(pl.)智力brake [breik] n.刹车;制动器branch[brɑ:ntʃ] n.树枝,分枝;(机构的) 分部;分支brand [brænd] n.商标,标记;烙印v.使铭记;打烙印brass [brɑ:s] n.黄铜;铜器adj.黄铜制的brave [breiv] adj.勇敢的bravery['breivər i] n.勇敢bread [bred] n.面包break [breik] n.(课间或工间)休息时间v.打破,打碎breakfa st ['brekfəs t] n.早餐breast[brest] n.胸脯,乳房breath[breθ]n.呼吸breathe[bri:ð] v.呼吸breed [bri:d] v.(使) 繁殖;产生,引起;抚养,饲养n.品种,种类brick [brik] n.砖,砖状物bride [braid] n.新娘bridegr oom ['braidgr u:m] n.新郎bridge[bridʒ] n.桥brief [bri:f] adj.简洁的;短暂的v.简短介绍,简要汇报bright[brait] adj.明亮的,晴朗的;聪敏的,机灵的;欢快的brillia nt ['briljən t] adj.光辉的,灿烂的;卓越的,才华横溢的n.宝石bring [briŋ]v.带来;拿来brisk [brisk] adj.轻快的;生气勃勃的;兴隆的;清新的Britain['britən] n.英国;不列颠British['britiʃ] adj.(大) 不列颠(人) 的,英国(人) 的n.总称英国人(与the连用)brittle['britl] adj.易碎的;脆(弱) 的;冷淡的broad [brɔ:d] adj.宽的,广阔的,辽阔的;宽宏的,豁达的adv.宽阔地,广阔地broadca st ['brɔ:dkɑ:st] v.广播,播送n.广播,播音brook [bruk] n.小河,溪v.忍受,容让broom [bru:m] n.扫帚brother['brʌðə] n.兄弟brow [brau] n.额头;眉毛,眉脊brown [braun] adj.棕色的n.棕色brush [brʌʃ] n.刷子,毛刷;画笔v.刷,擦brutal['bru:tl] adj.残忍的;兽性的;严酷的bubble['bʌbl] n.泡,水泡,气泡v.冒泡,起泡bucket['bʌkit] n.水桶;一桶之量bud [bʌd] v.发芽,含苞欲放n.芽,花苞budget['bʌdʒit] n.预算v.做预算,安排adj.合算的buffet['bʌfit, bə'fei] n.(火车站、餐车上的)饮食柜台;餐台build [bild] v.建立,修建,建造buildin g ['bildiŋ] n.建筑物;建筑;楼bulb [bʌlb] n.灯泡,球状物;球茎bull [bul] n.公牛;雄象(鲸等);像公牛一样的人;金牛座adj.公牛般的;大型的;雄的bullet['bulit] n.子弹bulleti n ['bulətin] n.公报,告示,新闻简报bunch [bʌntʃ] n.(一) 簇,束,捆,串bundle['bʌndl] n.捆,包,束burden['bə:dn] n.担子,负担;装载量bureau['bjuərəu] n.署,局,司,处;大书桌,写字台burn [bə:n] v.烧(掉),烧毁;烧焦n.灼伤;烧伤处burst [bə:st] v.爆裂,炸破;突然发生,突然发作n.突然破裂;爆发;一阵bury ['beri] v.埋葬,葬;掩埋,埋藏bus [bʌs] n.公共汽车bush [buʃ] n.灌木busines s ['biznəs] n.商业,生意,营业;事情,职责busy ['bizi] adj.忙but [bʌt] conj.可是,但是butcher['butʃə] n.屠夫,卖肉者butter['bʌtə] n.黄油v.涂黄油butterf ly ['bʌtəfla i] n.蝴蝶;轻浮的人button['bʌtn] n.钮扣;按钮(开关)v.扣紧buy [bai] v.买,购买by [bai] prep.用,借助于,以..的方式;靠近;经过bye [bai]interj.再见Ccabbage['kæbidʒ] n.卷心菜,洋白菜cabin ['kæbin] n.客舱,机舱;小(木) 屋cabinet['kæbinit] n.橱柜;内阁cable ['keibl] n.电缆cafe ['kæfei; (US) kæ'fei] n.咖啡馆cafeter ia ['kæfi'tiəriə] n.自助食堂,自助餐馆cage [keidʒ] n.笼v.关在笼子里cake [keik] n.饼,糕cal [kæl] abbr. 卡,小卡 (small calorie)calcula te ['kælkjul eit] v.计算,推算,核算;计划,打算calenda r ['kæləndə] n.日历,月历,历法call [kɔ:l] vt.叫,称呼;招呼;电话通知n.电话calm [kɑ:m] adj.平静的,安静的camel ['kæməl] n.骆驼camera['kæmərə] n.照相机,摄影机camp [kæmp] n.野营;营地v.设营,宿营campaig n [kæm'pein] n.战役;运动campus['kæmpəs] n.校园can [kæn, kən] aux.v.能,能够;可以Canada['kænədə] n.加拿大Canadia n [kə'neidjən] adj.加拿大的;加拿大人的n.加拿大人canal [kə'næl] n.运河;(沟) 渠cancel['kænsəl] v.取消,作废;删去cancer['kænsə] n.癌症;肿瘤candida te ['kændide it] n.候选人,候补者;报考者;申请者candle['kændl] n.蜡烛candy ['kændi] n.糖果;蜜饯cannon['kænən] n.大炮,火炮v.开炮;碰撞canoe [kə'nu:] n.独木舟,小游艇v.划独木舟cap [kæp] n.便帽,军帽;(笔、瓶等的) 盖套v.覆盖于…顶端capable['keipəbl] adj.能干的,有能力的capacit y [kə'pæsiti] v.容量,容积;才能,能力;接受力capital['kæpitəl] n.首都captain['kæptin] n.上尉,队长;船长capture['kæptʃə] n.捕获,俘获v.夺得,占领;捕获,俘虏car [kɑ:] n.小汽车card [kɑ:d] n.卡片care [kɛə] v.关心,介意n.小心,谨慎,注意career[kə'riə] n.生涯,经历;专业,职业careful['kɛəful] adj.小心的;谨慎的careles s ['kɛəlis] adj.粗心的,疏忽的cargo ['kɑ:gəu] n.船货,货物carpet['kɑ:pit] n.地毯;像地毯般的一层东西carriag e ['kæridʒ] n.(四轮) 马车;(火车的) 客车厢carrot['kærət] n.胡萝卜carry ['kæri] vt.运送cart [kɑ:t] n.大车,板车,手推车v.用大车运走cartoon[kɑ:'tu:n] n.漫画,幽默画;动画片v.画漫画carve [kɑ:v] v.(雕) 刻case [keis] n.情况,情形,事实;案件,案情;病例cash [kæʃ] n.现金,现款,现钱v.兑现,兑付cashier[kə'ʃiə] n.(银行、商店等的)出纳员cassett e [kɑ:'set] n.小盒子;盒式磁带cast [kɑ:st] v.投, 掷,抛;铸造;计算n.演员表;一掷;模型;性格castle['kɑ:sl] n.城堡casual['kæʒjuəl] adj.偶然的,碰巧的;临时的,非正式的;不拘礼的,随便的casualt y ['kæʒjuəl ti] n.伤亡人员;受害人;重大伤亡事故cat [kæt] n.猫catalog ue ['kætəlɔg] n.目录(catalog)catch [kætʃ] v.赶,追categor y ['kætigər i] n.种类,类别;范畴cathedr al [kə'θi:drəl] n.大教堂;(教区内的) 总教堂Catholi c ['kæθəlik] n.天主教教徒adj.天主教的cattle['kætl] n.牛;牲口,家畜cause [kɔ:z] n.原因,理由,缘故;事业,(奋斗的) 目标v.使产生,引起caution['kɔ:ʃən] n.小心,谨慎;警告,告诫v.警告cautiou s ['kɔ:ʃəs] adj.(of) 小心的,谨慎的cave [keiv] n.山洞,洞穴v.塌陷;(业余爱好) 探洞cease [si:s] v.&n.停止,中止ceiling['si:liŋ]n.天花板celebra te ['selibre it] v.庆祝;庆贺cell [sel] n.细胞;小囚房;蜂房;电池cellar['selə] n.地窖,地下室cement[si'ment] n.水泥;胶泥,胶接剂v.胶合;巩固,加强cent [sent] n.美分,分币center['sentə] (=centre)n.中心,中央;中心区,核心;中心人物central[sen'trɑ:l] adj.中心的,中央的,中部的;中枢的century['sentʃər i] n.世纪ceremon y ['serimən i] n.典礼,仪式;礼节,礼仪certain['sə:tn] adj.确凿的,无疑的;某一;一些certain ly ['sə:tənli] adv.一定,无疑;是的,当然,好certain ty ['sə:tənti] n.必然,肯定;必然的事certifi cate [sə'tifikit] n.证书;证明;执照chain [tʃein] n.链,链条;一连串;连锁v.用链条拴住chair [tʃɛə] n.椅子chairma n ['tʃɛəmən] n.主席chalk [tʃɔ:k] v.用粉笔写或画n.白垩;粉笔challen ge ['tʃælindʒ] n.挑战(书);艰巨任务v.挑战;要求比试chamber['tʃeimbə] n.房间,室champio n ['tʃæmpjən] n.冠军,得胜者;拥护者,斗士;战士adj.最好的;优胜的chance[tʃɑ:ns] n.机会chancel lor ['tʃɑ:nsələ] n.首相;大臣;司法官change[tʃeindʒ] n.零钱v./n.变化,改变changea ble ['tʃeindʒəbl] adj.变化的,易变的;不可预料的channel['tʃænl] n.海峡,水道;频道,波段chaos [' keiɔs] n.混乱,无序,浑沌chapter['tʃæptə] n.章charact er ['kæriktə] n.性格charact eristi c [,kæriktə'ristik] adj.特有的,独特的n.特性,特征charact erize['kæriktəraiz] v.(=charact erise)表示…的特性,描述…特征;刻画…的性格charge[tʃɑ:dʒ] v.收费,索价n.费用,价格charm [tʃɑ:m] n.吸引力,魅力;美貌,风韵v.迷人,(使) 陶醉;施魔法于charmin g ['tʃɑ:miŋ]adj.迷人的,可爱的chart [tʃɑ:t] n.图,图表;最畅销品目录(常用复数) chase [tʃeis] v.&n.追逐,追求;寻觅chat [tʃæt] v.&n.闲谈,聊天cheap [tʃi:p] adj.便宜的cheat [tʃi:t] v.欺骗;作弊n.骗子;欺骗行为check [tʃek] v.&n.检查;核对n.支票cheek [tʃi:k] n.面颊cheer [tʃiə] v.(使) 振奋;(使) 高兴;欢呼,喝彩n.振奋;欢呼,喝彩cheese[tʃi:z] n.乳酪,干酪chemica l ['kemikəl] adj.化学的n.(pl.)化学制品,化学药品chemist['kemist] n.化学家;药剂师chemist ry ['kemistr i] n.化学;人际感情cherish['tʃeriʃ] v.珍爱;怀有cherry['tʃeri] n.樱桃(树)chess [tʃes] n.国际象棋chest [tʃest] n.胸部,胸腔;柜子,橱chew [tʃu:] v. 咀嚼;思量chicken['tʃikin] n.小鸡;鸡肉chief [tʃi:f] adj.首要的,主要的n.首领,领袖child [tʃaild] n.儿童childho od ['tʃaildh ud] n.幼年,童年childis h ['tʃaildiʃ] adj.孩子气的,幼稚的chill [tʃil] n.寒冷,寒战;寒心v.(使) 寒冷chimney['tʃimni] n.烟囱,烟筒chin [tʃin] n.下巴,颏China ['tʃainə] n.中国Chinese['tʃai'ni:z] adj.中国的;中国人的,汉语的n.中国人;汉语chip [tʃip] n.切屑,碎片;(土豆等的)薄片;集成电路块v.碎裂;削下碎片chocola te ['tʃɔkəli t] n.巧克力choice[tʃɔis] n.选择,挑选,抉择;adj.上等的,精选的choose[tʃu:z] v.选择chorus['kɔ:rəs] n.合唱队;齐声说道, 副歌部分v.合唱Christi an ['kristʃən] n.基督教徒adj.基督教的Christm as ['krisməs] n.圣诞节church[tʃə:tʃ] n.教堂cigar [si'gɑ:] n.雪茄烟cigaret te [sigə'ret] n.香烟 (=cigaret)cinema['sinimə] n.电影院circle['sə:kl] n.圆圈,圆,圆周;集团;周期,循环v.转圈,盘旋circula r ['sə:kjulə] adj.圆(形) 的,环形的;循环的n.传单,通报circula te ['sə:kjuleit] v.(使) 循环;(使) 流通circums tance['sə:kəmstən s] n.(pl.)情况,形势,环境;经济情况,境遇circus['sə:kəs] n.马戏/杂技团;马戏/杂技场;马戏表演cite [sait] v.引用,引证,举例citizen['sitizn] n.公民,市民,平民city ['siti] n.城市civil ['sivl] adj.办公民的,市民的;国内、民间的;有礼貌的civiliz ation[,sivilai'zeiʃɚn;-li'z-] n.文明 (=civilis ation) civiliz e ['sivilai z] v.使文明,开化;开导(=civilis e) claim [kleim] v.要求;声称,主张;索赔;认领n.主张,断言;索赔要求;要求权,所有权clap [klæp] v.鼓掌,拍手n.鼓掌;霹雳声clarify['klærifa i] v.使澄清,使纯净;阐明,使清楚clasp [klɑ:sp] n.扣子,钩子;握手;拥抱v.扣住,钩住;紧握,紧抱class [klɑ:s] n.班级, 课,等级, 阶级v.分类classic['klæsik] n.(pl.) 经典作品,名著adj.一流的,不朽的;古典的classic al ['klæsikəl] adj.古典的classif y ['klæsifa i] v.分类(法),分等(级)classma te ['klɑ:smeit] n.同学classro om ['klɑ:srum] n.教室,课堂clay [klei] n.黏土,泥土,陶土clean [kli:n] adj.清洁的,干净的v.队把…弄干净,除去…的污垢clear [kliə] adj.清澈的,清楚的,清晰的,明亮的clerk [klɑ:k; klə:k] n.工作人员;职员clever['klevə] adj.聪明的,机灵的client['klaiənt] n.顾客;(诉讼) 委托人;病人cliff [klif] n.悬崖;峭壁climate['klaimit] n.气候;风气climax['klaimæk s] n.顶点,高潮climb [klaim] v.&n.攀登,爬cling [kliŋ]v.(to)粘住;依附;坚持clinic['klinik] n.诊所,门诊所;临床讲课,临诊课cloak [kləuk] n.斗篷;借口v.掩盖,掩饰clock [klɔk] n.钟close [kləuz] v.关,合拢;停业adj.靠近的,亲密的,密切的cloth [klɔ(:)θ]n.布,织物,衣料;(一块) 抹布clothes[kləuðz] n.衣服clothin g ['kləuðiŋ]n.(总称) 衣服,衣着cloud [klaud] n.云;阴影;一大群cloudy['klaudi] adj.有云的,多云的club [klʌb] n.俱乐部,社;球棒;警棍clue [klu:] n.线索,提示clutch[klʌtʃ] v.抓住,攫住;掌握n.爪子;毒手coach [kəutʃ] n.(铁路) 客车,长途汽车;辅导员,教练v.辅导,训练coarse[kɔ:s] adj.粗糙的,粗劣的;粗鲁的,粗俗的coast [kəust] n.海岸coat [kəut] n.衣,外套;表皮;层,覆盖物v.涂上,盖上cock [kɔk] n.公鸡;龙头,旋塞v.竖起,翘起;使向上code [kəud] n.代码coheren t [kəu'hiərənt] adj.黏附的;连贯的coil [kɔil] v.卷,盘绕民(一)卷,(一)圈;线圈;盘管coin [kɔin] v.铸造;创造(词语)n.硬币,货币coincid e [,kəuin'said] v.和…一致,相符,相同coke [kəuk] n.焦炭cold [kəuld] adj.冷的;寒冷的collabo rate [kə'læbərei t] v.协作,合作collaps e [kə'læps] v.&n.倒坍,崩溃;垮台collar['kɔlə] n.衣领v.抓住;握住colleag ue ['kɔli:g] n.同事,同僚collect[kə'lekt] v.收集collect ion [kə'lekʃən] n.收集物;收藏collect ive [kə'lektiv] n.集体adj.集体的;共同的college['kɔlidʒ] n.学院collisi on [kə'liʒən] n.碰撞,冲突colonia l [kə'ləunjəl] adj.殖民(地) 的n.殖民地居民colony['kɔləni] n.殖民地;侨民群体colour['kʌlə] n.颜色column['kɔləm] n.圆柱,柱;列;(报刊中的) 专栏comb [kəum] n.梳子v.梳理combat['kɔmbət] v.&n.战斗,反对,格斗combina tion [,kɔmbi'neiʃən] n.结合,联合,合并;化合(物) combine[kəm'bain] v.(with)(使) 结合,联合;(使)化合come [kʌm] v.来comedy['kɔmidi] n.喜剧;喜剧性事件comfort['kʌmfət] n.安慰;舒适v.使舒适;安慰comfort able ['kʌmfətəbl] adj.舒适的,舒服的command[kə'mɑ:nd] n.命令,指令;统帅,指挥(权)v.命令;指挥commend[kə'mend] v.表扬,称赞;推荐;委托comment['kɔment] n.注释,评论,意见v.(on) 注释;评论commerc e ['kɔmə(:)s] n.商业,贸易commerc ial [kə'mə:ʃəl] adj.商业的,贸易的n.(广播或电视上推销商品的)商业广告节目commiss ion [kə'miʃən] n.委员会;委任,委托(书),代办;佣金,手续费commit[kə'mit] v. 把…交托给;犯错误,干坏事committ ee [kə'miti] n.委员会commodi ty [kə'mɔditi] n.商品,物品common['kɔmən] adj.共同的commonw ealth['kɔmənwe lθ]n.共和国,联邦,共同体communi cate [kə'mju:nikeit] vi.交流vt.传染;传播communi cation[kə,mju:ni'keiʃn] n.交流,联系;交通communi sm ['kɔmjuni zəm] n.共产主义communi st ['kɔmjuni st] n.共产主义者,共产党人adj.共产主义的;共产党的communi ty [kə'mju:niti] n.社会,社区;共同体;公众commute[kə'mju:t] v.乘车(或船等) 往返于两地compani on [kəm'pænjən] n.伴侣,同伴,志趣相投的人company['kʌmpəni] n.公司compara ble ['kɔmpərəbl] adj.(with, to)比得上的,相似的compara tive [kəm'pærətiv] adj.比较的,相当的n.匹敌物;比较级compare[kəm'pɛə] v.比较,对照compari son [kəm'pærisn] n.比较,对照;比拟compart ment [kəm'pɑ:tmənt] n.卧车包房,(客车厢内的) 隔间;分隔的空间;水密舱compass['kʌmpəs] n.罗盘,指南针;(pl.)圆规;(正式)范围compel[kəm'pel] v.强迫,迫使compens ate ['kɔmpəns eit] v.(for) 补偿,赔偿compens ation[kɔmpen'seiʃən] n.补偿,赔偿compete[kəm'pi:t] v.比赛;竞争compete nt ['kɔmpitənt] adj.有能力的,胜任的;应该做的,被许可的;足够的;有法定资格的competi tion [kɔmpi'tiʃən] n.竞赛,竞争competi tor [kəm'petitə] n.竞争者,敌手complai n [kəm'plein] v.抱怨;申诉complai nt [kəm'pleint] n.抱怨;申诉;疾病complem ent ['kɔmplimənt] v.补充,补足民补足n.补充;补语complet e [kəm'pli:t] adj.完整的,完全的;完成的v.完成,使完整complex['kɔmplek s] adj.复杂的;合成的,综合的n.复杂;联合体complic ate ['kɔmplik eit] v.(使) 变复杂complic ated ['kɔmplik eitid] adj.错综复杂的,麻烦的,难解的complim ent ['kɔmplimənt] n.(pl.) 问候,致意;称赞,恭维v.称赞,恭维comply[kəm'plai] v.遵照,应允compone nt [kəm'pəunənt] n.组成部分,成分,元件adj.组成的,合成的compose[kəm'pəuz] v.组成,构成;创作(作曲、诗歌等) composi tion [kɔmpə'ziʃən] n.作文,写作;乐曲;构成,组成,结构compoun d ['kɔmpaun d] n.混合物,化合物adj.混合的,化合的,复合的v.使复合,使混合;和解compreh end [,kɔmpri'hend] v.理解;包含compreh ension[,kɔmpri'henʃən] n.理解compreh ensive[,kɔmpri'hensiv] adj.内容广泛的,综合的;理解的compres s [kəm'pres] v.压缩,浓缩compris e [kəm'praiz] v.包含,构成comprom ise ['kɔmprəm aiz] v.妥协;折衷compuls ory [kəm'pʌlsəri] adj.强制的,义务的,必修的compute[kəm'pju:t] n.计算,估计compute r [kəm'pju:tə] n.计算机comrade['kɔmrid] n.同志,同事conceal[kən'si:l] v.隐藏,隐瞒;隐蔽concent rate ['kɔnsntr eit] v.(on)集中,专心;浓缩n.浓缩物concept['kɔnsept] n.概念,观念;思想concern[kən'sə:n] v.涉及,关系到;(使) 担心,(使) 关切n.关心,挂念;(利害) 关系concern ing [kən'sə:niŋ]prep.关于concert['kɔnsət] n.音乐会,演奏会;一齐,一致concess ion [kən'seʃən] n.迁就,让步concise[kən'sais] adj.简明的,简洁的。
aging and disease endnote -回复
aging and disease endnote -回复Aging and Disease: Understanding the RelationshipIntroductionAging is a natural process that affects all living organisms, including humans. As we age, our bodies undergo various changes, which can lead to the development of diseases. This article aims to explore the relationship between aging and disease, discussing the underlying mechanisms and potential interventions to mitigate the impact of aging-related diseases.1. Theories of AgingTo comprehend the connection betw een aging and disease, it is important to firstunderstand the theories of aging. There are several theories proposed byscientists to explain the aging process, including the telomere shortening theory, mitochondrial dysfunction theory, and oxidative stre ss theory. Each theory emphasizes different aspects of cellular and molecular changes that occur as we age.2. Cellular Senescence and DiseaseCellular senescence refers to the irreversible state of growth arrest cells enter as a response to various stres sors. This phenomenon plays a crucial role in aging and disease development. Senescent cells accumulate over time and secrete pro-inflammatory molecules, resulting in chronic inflammation, which is associatedwith numerous age-related diseases, such as car diovascular disease, neurodegenerative disorders, and cancer.3. Immune System and AgingThe immune system plays a critical role in protecting our bodies against pathogens and diseases. However, with age, the immune system undergoes significant changes, l eading to decreased immunity and increased susceptibility to infections and age-related diseases. This phenomenon, known as immunosenescence, ischaracterized by alterations in both innate and adaptive immune responses. Understanding the mechanisms ofimmu nosenescence is crucial fordeveloping interventions to enhanceimmune function in older individuals.4. Age-Related DiseasesAs we age, our risk of developing various diseases increases. Some prominent age-related diseases include cardiovascular diseases,neurodegenerative disorders (such as Alzheimer's and Parkinson's disease), cancer, osteoporosis, and diabetes. Exploring the common underlying mechanisms of these diseases can help us identify potential strategies to prevent or delay their onset.5. Int erventions to CounteractAging-Related DiseasesWhile aging is an inevitable process,researchers are actively working on identifying interventions to mitigate the impact of aging-related diseases. Some potential interventions include caloric restriction, which has been shown to extend lifespan and delay the onset of age-related diseases in various organisms. Other strategies being explored include targeted therapies to clear senescent cells, genetic and epigenetic interventions, and pharmacological interventions that target specific molecular pathways involved in aging.Conclusion。
TAM 受体及其信号通路在免疫调节中作用的研究进展
TAM 受体及其信号通路在免疫调节中作用的研究进展唐红梅;赵丽娜;贾长虹;丁存宝;李巍伟;李明【摘要】Tyro3、Axl和Mer受体酪氨酸激酶简称TAM受体,是受体酪氨酸激酶亚家族之一。
TAM受体的配体是结构相似的生长停滞特异性基因6(Gas6)和S 蛋白(ProS)。
TAM受体和配体广泛表达于哺乳动物多种细胞表面,具有抑制细胞凋亡,促进细胞增殖,介导细胞黏附、迁移、吞噬等生理功能,参与机体的免疫调节。
缺失TAM受体的小鼠患有慢性炎症和自身免疫病等免疫性疾病,这与TAM受体信号通路介导的清除凋亡细胞和抑制天然免疫等作用密切相关。
【期刊名称】《山东医药》【年(卷),期】2016(056)044【总页数】3页(P105-107)【关键词】TAM受体;TAM信号通路;受体酪氨酸激酶;细胞黏附;细胞迁移;细胞吞噬;自身免疫性疾病【作者】唐红梅;赵丽娜;贾长虹;丁存宝;李巍伟;李明【作者单位】华北理工大学生命科学学院,河北唐山063000;华北理工大学生命科学学院,河北唐山063000;华北理工大学生命科学学院,河北唐山063000;华北理工大学生命科学学院,河北唐山063000;华北理工大学生命科学学院,河北唐山063000;华北理工大学生命科学学院,河北唐山063000【正文语种】中文【中图分类】R34Tyro3、Axl和Mer受体酪氨酸激酶简称TAM受体,属于受体酪氨酸激酶亚家族之一,其共同配体是生长停滞特异性基因6(Gas6)和S蛋白(ProS)。
TAM受体和配体广泛表达于哺乳动物免疫、血液、生殖、循环和神经等系统的多种细胞中,具有抑制细胞凋亡、促进细胞增殖和介导细胞黏附、迁移、吞噬凋亡细胞等多种生物学功能。
本研究对TAM受体及其信号通路在免疫调节中作用的研究进展进行综述。
1.1 TAM受体 Tyro3、Axl和Mer基因的DNA序列非常相似,大小均为3~5 kb。
Tyro3和Axl含有20个外显子,Mer含有19个外显子[1~3]。
受体酪氨酸激酶Axl及其配体Gas6与肝细胞癌的关系
7$受体酪氨酸激酶Axl及其配体Gas6与肝细胞癌的关系吴 雨,钱平安,范兴良,祝峻峰上海中医药大学附属市中医医院肝病科,上海201203摘要:受体酪氨酸激酶Axl作为酪氨酸激酶受体之一,是上皮-间质转化的重要下游调节剂,与配体Gas6蛋白结合,通过激活下游信号转导途径,与肝细胞癌的血管侵袭、肿瘤转移和复发以及较低的存活率密切相关。
目前针对Gas6/Axl信号通路的研究证实,Axl抑制剂在肝癌治疗中具有重要作用,是潜在的肝癌治疗靶点。
主要介绍了Axl及配体Gas6与肝癌发生、发展的关系及在肝癌诊断和治疗中的应用,为早期诊断肝癌及抗癌治疗的临床研究提供新思路。
关键词:癌,肝细胞;Axl;生长停滞特异性蛋白6中图分类号:R735.7 文献标志码:A 文章编号:1001-5256(2021)01-0184-04ResearchadvancesintheassociationofthetyrosinekinasereceptorAxlanditsligandGas6withhepatocellularcarcinomaWUYu,QIANPing’an,FANXingliang,ZHUJunfeng.(DepartmentofHepatology,ShanghaiMunicipalHospitalofTraditionalChineseMedicine,ShanghaiUniversityofTraditionalChineseMedicine,Shanghai201203,China)Abstract:Asoneofthetyrosinekinasereceptors,Axlisanimportantdownstreamregulatorofepithelial-mesenchymaltransition(EMT)andcanbindtoitsligandGas6protein.Byactivatingthedownstreamsignaltransductionpathways,Axliscloselyassociatedwithvascularinvasion,tumormetastasis,recurrence,andlowsurvivalrateofhepatocellularcarcinoma.CurrentstudiesontheGas6/AxlsignalingpathwayhaveconfirmedthatAxlinhibitorsplayanimportantroleinthetreatmentoflivercancerandtheGas6/Axlsignalingpathwaymaybeapotentialtherapeutictargetforlivercancer.ThisarticlemainlyintroducestheassociationofAxlanditsligandGas6withthedevelopmentandprogressionoflivercancerandtheirapplicationinthediagnosisandtreatmentoflivercancer,inordertoprovidenewideasfortheearlydiagnosisoflivercancerandclinicalresearchonanti-cancertreatment.Keywords:Carcinoma,Hepatocellular;Axl;GrowthArrestSpecific-6DOI:10.3969/j.issn.1001-5256.2021.01.040收稿日期:2020-06-07;修回日期:2020-08-17基金项目:上海市科学技术委员会科研计划项目(17401933600);上海市中医药新兴交叉学科资助计划(中医分子肝病学2017—2020);促进市级医院临床技能与临床创新能力三年行动计划项目(16CR3075B);中医优势病种培育项目(zybz-2017012)作者简介:吴雨(1988—),女,博士,主治医师,从事中医药防治慢性肝病的临床和基础研究通信作者:祝峻峰,zhujftongling@163.com 肝细胞癌(HCC)是目前我国常见的恶性肿瘤之一,因其发病隐匿、发病率高、死亡率高、复发率高,被公认为重大疑难疾病[1]。
Axl及其配体Gas6在宫颈鳞癌中的表达与意义
Axl及其配体Gas6在宫颈鳞癌中的表达与意义程甜甜;杨贤子;骆志国【摘要】目的:探讨Axl及其配体Gas6蛋白在官颈鳞癌组织中的表达情况及其与临床特征的关系.方法:收集87例经手术切除的宫颈鳞癌组织、42例官颈上皮内瘤变(cervical intraepithelial neoplasia,CIN)组织和28例正常宫颈组织.采用免疫组化SP法分别检测Axl及其配体Gas6蛋白的表达情况,并分析其表达在良恶性组织之间和不同临床病理状态下的差异.结果:Axl及Gas6蛋白在宫颈鳞癌组织中的阳性表达率较高,而在CIN组及正常宫颈组织中较低,差异有统计学意义(P<0.05).Axl 及Gas6蛋白的表达在不同宫颈鳞癌组织分化程度和盆腔淋巴结转移之间差异有统计学意义(P<0.05).而在年龄、临床分期和肿瘤大小之间无统计学意义,P值均>0.05.经Spearman等级相关分析发现宫颈鳞癌组织中Axl和Gas6蛋白表达存在正相关(r,=0.74,P=0.03).结论:Axl及其配体Gas6蛋白的表达水平与宫颈鳞癌发生、增殖、侵袭及盆腔淋巴结转移关系密切.深入机制的研究可能使Axl蛋白成为宫颈鳞癌靶向治疗一个新的潜在的分子靶点.【期刊名称】《川北医学院学报》【年(卷),期】2016(031)002【总页数】4页(P228-231)【关键词】子宫颈癌;Axl;Gas6;免疫组织化学【作者】程甜甜;杨贤子;骆志国【作者单位】湖北省十堰市太和医院·湖北医药学院附属医院肿瘤科,湖北十堰442000;湖北省十堰市太和医院·湖北医药学院附属医院肿瘤科,湖北十堰442000;湖北省十堰市太和医院·湖北医药学院附属医院肿瘤科,湖北十堰442000【正文语种】中文【中图分类】R735.33Axl 是构成TAM受体酪氨酸激酶的蛋白分子之一,该酶还包括Tyro 3、Mer两个蛋白分子。
Axl蛋白拥有两个配体:生长停滞特异性蛋白6(growth arrest-specific protein 6, Gas6)和人血浆抗凝蛋白 S(Protein S)[1]。
英语词根词缀记忆大全
英语词根词缀记忆大全第一部分通过词缀认识单词(常用前缀一)1、a-①加在单词(形容词)或词根前面,表示"不,无,非" acentric[ə'sentrik] a 无中心的(a+centric中心的)asocial [ei'səuʃəl] a 不好社交的(a+social好社交的)amoral[ə'mɔrəl] a 非道德性的(a+moral道德的;注意:immoral不道德的)apolitical.[,eipə'litikəl] a 不关政治的(a+political政治的)anemia[ə'ni:miə] a 反常的(a+nomal正常的+ous)②加在单词(名词)前,表示"在…,…的"asleep [ə'sli:p] ad 睡着的(a+sleep睡觉)aside[ə'said] ad 在边上(a+side旁边)ahead [ə'hed] ad 在前地(a+head头)alive[ə'laiv] a 活的(a+live活)awash [ə'wɔʃ] a .泛滥的(a+wash冲洗)2、ab-,abs-加在词根前,表示"相反,变坏,离去"等abnormal [æb'nɔ:məl] 反常的(ab+normal正常的)abuse [ə'bju:z] 滥用(ab+use用→用坏→滥用)absorb [əb'sɔ:b] 吸收(ab+sorb吸收→吸收掉)absent ['æbsənt] 缺席的(ab+sent出现→没有出现→缺席的)abduct [æb'dʌkt] 诱拐(ab+duct引导→引走→诱拐)abject ['æbdʒekt] 可怜的(ab+ject抛→抛掉→可怜的)abstract ['æbstrækt] 抽象的;心不在焉的(abs+tract拉→被拉开→心不在焉)abstain [əb'stein] 戒绝(abs+tain拿住→不再拿住→戒绝)abscond [əb'skɔnd] 潜逃(abs+cond藏→藏起来→潜逃)abscind 废除(abs+cind剪切→切掉→废除)abscise 切除(abs+cise剪→剪掉→切除)abstinence ['æbstinəns] 节制;禁欲(abs+tin拿住+ense→不在拿住→戒除,禁欲)3、ab-,ac-,ad-,af-,ag-,an-,ap-,ar-,as-,at-等加在同辅音字母的词根前,表示"一再"等加强意accompany[ə'kʌmpəni]陪伴(ac+company伙伴→陪伴)accelerate [æk'seləreit] 加速(ac+celer速度→一再增加速度)accentuate [æk'sentjueit] 强制(ac+cent唱歌→一再唱出→强调)accumulate[ə'kju:mjuleit]积累(ac+cumul堆积+ate→堆积起来→积累)accustom [ə'kʌstəm] 使习惯(ac+custom习俗→习惯习俗)addict [ə'dikt] 上瘾,入迷(ad+dict说→一再说起→对……入迷)addictive[ə'diktiv]上瘾的(addict的形容词)adduce[ə'dju:s]引证,举例(ad+duce引导→一再引导→举例说明)affable ['æfəbl] 亲切的(af+fable说话→不断可以说话→亲切)afford [ə'fɔ:d] 买得起(af+ford拿出→一再拿出{钱}→买得起)affirm [ə'fə:m] 肯定(af+firm坚定→肯定)aggression[ə'greʃən] 侵略,进攻(ag+gress走+ion→一再往前走→进攻)aggrandize[ə'grændaiz] 扩大(ag+grand大→一再大→扩大[权力]等)aggravate['ægrəveit]恶化(ag+grav重+ate病加重)announce [ə'nauns] 通告(an+nounce通知→通告)appal [ə'nauns] 使震惊(ap+pal白色→[脸]变白→受惊)applause [ə'plɔ:z] 鼓掌(ap+pease赞扬→一再赞扬→鼓掌)appreciate [ə'pri:ʃieit] 欣赏(ap+reci价值+ate→一再给价→欣赏)appoint[ə'pɔint] 指定,任命(ap+point指→指定)arrange[ə'reindʒ] 安排(ar+range排列→安排)arrest [ə'rest] 逮捕,阻止(ar+rest休息→不让动→逮捕)arrive [ə'raiv] 到达(ar+rive河→到达河边→达到目标)assault [ə'sɔ:lt] 进攻(as+saul跳→跳起来→进攻)assiduous[ə'sidjuəs] 勤奋的(as+sid坐+uous→一再坐着[学习] →勤奋)assist [ə'sist] 帮助(as+sist站→站过来→帮助)associate [ə'səuʃieit] 联合,结合(as+soci社团+ate→结成团队→联合)assimilate[ə'simileit] 吸收;同化(as+simil相同+ate→成为相同→同化)assure [ə'ʃuə] 肯定;确信(as+sure确定→一不再确定→肯定)attach [ə'tætʃ] 附上;依恋(at+tach接触→接触上→附上)attain[ə'tein]达到;获得(at+tain拿住→获得)attend[ə'tend]参加(at+tend关心→关心到了→出度)attract[ə'trækt] 吸引(拉→拉过来→吸引)attest[ə'test] 证实(at+test试验→一再试验→证实)4、ad-加在在单词或词根前,表示"做…,加强…"adapt [ə'dæpt] 适应(ad+apt能力→有适应能力)adept ['ædept, ə'dept] 熟练的(ad+ept能力→有做事能力→熟练的)adopt [ə'dɔpt] 收养;采纳(ad+opt选择→选出来→采纳)adhere [əd'hiə] 坚持(ad+here粘→粘在一起→坚持)adjacent[ə'dʒeisənt]邻近的(ad+jacent躺→躺在一起→邻近的)adjoin [ə'dʒɔin]贴近;毗连(ad+join参加→参加在一起→贴近)administrate [əd'ministreit] 管理;执行(ad+ministr部长+ate→做部长→管理)admire [əd'maiə] 羡慕(ad+mire惊奇→惊喜;羡慕)adumbrate ['ædʌm,breit] 预示(ad+umbr影子+ate→[将来的]影子出现→预示)adjust ə'dʒʌst] 调整(ad+just+正确→弄正确→调整)adventure [əd'ventʃə] 冒险(ad+venture冒险)admonish[əd'mɔniʃ] 告诫,警告(ad+mon警告+ish→一再警告)advent ['ædvənt] 来临,来到(ad+vent来→来到)5、amphi-表示"两个,两种"amphibian [æm'fibiən] 两栖动物(amphi+bi生命+an→两个生命→两栖动物)amphicar ['æmfi,kɑ:] 水陆两用车(amphi+car车→两用车)6、an-在词根前,表示"不,无"anarchism['ænəkizəm]无政府主义(an+arch统治+ism→无统治→无政府主义)anharmonic[ænhɑ:mɔnik] 不和谐的(an+hamonic和谐的→不和谐的)anechoic [,æne'kəuik] 无回声的(an+echo回声+ic→无回声的)anonymous[ə'nɔniməs] 匿名的(an+onym名字+ous→匿名的)7、ana-表示"错误,在旁边,分开"analogy[ə'nælədʒi] 类比;类似(ana+logy讲话→再旁边讲→讲一样的东西→类似)analogous[ə'næləgəs] 类似的(analogy的形容词)analysis [ə'næləsis] 分析(ana+lysis分开→分开来→分析)8、ante-表示"前面,先"antedate['ænti'deit] 提前写日期;先于,早于(ante+date日期→提前写日期)anterior[æn'tiəriə] 前面的(ante+erior[…的] →前面的)antecedent [,æntə'si:dənt]前情,先行词(aute+ced走+ent→走在前面的[事] →前事)9、anti-表示"反对,相反"antiwar [,æntai'wɔ:] 反战的(anti+war战争)antipathy [æn'tipəθi] 反感(anti+pathy感情)antithesis [æn'tiθisis] 对立;反论(anti+thesis论文;观点)antibacterial [,æntibæk'tiəriəl] 抗菌的(anti+bacterial细菌的)antibody ['ænti,bɔdi] 抗体(anti+body身体)10、人,人类-anthrop(o)anthropology[ænθrə'pɔlədʒi] [anthropo 人类,-logy…学者]人类学anthropologist[ænθrə'pɔlədʒist] [anthropo 人类,-logist…学者]人类学者anthropogeography[,ænθrəpəudʒi'ɔɡrəfi] [anthropo 人类,gegoraphy地理学]人类地理学anthropomorphous[ænθrəpə'mɔ:fəs][anthropo 人,morph 形,-ous…的]有人形的,似人的anthroposociology[,ænθrəpəudʒi'ɔɡrəfi] [anthropo 人类,sociology社会学]人类社会学11、人民―(1)populpopulation [,pɔpju'leiʃən] [popul 人民→居民,-ation名词字尾]全体居民,人口populous['pɔpjuləs] [popul 人民→居民,-ous…的]人口稠密的populate[pɔpjʊleit] [popul 人民,-ate动词字尾,使…,做…]使人民居住于…中,使人口集中在…之中,移民于…. repopulate [ri:'pɔpjʊleit] [re-再,重新,见上]使人民重新居住于…depopulate [di:'pɔpjuleit] [de-除去,去掉,popul人民→人口,-ate使…]使(某地)人口减少,减少人口popularity [,pɔpju'læriti] [见上,-ity名词字尾,表示性质]大众性,通俗性popularize['pɔpjuləraiz] [见上,- ize…化,使…](使)大众化,(使)普及,推广popularizer ['pɔpjʊləraizə(r)] [见上,-er者]普及者,推广者popularization[,pɔpjulərai'zeiʃn][见上,-ation表示行为]普及,推广,通俗化populace ['pɔpjuləs] [popul 人民→平民,-ace名词字尾]平民,大众人民-(2)dem(o)democracy [di'mɔkrəsi] [demo 人民,cracy统治;"人民统治"→人民做主→]民主;民主政治,民主政体;民主主义democrat['deməkræt][见上,crat主张…统治的人]民主主义者democratism[di'mɔkrətizm] [见上,-ism主义]民主主义democratize [di'mɔkrətaiz] [见上,-ize…化]民主化;使民主化democratic [,demə'krætik] [见上,-ic…的]民主的,民主主义的;民主政体的demography[di:'mɔɡrəfi][demo人民→人数,人口,graphy 写,记录→统计]人口统计学demographic [demə'ɡræfɪk] [见上,-ic…的]人口统计的epidemic [,epi'demik] [epi-在…之间,dem人民,-ic…的;"流行于人民之中的" →]流行的,传染的;流行病,时疫epidemiology [,epi,di:mi'ɔlədʒi] [见上,- io-连接字母,-logy…学]流行病学epidemiologist ['epi,di:mi'ɔlədʒist] [见上,-logist…学者]流行病学者epidemiological [epidi:miə'lɔdʒikəl][见上,-logical…学的]流行病学的男-(1)andr(o)androgyne['ændrɔdʒain][andro男人,gyn女人]具有男妇两性的人,阴阳人androgynism [andro男,gyn女,-ism表性质状态]半男半女男-(2)virvirile ['virail] [vir男,ile形容词字尾,…的]男的,男性的,男子的,有男子气概的,有男性生殖力的virilism['virilizəm][见上,-ism表示现象]男性现象virility [vi'riliti] [见上,-ity表示性质]男子气概,男生殖力,男子的成年女-(1)gyn(o); gynec(o)gynecology [gainə'kɔlədʒi] [gyneco妇女,-logy…学]妇科学,妇科gynecologist[gainə'kɔlədʒist][见上,-ist人]妇科医生*gynecian [gynec妇女,-ia n…的]妇女的,妇人的女-(2)fem; feminfemale['fi:meil][fem女,妇女]女性的,妇女的;女子feminine ['feminin] [femin女,-ine…的]女性的,妇女的feminality [femi'næliti] [femin女,-ality表示性质]女性,妇女的特性femininity [femi'niniti][feminine(e)女性的,-ity表示性质]女子的气质,女人气,妇女总称feminism['feminizm][femin女,-ism主义]男女平等主义;[-ism表示行为]争取女权运动femme [fem]妇女;妻子12、be-①构成动词,表示"使…成为"beguile [bi'ɡail]欺骗(be+guile欺骗)belie[bi'lai]掩盖(be+lie说慌)bequeath [bi'kwi:ð] 遗留给,传下(be+queath要求→要求给某人→遗留给)besiege[bi'si:dʒ]围攻(be+siege包围→包围起来)beware[bi'wɛə]注意(be+ware注意)befriend [bi'frend]友好对待(be+friend朋友)befool[bi'fu:l] 欺骗(be+fool笨蛋→使人成笨蛋→欺骗别人)befall [bi'fɔ:l] 降临;发生(be+fall掉下→掉下来→发生)belittle[bi'litl]小看(be+little小→小看人)bewilder [bi'wildə] 使…迷惑(be+wilder迷惑)②构成一些介词before [bi'fɔ:]在前面(be+fore前面)beneath [bi'ni:θ]在下面(be+neath下面)13、bene- 表示"善,好"benevolent [bi'nevələnt] 好意的(bene+vol意愿+ent→好意的)benefaction[beni'fækʃən]好事;恩惠(bene+fact做+ion→好事)benefit ['benifit] 好处,利益(bene+fit做→做事后的好处→利益)benediction[beni'dik∫ən]祝福(bene+dict说+ion→说好话)beneficent仁慈的,善行的(bene+fic做+en t→做好事的)14、bi-表示"两个,两"biweekly ['bai'wi:kli]双周刊(bi+week星期+ly→两星期)bilingual[bai'liŋɡwəl]双语种的(bi+lingu语言+al→双语的)biennial [bai'eniəl]两年一次的(bi+enn年+ial→两年〔一次〕的)biannual [bai'ænjuəl]一年两次的(bi+ann[年]+ual→一年两次的)15、by-表示"在旁边,副的"byproduct ['baiprɔdəkt] 副产品(by+product产品)byroad 辅路(by+road路)byway ['bai,wei] 小道(by+way小路)bygone ['bai,gɔ:n] 过时的(by+gone过去的)bypass ['bai,pɑ:s] 旁路;忽略(by+pass通过→从旁边通过→忽略)bywork 副业(by+work工作)16、circum-表示"环绕,周围"circumcise['sə:kəmsaiz]环割(circum+cise切→环切)circumference [sə'kʌmfərəns] 周长(circum+fer带来→ence→带来一圈→周长)circumnavigate[͵sə:kəm'næviɡeit]环航世界(circum+navigate航行)circumscribe['sə:kəmskraib,,sə:kəm'skraib]限制(circum+scribe写→规定范围→限制)circumspect ['sə:kəmspekt] 小心谨慎的(circum+stance站→站在周围→环境)circumvent [͵sə:kəm'vent] 回避(circum+vent走→绕圈走→回避)17、co-表示"共同",通常放在元音词根前cooperation[kəu,ɔpə'reiʃən] 合作(co+operation操作→共同操作→合作)coagulate[kəu'æɡjuleit] 凝结(co+agul凝聚+ate→凝聚起来) coalesce[,kəuə'les]联合;合作(co+al=ally联盟+esce) coexist [kəuig'zist] 共存(co+exist存在)cohere [kəu'hiə] 附着;粘着(co+here粘→粘在一起) coincide[,kəuin'said]一致;符合,巧合(co+in进+cide掉下→共同掉进来→巧合)coordinate [kəu'ɔ:dinit] 协调:同等的(co+ordin顺序+ate→顺序一样→同等的引申为平等;协调)18、col-,cor在同辅音词根前,表示"共同"collaboration[kə͵læbə'rei∫ən]协作;合著(col+labor劳动+ation→共同劳动)collocate ['kɔləkeit] 并置,排列(col+loc地方+ate→放在同一地方→排列)collingual 用同一种语言的(col+lingu语言+al→同语言的) collapse [kə'læps] 倒塌(col+lapse滑倒→全部滑倒→倒塌) collate [kɔ'leit] 校对(col+late放→放到一起→校对)collateral[kə'lætərəl]并列的,并行的(col+later边→al→周边的→并列的)colleague ['kɔli:g] 同事(col+→league捆绑→捆绑在一起的人→同事)collect[kə'lekt]收集(col+lect选择→放在一起选择→收集) collegiate [kə'li:dӡiit]学院的;学生的(col+legi读+ate→共同读书→学院的)colloquial[kə'ləukwiəl]口语的(col+loqu说+ial→两人一起说→口语会话的)collusion [kə'l(j)u:ʒən] 共谋,勾结(col+lus玩+ion→共同玩弄→共谋)correct [kə'rekt] 改正,纠正(cor+rect正→全部改正→纠正) correspond [kɔris'pɔnd] 通信;符合(cor+respond反应→共同反应→相互通信)corrupt [kə'rʌpt] 腐败的;变环的(cor+rupt断→全部断→变坏的,腐败的)corrigible['kɔridӡəbl]能够改正的(cor+rig改正+ible→全部改正的)corroborate[kə'rɔbəreit]证实(cor+robor力量+ate→用力量→证实)19、com-,con-表示"共同"combine [kəm'bain] 联合,结合(com+bine捆→捆在一起→结合)compassion [kəm'pæʃən] 同情(com+passion爱国者→同胞) compatriot [kəm'pætriət] 同胞(com+patriot动→大家一起动→动乱)commend [kə'mend] 赞扬;推荐(com+mend信任;命令→大家信任→赞扬;参考;recommend)commemorate [kə'meməreit] 纪念(com+memor记住+ate→大家一起记住→纪念)commensurable [kə'men∫ərəbl]相等的,相称的(com+mensur 测量+abl e→能放在一起的测量→相等的)comparison[kəm'pærisn]比较(com+pari平等+son→一起平等→比较)compact ['kɔmpækt] 紧密的;合同(com+pact压紧→全部压紧→紧密的)comfort ['kʌmfət] 安慰(com+fort加强→[精神]强大→安慰) commodious[kə'məudiəs]宽敞的(com+mod动+ious→共同动→有动的地方→宽敞的)compete [kəm'pi:t] 比赛(com+pete追求→一起追→比赛) component [kəm'pəunənt] 成分(com+pon放+ent→放到一起[的东西]→成分)compress [kəm'pres] 压缩(com+press压→一起压→压缩) concentric [kɔn'sentrik] 同中心的(con+centric中心的) contemporary [kən'tempərəri] 同时代的(con+tempor时间+ary→同时间的)conclude [kən'klu:d]结束;总结(con+clude关闭→全部关闭→结束)confirm [kən'fə:m] 坚定;证实(con+firm坚定)condense [kən'dens] 凝结;浓缩(con+dense 浓密的) consolidate [kən'sɔlideit] 巩固,加强(con+solid坚固+ate→成为大家的财产→没收)conflict ['kɔnflikt] 冲突(con+flict打→一起打斗→冲突)confluence ['kɔnfluəns] 汇流(con+flu流+ence→共同流→汇流)congregate ['kɔŋɡriɡeit] 集合的,聚集的(con+greg集合+ate→集合到一起→聚集的)console [kən'səul] 安慰(con+sole安慰→一起安慰)20.contra-表示"反对,相反"contrary ['kɔntrəri] 相反的(contra+ary→相反的)contradict [kɔntrə'dikt] 反驳;矛盾(contra+dict说→反着说→反驳)contravene [,kɔntrə'vi:n] 违反,违背(contra+vene走→反着走→违反)contraband ['kɔntrə,bænd] 走私(contra+band命令→违反命令做事→走私;参考:ban禁止)21.counter-表示"反对,相反"counteract [,kauntə'rækt] 对抗;抵消(counter+act行为→反着行动→对抗)counterbalance[,kauntə'bæləns] 平衡(counter+balance平衡→两边一样→达到平衡)countermand [,kauntə'mɑ:nd] 撤消(counter+mand命令→反命令→撤消〔命令〕)22.de-①表示"去掉,变坏,离开,变慢,向下"等destruction[dis'trʌkʃən]破坏(de+struct结构;建造+ion→弄坏结构→破坏)desalt [di:'sɔ:lt] 除去盐分(de+salt盐→去掉盐分)deforest[di'fɔrist]砍伐森林(de+forest森林→去掉森林)devalue [di:'vælju:] 降低价值(de+value价值→去掉价值)depress [di'pres] 压制,压抑(de+press压→向下压→压制)detrain [di:'trein] 下火车(de+train火车)decelerate [di:'seləreit] 减速(de+celer速度+ate→使速度变慢)decode [,di:'kəud] 破译(de+code密码→去掉密码)defame[di'feim] 诽谤,中伤(de+fame名声→名声变坏→诽谤)②表示"使…成为,加强"等delimit [di:'limit]划定界限(de+limit限定→加强限定)depict [di'pikt] 描绘(de+pict图画→成为图画→描绘)design [di'zain]设计;计划(de+sign做标志→设计)definition [,defi'niʃən] 定义;清晰(de+fin界限+ition→划出界限→定义)23.di-①表示"两个,双"dichromatic[͵daikrə'mætik]两色的(di+chrom颜色+atic→两色的)dioxide[dai'ɔksaid]二氧化物(di+ox氧+ide→二氧化物)dilemma [di'lemə, dai-] 进退两难(di+lemma争论→二种争论→进退两难)dichotomize [di'kɔtəmaiz]分成二,对分(dicho=di+tom切割+ize→切成二分)②表示"使…变成,分开,离开"dilate[dai'leit]膨胀,扩大(di+late放→分开放→扩大)dilute[dai'lju:t͵di'l-]冲淡,稀释(di+lute冲洗→冲洗开→冲淡) digest di'dʒest; dai'dʒest]消化;文摘(di+gest带→带下去→消化→经过消化后的精华→文摘)diminish[di'miniʃ]减少;消失(di+mini小+ish→变小,减少)digress [dai'gres] 离题(di+gress走→走开→离题)divide [di'vaid] 分开(di+vide分开→分开)divorce [di'vɔ:s] 离婚(di+vorce=vert转→从〔丈夫身边〕转开→离婚;参考:divert转开)父,祖-patr(i); part(o); paterpatriarch ['peitrɑ:k] [patri父,祖arch首脑,长]家长;族长patriarchal[͵peitri'ɑ:kəl] [见上,-al…的]家长的;族长的;家长似的patriot ['peitriət,'pæt-] [patri 祖→祖国,-ot名词字尾,表示人]爱祖国者,爱国主义者patriotic [͵pætri'ɔtik,͵peitri-]〔见上,-otic形容词字尾,…的〕爱国的patriotism['pætriətizəm,'pei-] [见上,-ism主义]爱国主义;爱国心unpatriotic ['ʌnpætri'ɔtik]〔un-不,见上〕不爱国的paternal 〔pater父,-n-,-al…的〕父亲的,父系的paternalism [ pə'tз:nəlɪzəm] [见上,-ism表示行为,现象]家长式统治,家长作风母-matr(i); mater; metromatriarch['meitriɑ:k][ matri母→女性,arch首脑,长]女族长;女家长matrimony ['mætriməni][matri母→婚姻,-mony名词字尾]婚姻,结婚matrimonial [͵mætri'məunjəl,-niəl〔见上,-al…的〕婚姻的,结婚的matron 〔mart母,-on表示人〕主妇,老妇matronage[`meɪtrənɪdӡ][见上,-age名词字尾]主妇的身份或职责maternal [mə'tə:nl] [matr母,-n-,-al…的]母亲的,母性的maternity [mə'tə:niti] [见上,-ity名词字尾]母性的,母性的metropolis [mɪ'trɔpəlɪs] [metro母,polis城市;"母城" →首城,最大的城]大城市,主要城市,大都会,首府24.dia-表示"穿过,二者之间"dialogue ['daiəlɔg] 对话(dia+logue话→对着说话)diameter [dai'æmitə] 直径(dia+meter测量→对着测量〔圆〕直径)diaphanous [dai'æfənəs]透明的;精致的(dia+phan显示+ous→对面显示〔影子〕→透明的)dialectic [͵daiə'lektik]辩证法(dia+lect讲+ic→二人对讲→辩证法)diagnosis [,daiəg'nəusis] 诊断(dia+gnosis知道→穿过〔皮肤〕知道→诊断)diagram ['daiəgræm]图表(dia+gram→交叉对着画→图表)25.dif-和辅音重复表示"不,否定,分开"differ[ 'difə ]不同(dif+fer带来→带来不同→不同)difference ['difərəns]不同(differ的名词)diffident ['difidənt]自卑的(dif+fid相信+ent→不相信〔自己〕→自卑的)diffuse [di'fju:z]散布的,散开的(dif+fuse流→分开流→散布的)difficult ['difikəlt]困难的(dif+fic做+ult→不好做→困难的)difform [di'fɔ:m]不同形式的;不规则的(dif+form形状→形状不同)26.dis-①表示"不,消失掉"dislike [dis'laik]不喜欢(dis+like喜爱→不喜爱)disorder [dis'ɔ:də]无秩序(dis+order顺序→没有顺序)dishonest [dis'ɔnist] 不诚实的(dis+honest诚实的)disappear [,disə'piə] 消失(dis+appear出现→不出现→消失)disproof ['dispru:f] 反证,反驳(dis+proof证实→不证实→反证)discourage [dis'kʌridʒ]使失去勇气(dis+courage勇气)disarm [dis'ɑ:m, diz-] 解除武装(dis+arm武装→去掉武装)dispel [dis'pel] 驱除,消除(dis+pel推→推开→驱除)dispassionate[dis'pæʃənit]平心静气的(dis+passionate有激情的)discover [dis'kʌvə]发现(dis+cover盖→把盖揭开→发现)dismay [dis'mei]沮丧(dis+may能够→不能做事→沮丧;参考:五月能种粮食,所以叫May)②表示"分开,分离"disseminate [di'semineit]散布,传播(dis+semin种子+ate→散布〔种子〕)dispense [dis'pens]分配(dis+pense花费→分开花费→分配〔财富等〕)distract [dis'trækt]分心(dis+tract拉→把〔心〕拉开→分心)distend [dis'tend] 膨胀(dis+tend拉→分开拉→膨胀)discriminate [dis'krimineit]辨别;歧视(dis+crimin分辨→ate→分辩开)dismiss [dis'mis] 解散;开除(dis+miss送→送出→解散)disburse [dis'bə:s]支付,支出(dis+burse钱包→从钱包中分出→支出)discard [dis'kɑ:d]丢弃,抛弃(dis+card扔→扔出去)discuss [dis'kʌs]讨论(dis+cuss敲打→把〔问题〕分开敲→讨论)27.dys-表示"坏,不良"dyspepsia [dis'pepsiə]消化不良(dys+peps消化;胃+ia病→消化不好)dystrophy ['distrəfi]营养不良(dys+trophy营养)28.e-,ef-表示"出,出来"elongate ['i:lɔŋɡeit]延长,拉长(e+long长+ate→长出来)elaborate[ɪ'læbərət]精工细做的(e+labor劳动+ate→劳动出来→精做的)eject[i'dʒekt]投出,掷出(e+ject掷→掷出)emerge 浮现(e+merge投入;淹没→淹没的东西出现→浮现)evade [i'veid]逃出,逃避(e+vade走→走出去→逃避)eradicate [i'rædikeit]根除,灭绝(e+radic根+ate→把根挖出→根除)effluence 流出(ef+flu流+ence→流出)29.em-,en-①表示"进入…之中,包围"embrace [im'breis]拥抱(em+brace胳膊→进入怀抱)embed [im'bed]安置;嵌于(em+bed范围;床→进入范围→安置)empathy ['empəθi]感情相融的(em+pathy感情→进入感情)embarrass [im'bærəs]使难堪(em+barrass套子→进入套子→难堪)embattle [im'bætl]整军备战(em+battle战斗)enroll [in'rəʊl]注册,记入名册(en+roll名单)encage 关入笼中(en+cage笼子)enchain [in'tʃein, en-]束缚(en+chain锁链)②表示"使…进入状态"empower 授权(em+power权力)embitter使痛苦(em+bitter痛苦的)embody体现(em+body身体→〔精神〕进入身体→体现)embellish装饰(em+bell美好+ish→进入美好→装饰)emboss使凸出(em+boss凸出→使凸出)empyreal[͵empai'ri:əl,em'piriəl]天空的(em+pyre火+al→进入火、太阳→天空的)enact制定;颁布(en+act行动→进入行动→颁布〔法令〕)enchant使迷醉(en+chant咒语→被咒语所迷醉)encompass包围,围绕(en+compass包围)endanger使危险(en+danger危险)encourage鼓励(en+courage勇气→使人进入勇气→鼓励)enlighten启发,开导(en+light光+en→给人光明→启发)30.epi-表示"在….上,在….周围,在….后面"epidemic流行性的(epi+dem人民+ic→在人民周围→流行的)epigram['epiɡræm] 警句,格言(epi+gram写→写在上面的话→格言)epilogue['epilɔɡ] 后记,结尾部分(epi+logue说→在后面说的话→后记)episode一段经历,片段(epi+sode路→在路上→一段经历;片段)epitome [i'pitəmi]梗概,缩影(epi+tome卷册→〔一卷书后的〕梗概)31.eu-表示"好,优秀"eulogize ['ju:lədӡaiz]赞美(eu+log说+ize→说好话)euphemism ['ju:fimizəm]委婉的词语(eu+phem讲话+ism→讲好话)euphonious [ju:'fəuniəs]声音优美的(eu+phon声音+ious→声音好听的)eurhythmic [ju:'riθmik]协调的(eu+rhythm节奏+ic)euphoria [ju:'fɔ:riə]幸福愉快感(eu+phor带来+ia→带来美好→愉快)eugenics [ju:'dӡenɪks] 优生学(eu+gen产出+ics→产生优秀〔后代〕→优秀生)32.ex-①表示"出,出去"exclude 排外(ex+clude关闭→关出去→排外)expel 赶出,逐出(ex+pel推→推出去→逐出)expose 暴露(ex+pose放→放出去→暴露)exalt 使升高(ex+alt高→高出来→升高)extract 抽出,拔出(ex+tract拉→拉出→拔出)excise 切除(ex+cise切→切出→切除)exceed 超过,超出(ex+ceed走→走出→超出)exhale 呼气(ex+hale气→出气→呼气)exhume [eks'hju:m]掘出,挖出(ex+hume土→出土→挖出)expurgate ['ekspə:ɡeit]净化;删去(ex+purg冲洗+ate→冲洗出来→净化)②表示"前面的,前任的"ex-wife 前妻(ex前+wife妻子)ex-president 前任总统(ex前+president总统)33.exo-表示"外部的,外面"exotic [ig'zɔtik]来自异国的(exo+tic→从外面来的)exoteric [͵eksəu'terik]外界的,外面的(exo+teric→外面的)exocentric [͵eksəu'sentrik]外向的,离心的(exo+centric中心的)exosphere ['eksəsfiə]外大气层(exo+sphere球;大气层)exodus ['eksədəs]大批移出(exo+odus大批量)exothermic[,eksəʊ`θз:mɪk]放出热量的(exo+therm热+ic→热外出→放热)34.extra-表示"以外的,超过的"extracurriculum [,ekstrəkə`rɪkjʊləm]课外的(extra+curriculum课程表)extraordinary 格外的(extra+ordinary变通的→超出普通)extrasolar[,ekstrə'səulə]太阳系以外的(extra+solar太阳的)extraneous [eks'treinjəs]外来的(extra+aneous…的→从外面来的)extravagant [iks'trævəgənt]奢侈的(extra+vag走+ant→走得过分→奢侈的)extrovert ['ekstrəuvə:t]性格外向的(extra+vert转→〔性格〕向外转→外向)extrapolate [eks'træpəleit]推断(extra+polate放→放到〔事实〕外→推断)extraviolet[,ekstrə'vaiəlit]紫外线的(extra+violet紫色的)35.fore-表示"前面,预先"forestall [fɔ:'stɔ:l]阻止(fore+stall阻止)forebode [fɔ:'bəud]预兆;凶兆(fore+bode兆头→预兆)forefather 前人,祖先(fore+father父亲;祖先)forearm 前人,祖先(fore+arm胳膊)forecast 预料(fore+cast扔→预先扔下→预料)foreshadow 预示,暗示(fore+shadow影子→影子预先来)36.hetero-表示“异类,异种”heterosexual [͵hetərəu'seksjuəl]异性的(hetero+sexual性别的)heterodoxy ['hetərəʊdɔksɪ]异教,异端(hetero+doxy观点→观点不同)heterogeneous [͵hetərəu'dӡi:niəs]异类的,不同的(hetero+gen产生+eous→产生不同的)37.homo-表示“同类的”homogeneous [͵hɔməu'dӡi:njəs]同类的;同族的(homo+gen 产生+eous→产生相同的)homosexual 同性恋的(homo+sexual性别的)homocentric [hɔməu'sentrik]同中心的(home+centric中心的)相同的方面治疗)homogenize[hə'mɔdӡənaiz]使一致(home+gen产生+ize→产生一致→使一致)38.hyper-表示“超过,太多”hyperactive [͵haipə(:)'ræktiv]活动过度的(hyper+active活动的)hypersensitive 过敏的(hyper+sensitive敏感的)hypercritical [͵haipə(:)'kritikəl]吹毛求疵的(hyper+critical批评的)hyperbole [hai'pə:bəli]夸张法(hyper+bole抛→活抛得高→夸张)hypertension 过度紧张;高血压(hyper+tension紧张)39.hypo-表示“下面,次等”hypodermic [͵haipəu'də:mik]皮下的(hypo+derm皮+ic)hypothesis [hai'pɔθisis]假说,假设(hypo+thesis论文→还不是正式的理论→假说)hypomnesia [,haɪpəm`ni:zɪə]记忆力减退(hypo+mnes记忆+ia→记忆变得不好)hypotrophy [hai'pɔtrəfi]发育不良(hypo+trophy营养→营养不够→〔导致〕发育不良)40.il-,ir-①放在同辅音词根前表示“不,无”illegal [i'li:gəl]非法的(il+legal合法的)illiterate[i'litərit]不识字的(il+literate认字的)illogical [i'lɔdʒikəl]不合逻辑的(il+logical逻辑的)illimitable [i'limitəbl]无限的(il+limit限制+able)irregular [i'regjulə] 不规则的(ir+regular规则的)irrational [i'ræʃənəl] 不合理的(ir+rational合理的)irrelative [i'relətiv]无关的(ir+relative相关的)irresolute [i'rezəlju:t]无决断力的(ir+resolute果断的)irreproachable [,iri'prəutʃəbl]无可指责的(ir+reproachable能被指责的)irrefutable [i'refjutəbl]无可反驳的(ir+refutable可反驳的)irresistible [,iri'zistəbl] 不可抗拒的(ir+resistible可抗拒的)irrevocable [i'revəkəbl] 不可取消的(ir+revocable可取消的;来自:revoke取消)②表示“使….成为,进入”illustrate 说明,阐明(il+lustr光+ate→进入光明→说明)illuminate [i'lju:mineit]照亮;使明白(il+lumin光+ate→进入光明→说明)illusion[i'lu:ʒən, i'lju:-] 幻觉(il+lus玩弄+ion→被〔幻觉〕玩弄→幻觉)illusory[i'lju:səri] 虚幻的(来自illusion)irruption 闯入,冲入(ir+rupt断+ion→打断〔别人〕→闯入)irradiate[i'reidieit]使明亮,生辉(ir+radi发光+ate→发光→生辉)irritate 激怒;刺激(ir+rit擦+ate→进入磨擦→激怒)41.im-,in-①表示“不,无,非”impossible 不可能的(im+possible可能的)immoral 不道德的(im+moral道德的)impolite 无礼的(im+polite礼貌的)impartial 公平的(im+partial有偏见的)impassive 无动于衷的(im+pass感情+ive→没感情)impeccable[im'pekəbl]无瑕疵的(im+pecc斑点+able→无斑点的)immortal 不朽的(im+mortal死的)immutable [i'mju:təbl]不变的(im+mutable可变的)inglorious[in'ɡlɔ:riəs] 不光彩的(in+glori光荣+ous→不光荣的)incapable[in'keipəbl] 无能力的(in+capable有能力的)inhuman 不人道的(in+human人道的)injustice [in'dӡʌstis]不公正(in+justice公正)incorrigible[in'kɔridӡəbl]积习难改的(in+corrigible可改正的)inconstant 多变的,无常的(in+constant稳定的)indifferent 冷漠的(in+different不同的→同与不同的“事不关已” →冷漠的)innocuous [i'nɔkjuəs]无害的(in+noc毒害+ous→无害的)inimitable [i'nimitəbl]无可比拟的(in+imit模仿+able→不能模仿的)insubordinate[͵insə'bɔ:dnit] 不服从的,反抗的(in+subordinate 服从的)②表示“向内,进入”imprison 监禁(im+prison监狱)impel 驱动(im+pel推→推进,驱动)imperil[im'peril]处于危险中(im+peril危险)impulse 冲动(im+pulse跳动→冲动)implicit[im'plisit]含蓄的(im+plic重叠+it→进入重叠→不直说→储蓄的)impersonate [im'pə:səneit]扮演,模仿(im+person人+ate→进入别人→扮演别人)inborn 天生的(in+born出生的)inaugurate [i'nɔ:ɡjureit]举行就职典礼(in+augur预兆,开始+ate→进入开始→就职;参考:augury预兆)incentive [in'sentiv] 激励(in+cent唱歌+ive→把精神唱进去→激励)incorporate [in'kɔ:pəreit]合并,并入(in+corpor团体+ate→成为团体)inflame 使燃烧;激怒(in+flame火焰)inspired 有灵感的(in+spired有呼吸的→有生命的,有灵感的)indoor 户内的(in+door门→门内的)42.inter-表示“在…之间,相互”international 国际的(inter+national国家的)interpersonal 人与人之间的(inter+personal个人的)interpose 置于,介入(inter+pose放→放在二者之间)intersect 横断(inter+sect切割→在中间切→横断)intervene 干涉(inter+vene走→走在二者之间→干涉)interaction 相互影响(inter+action行动→相互行动→影响)interchangeable 可互换的(inter+changeable可改变的)interlude ['intə(:)͵lu:d,-lju:d] (活动间的)休息(inter+lude玩→在中间玩→活动间休息)interrelate 相互关连(inter+relate关连)43.intro-表示“向内,入内”introduce [͵intrə'dju:s]引入,介绍(intro+duce引→引进)introspect [͵intrəu'spekt]内省,反省(intro+pect看→向内看→内省)introvert [͵intrəu'və:t]内向(intro+vert转→向内转→内向)intromit [͵intrəu'mit]插入,干预(intro+mit放→放进去→插入)introversible[͵intrəu'və:səbl][͵i ntrəu'və:səbl]可向内翻的(intro+vers转+able→能向内转的)44.macro-表示“宏伟,大”macroworld 宏观世界(macro+world世界)macrostructure [͵mækrəu'strʌkt∫ə]宏观结构(macro+structure结构)macroscale 大规模的(macro+scale规模)macrobian [mək'rəubiən]长寿的(macro+bi生命+an→大生命→长寿)macroclimate 大气候(macro+climate气候)45.mal-表示“坏,恶”(亦作male)malcontent 不满的(mal+content满意的)malpractice 不法行为(mal+practice做事,实践→做坏事)malnutrition 营养不良(mal+nutrition营养)malediction [,mæli'dikʃən] 诅咒(male+dict说+ion→说坏话)malefaction 坏事,恶行(male+fact做+ion→做坏事)malodor [mæ'ləudə]恶臭(mal+odor气味)maltreat [mæl'tri:t]虐待(mal+treat对待)malapropism ['mælə'prɔpizəm]字的误用(mala+prop恰当+ism→[用字]不恰当;来自一喜剧中的Mrs.Malaprop,以用词错误闻名)malevolent 恶意的(male+vol意志+ent→坏意志)maladroit [͵mælə'drɔit]笨拙的(mal+adroit灵巧的)46.micro-表示“微,小”microscope 显微镜(micro+scope看→看小东西→显微镜)microworld 微观世界(micro+world世界)microskirt 超短裙(micro+skirt裙子)microwave 微波(micro+wave波)microbe 微生物(micro+be=bi生命→小生命→微生物)microbiology 微生物学(micro+bilolgy生物学)microfilm 微缩胶卷(micro+film胶片)47.mini-表示“小”minibus 小公共汽车(mini+bus公共汽车)miniskirt 超短裙(mini+skirt裙子)miniwar 小规模战争(mini+war战争)miniature['minjət∫ə]小画象,缩影(mini+ature表示物品→小物品→小画象)minify 使…缩小(mini+fy→小化)minimal 最低限度的(minim=mini+al→最小的)minimum 最小量(minim+um)minion 仆人(minim+on→小人〔仆人自称小人〕)diminish 缩小的,减少的(de+mini小+ish→使…小→缩小)48.mis-表示“错误,坏”mistake 错误(mis+take拿→拿错→错误)misspell 拼写错误(mis+spell拼写)misunderstand 误解(mis+understand理解)misdoing 坏事(mis+doing做事)misrule 对…施暴政(mis+rule统治→统治不善)misfortune 不幸(mis+fortune幸运的)mistrust 不信任(mis+trust相信)misanthrope ['mɪsənθrəʊp]愤世嫉俗者(mis+anthrope人→不喜欢人)miscreant ['miskriənt]恶棍(mis+creant做事的人→做坏事的人)mishap 坏运气,不幸(mis+hap运气→运气不好)mischievous ['mist∫ivəs]恶作剧的(mis+chiev=chief首领+ous→做坏事的首领)49.mono-表示“单个,一个”monarch ['mɔnək]君主,独裁者(mon+arch统治者→一个统治者)monogamy [mɔ'nɔɡəmi]一夫一妻制(mono+gamy婚姻)monologue ['mɔnəlɔɡ]独白(mono+logue说话→一个人说话→独白)monopoly[mə'nɔpəli]垄断(mono+poly→独家卖→垄断)monotonous [mə'nɔtənəs]单调的(mono+ton声音+ous→一个声音→单调的)50.multi-表示”很多,很多”multilingual ['mʌlti'liŋgwəl] a. 多种语言的(multi+lingual语言的)multidirectional[,mʌltidi'rekʃənəl; -dai'r-] a. 多方向的(multi+directional方向的)multiple a. 多样的;多功能的(multi+pile→多的→多功能的) multiply a. 乘;繁殖(multi+ply表动词→变多→乘)multiform a. 多种多样的(multi+form形式)multicultural a. 多种文化的(multi+cultural文化的) multimedia a. 多媒体的(multi+media媒介)multitude ['mʌltitju:d] a. 多数;群众(multi+tude状态→多的状态→多数)51.neo-表示”新的”neonatal [͵ni:əu'neitəl] a. 新生的,被生的(neo+natal出生的) neogamist a. 新婚者(neo+gamist结婚者)neolithic a. 新石器时代的(neo+lith石头+ic)neophilia [͵ni:əu'filiə] a. 喜新成癖(neo+phil爱+ia 病→爱新的病)neologism [ni:'ɔlədӡɪz(ə)m] a. 新词(neo+log词语+ism→新词语)neoteric [ni(:)əu'terik]a. 新近的;现代的(neo+oteric表形容词→新近的)52.non-表示”不,非”nonexistent [,nɔnɪɡ`zɪstənt]a. 不存在的(non+existent存在的)nonsmoking [nɔn'sməukiŋ] a. 不准吸烟的(non+smoking吸烟的)nonstop a. 直达的(non+stop停止→不停→直达的) nonchalant ['nɔnʃələnt] 冷漠的(non+chalant关心的→不关心的)nonconformist ['nɔnkən'fɔmist]n. 不遵循传统竽活的人(non+conform一致+ist→[和传统]不一致的人)53.omni-表示”全部.到处”omnipresent [ɔmnɪ'prezənt]a. 无所不在的(omni+present出现的)omnipotent[ɔm'nipətənt] a. 全能的(omni+potent的能力的) omniscient[ɔm'nisiənt,-'niʃənt] a. 无所示在的(omni+scient 知道的)54.out-①表示”超过.过度”outdo v. 胜过,战胜(out+do做→做得超出别人)outlive v. 活比…长(out+live活→超过别人活着)outnumber v. 在数量上超过(out+number数量)outsize a .过大的(out+size范围→范围超出)outwear v. 穿破(out+wear穿→穿出了[洞])outwit v 以机智取胜(out+wit机智→机智超出别人)outbid v. 出价多于(他人)(out+bid出价→出价超出)outlaw n. 歹徒(out+law法律→超越法律之人)②表示”出去.过时”outside ad. 在外面(out+side旁边→在外边)outgoing a. 友善的(out+going走→走出来→心胸宽→待人友善的)。
脂肪细胞的基础知识
脂肪细胞的基础知识脂肪细胞的生长全过程及其形态变化脂肪母细胞,是指能向脂肪细胞分化的ADSCs在激素、生物活性因子、寒冷等因素刺激下均能逐渐分化成为单能干细胞。
它可保持着干细胞增殖活跃的特性,脂肪母细胞再进一步分化为前脂肪细胞,即通常人们所说的脂肪细胞前体。
前脂肪细胞再经历细胞融合、接触抑制和克隆扩增等步骤启动向成熟脂肪细胞分化,并在胰岛素、地塞米松等诱导剂作用下完成向成熟脂肪细胞的分化。
全过程可以表示为:多能干细胞——脂肪母细胞——前脂肪细胞——不成熟脂肪细胞——成熟脂肪细胞。
生长期前脂肪细胞的形态与成纤维细胞相似,经诱导分化,其细胞骨架和细胞外基质发生变化,开始进入不成熟细胞向成熟细胞转变。
细胞形态由成纤维细胞样逐渐趋于类圆或圆形,胞体逐渐增大,胞质中开始出现小脂滴,脂质开始累积,以后小脂滴增多并融合为较大的脂滴,可经油红“O”染色等方法于显微镜下显色,从而获得成熟脂肪细胞的形态特征。
此时的细胞无分裂增殖能力,为脂肪细胞分化的终末阶段。
张高娜,梁正翠.动物脂肪细胞的研究进展[J].饲料工业,2009,30(2):42-44.脂肪细胞由起源于中胚层的间充质干细胞逐步分化形成,按间充质干细胞→脂肪母细胞→前脂肪细胞→不成熟脂肪细胞→成熟脂肪细胞的过程发展。
前脂肪细胞在多种转录因子调控下,激活脂肪组织相关基因,并在这些基因的顺序性调控下,经一系列复杂的步骤分化为成熟脂肪细胞。
张艳.脂肪细胞分化过程中的分子事件[J].儿科药学杂志,2008,14(1):56-57.间充质干细胞概念:不同文献中,分别命名为抽脂处理细胞(processed lipoaspirate cells, PLA),脂肪基质微管碎片细胞(stromal vascularfraction cells, SVF),脂肪组织源基质细胞(adipose-tissue derived stromal cells, ATSCs),脂肪源中胚层干细胞(adipose-derived mesodermal stem cells, ADMSCs)等。
hedgehog信号通路的负调控基因在早期非小细胞肺癌中的甲基化状态及其意义
hedgehog信号通路的负调控基因在早期非小细胞肺癌中的甲基化状态及其意义耿峻峰;孙晋枫;林强;顾峻;赵仰星;王韦;张红宇;何英华;余坚【摘要】目的:研究hedgehog信号通路的负调控基因生长停顿特异蛋白1(growth arrest specific1,GAS1)、人类hedgehog相互作用蛋白(human hedgehog interacting protein,HHIP)和patched1 (PTCH1)在早期非小细胞肺癌(NSCLC)中的甲基化状态并初步探讨此3个基因对早期NSCLC的诊断价值.方法:收集Ⅰ期NSCLC患者85例(NSCLC组)并以同期住院的23例非肿瘤性肺部疾病患者作为对照组.采用甲基化特异性聚合酶链反应(methylation-specific polymerase chain reaction,MSP)检测GAS1、HHIP和PTCH1在5个NSCLC 细胞株A549、NCI-H1299、NCI-H460、LTEP-a-2、SPC-A-1中的甲基化状态及其在NSCLC组患者的肺癌组织中、对照组的肺部病变组织中的甲基化状态;分析3个基因诊断Ⅰ期NSCLC的敏感性和特异性.结果:hedgehog信号通路的3个负调控基因除在NCFH1299中均呈去甲基化状态外,在其他4个肺癌细胞株中均有1~2个基因呈甲基化状态.GAS1、HHIP和PTCH1在NSCLC组的甲基化率高于对照组,差异有统计学意义(P<0.05).GAS1用于临床Ⅰ期NSCLC诊断时敏感性和特异性分别为69.41%、69.57 %;HHIP分别为49.41%、82.61 %;PTCH1则分别为34.12%、100.0%.结论:PTCH1、HHIP和GAS1在Ⅰ期NSCLC中存在显著的异常甲基化,提示hedgehog的异常激活可能参与了NSCLC的发生和发展.对3个基因在早期NSCLC患者血浆游离DNA中甲基化状态的进一步研究可望为NSCLC的早期诊断提供新的肿瘤分子学标志物.%Objective:To study the methylation status of three negative regulators for hedgehog pathway including growth arrest specific 1 (GAS1),human hedgehog interactingprotein(H HIP) and patched1 (PTCH1),in order to investigate the value of them in the early diagnosis of stage Ⅰ non-small-cell lungcancer(NSCLC).Methods:A total of 85 patients with stage Ⅰ NSCLC (NSCLC group) and 23 patients with non-cancerous lung diseases(control group) have been enrolled in this study.Methylationspecific polymerase chain reaction(MSP) was used to detect the methylation status of three genes in five lung cancer cell lines A549,NCI-H1299,NCI-H460,LTEP-a-2 and SPC-A-1,as well as in the cancer tissue samples from NSCLC group and lung lesions from control group.The sensitivity and specificity of three genes were analyzed when the methylation detection of each of them was applied for the diagnosis of stage Ⅰ NSCLC.Results:Although in NCI-H1299,all of three genes presented unmethylation; in the other four lung cancer cell lines there were at least one to two genes presenting methylation.The methylation rates of GAS1,HHIP and PTCH1 in NSCLC group were higher than those in control group(P<0.05).The sensitivity and specificity were 69.41% and 69.57 % when the methylation of GAS1 was used for the diagnosis of stage Ⅰ NSCLC,while they were 49.41% and 82.61 % for HHIP,and 34.12 % and 100.0 % forPTCH1.Conclusions:PTCH1,HHIP and GAS1 have been found abnormally hypermethylated in the tumor tissues from stage Ⅰ NSCLC patients,which suggests that the abnormal activation of hedgehog pathway may be involved in the genesis and development of NSCLC.Further study of the methylation status of these genes in the cell-free serum DNA from stageⅠ NSCLC patients may provide novel methylation biomarkers for the diagnosis of NSCLC at early stages.【期刊名称】《中国临床医学》【年(卷),期】2013(020)003【总页数】4页(P252-255)【关键词】非小细胞肺癌;早期;hedgehog信号通路;甲基化【作者】耿峻峰;孙晋枫;林强;顾峻;赵仰星;王韦;张红宇;何英华;余坚【作者单位】上海交通大学附属胸科医院胸外科,上海200030;复旦大学附属中山医院,上海200032;上海交通大学附属胸科医院胸外科,上海200030;上海交通大学医学院仁济医院,上海市肿瘤研究所,癌基因及相关基因国家重点实验室,上海200032;上海交通大学医学院仁济医院,上海市肿瘤研究所,癌基因及相关基因国家重点实验室,上海 200032;上海交通大学医学院仁济医院,上海市肿瘤研究所,癌基因及相关基因国家重点实验室,上海 200032;上海交通大学医学院仁济医院,上海市肿瘤研究所,癌基因及相关基因国家重点实验室,上海 200032;上海交通大学医学院仁济医院,上海市肿瘤研究所,癌基因及相关基因国家重点实验室,上海 200032;上海交通大学医学院仁济医院,上海市肿瘤研究所,癌基因及相关基因国家重点实验室,上海200032【正文语种】中文【中图分类】R734.2近年来,我国的肺癌发病率不断升高,肺癌的病死率已跃居肿瘤死因之第一位[1]。
- 1、下载文档前请自行甄别文档内容的完整性,平台不提供额外的编辑、内容补充、找答案等附加服务。
- 2、"仅部分预览"的文档,不可在线预览部分如存在完整性等问题,可反馈申请退款(可完整预览的文档不适用该条件!)。
- 3、如文档侵犯您的权益,请联系客服反馈,我们会尽快为您处理(人工客服工作时间:9:00-18:30)。
A product of growth arrest-speci¢c gene6modulates scavenger receptorexpression in human vascular smooth muscle cellsKoji Murao a Y*,Hitomi Imachi a,Yoshitaka Sayo a,Hitoshi Hosokawa a,Makoto Sato a, Toshihiko Ishida a,Toru Nakano b,Tatsuhiko Kodama c,Yasuyuki Sasaguri d,Jiro Takahara aa First Department of internal Medicine,Kagawa Medical University,Kagawa761-0793,Japanb Shionogi Research Laboratories,Shionogi p Co.,Ltd,Osaka553-0002,Japanc Research Center for Advanced Science and Technology,University of Tokyo,Tokyo153-8904,Japand The Department of Pathology,University of Occupational and Enviroment Health,Kitakyushu807-8555,JapanReceived23August1999;received in revised form15September1999Abstract Although Gas6is identified as a growth factor for vascular smooth muscle cells(VSMCs),its roles in these cells have not been clearly elucidated.To examine the role of Gas6in atherosclerosis,we examined the effects of Gas6on scavenger receptor family expression in VSMCs.Scavenger receptor class A,one of the scavenger receptor family members,was upregulated in VSMCs by Gas6.Furthermore,the atherogenic lipoprotein,oxidized LDL,induced Gas6production in these cells.These results indicate that Gas6plays an important role in foam cell formation in human VSMCs.z1999Federation of European Biochemical Societies.Key words:Growth arrest-speci¢c gene6;Scavenger receptor;Vascular smooth muscle cell1.IntroductionGas6,the product of growth arrest-speci¢c gene6,poten-tiates the proliferation and prevents the cell death of vascular smooth muscle cells(VSMCs)[1,2].Gas6was originally cloned as one of the growth arrest-speci¢c genes isolated by subtractive hybridization on the basis of preferential expres-sion in the G0phase of the cell cycle[3].It has been demon-strated that Gas6is a ligand of receptor tyrosine kinases,Axl [4].Recent reports indicated that Gas6promotes Axl-medi-ated adhesion,suggesting adhesion as one function for the Gas6-Axl interaction[5],and Gas6can act as a chemoattrac-tant for migration in both rat and human primary VSMCs[6]. However,Gas6's biological activity is still poorly understood. During atherogenesis,VSMCs migrate from the media to the intima of the arterial wall,where they proliferate and accumulate lipid,becoming foam cells.Although the factors contributing to the regulation of smooth muscle cell scavenger receptor activity in vivo are unknown,several cytokines are reported to regulate the activity of scavenger receptor in VSMCs[7,8].Thus,these cytokines are presumed to play important roles in the phenotypic change of VSMCs acting in an autocrine or paracrine manner[9].It has been proposed that modi¢ed LDL is the atherogenic ligand for scavenger receptor on macrophages and smooth muscle cells that causes the massive accumulation of lipid and foam cell formation[10].The uptake of oxidized low density lipoprotein(OxLDL)by macrophages is a key event implicated in the initiation and development of atherosclerotic lesions.Several macrophage surface receptors,CD36(a class B scavenger receptor)[11],CD68[12]and the macrophage scavenger receptor(a class A scavenger receptor;SRA)[13], have been identi¢ed as the major receptors that bind and internalize OxLDL.Scavenger receptor is detected in VSMCs in the intima but not in normal VSMCs,demonstrating that smooth muscle cell scavenger receptor activity is upregulated in atherosclerotic lesions[7,8].In this study,the regulation of scavenger receptor expres-sion in VSMCs was investigated using an established human vascular smooth muscle cell line.2.Materials and methods2.1.MaterialsInterferon-Q(IFN-Q)and interleukin-1L(IL-1L)were obtained from Research Biochemicals International(Natick,MA,USA).Phorbol 12-myristate13-acetate(PMA)was purchased from Sigma(St.Louis, MO,USA).OxLDL was prepared as described previously[12].All other reagents were of analytical grade.2.2.Cell cultureA human vascular smooth muscle cell line,ISS10,was established as described previously[14].ISS10cells were plated in DMEM me-dium(Gibco BRL,Osaka,Japan)supplemented with10%fetal calf serum,100W g/ml streptomycin and100U/ml penicillin in a humidi-¢ed atmosphere containing5%CO2.2.3.Preparation of recombinant human Gas6and anti-human Gas6antibodyCHO cells were transfected with human Gas6expression plasmid. Con£uent cells were cultured in protein-free culture medium,PM-1000(Eiken,Tokyo,Japan),in the presence of4W M vitamin K2. Recombinant human Gas6was puri¢ed from the culture medium as described elsewhere[1].Rabbits were immunized with recombinant human Gas6.Anti-human Gas6IgG was puri¢ed using the Ampure PA kit(Amersham,Arlington Heights,IL,USA).2.4.RNA isolation and RT-PCR analysisTotal RNA was isolated from ISS10cells by single-step acid gua-nidinium thiocyanate-phenol-chloroform extraction[18].Axl and SRA expression was determined by PCR analysis of the reverse tran-scribed RNA as described previously[15].A primer pair was designed as matching the published sequence of Axl[16](sense:5P-GG-TGGCTGTGAAGACGATGA-3P and antisense:5P-CTCAGATA-0014-5793/99/$20.00ß1999Federation of European Biochemical Societies.All rights reserved. PII:S0014-5793(99)01290-9CTCCATGCCACT-3P)and SR-A[13];(5P common type I and type II sense primer:5P-GGGAACATTCTCAGACCTTGAG-3P,3P type I-speci¢c antisense primer:5P-TGTCCATAGTGAGCTGCCTTGT-3P,and3P type II-speci¢c primer:5P-TGCCCTAATATGATCAGT-GAGTTG-3P).As a control,L-actin was ampli¢ed and analyzed under identical conditions using an appropriate set of primers.2.5.Proliferation assayISS10cells(105)were cultured in96-well plates in200W l of DMEM complete medium.Four hours before harvesting,cells were pulsed with1W Ci/well[3H]TdR(speci¢c activity=6.7Ci/mmol,DuPont Company,Wilmington,DE,USA)and then harvested onto glass¢ber ¢lters using an automated cell harvester and counted in a Packard liquid scintillation counter(Hewlett-Packard Co.,Palo Alto,CA, USA).The data are presented as the mean cpm of triplicate cultures þS.E.M.2.6.Western blot analysisISS10cells were washed and scraped in phosphate-bu¡ered saline (PBS)and lysed as described previously[17].The proteins were frac-tionated by size on7.5%SDS-polyacrylamide gels,and transferred to polyvinylidene di£uoride membranes for immunoblotting.The mem-branes were incubated with0.1%Tween20in PBS(PBS-T)contain-ing anti-SRA antibody(diluted1/3000from whole antiserum),anti-cyclophilin A,or anti-Gas6antibody.The membranes were then washed with PBS-T,and incubated for1h at room temperature in PBS-T containing horseradish peroxidase-linked second antibodies. The antibody binding was visualized by chemiluminescence detection (ECL,Amersham Corp.,Arlington Heights,IL,USA).2.7.Uptake of AcLDL in ISS10cells1,1P-Dioctadecyl-1-13,3,3P3P-tetramethyl-indo-carbocyanine perchlo-rate-labeled acetyl-LDL(DiI-AcLDL;Biomedical Technologies Inc., Stoughton,MA,USA)was added to the culture medium at a¢nal concentration of10W g/ml.The cells were incubated for4h at37³C, washed with PBS,and then¢xed and analyzed using a£uorescence microscope.2.8.Statistical analysisStatistical comparisons were made by one-way analysis of variance and Student's t-test,with P60.05considered signi¢cant.3.Results3.1.Gene expression of the receptor for Gas6and e¡ects ofGas6on smooth muscle cell line growthGas6is a common ligand for Axl,one of the members of the Axl/Sky receptor family[4].To examine Axl gene expres-sion in a vascular smooth muscle cell line,we employed the reverse-transcribed PCR analysis with mRNA from ISS10 cells.Although a previous study reported that Axl was upre-gulated in a human leukemia cell line,K562treated with PMA[16],Axl mRNA was detected in ISS10cells at the same level found in K562treated with PMA(Fig.1A).When ISS10cells were stimulated for24h in the presence of Gas6at given concentrations,their proliferative response to Gas6was increased in a dose-dependent manner(Fig.1B).3.2.E¡ects of Gas6on scavenger receptor expression in humansmooth muscle cellsWe analyzed the e¡ects of Gas6on scavenger receptor ex-pression in ISS10cells with a speci¢c antibody against human SRA.Fig.2A shows that Gas6stimulated SRA expression in ISS10.Positive controls(IFN-Q)also increased SR-A expres-sion in ISS10(Fig.2).To determine whether enhanced SRA expression by Gas6depends on increased levels of SRA mRNA,RT-PCR analyses were performed.ISS10cells were incubated with10ng/ml of Gas6for24h,and total RNA was extracted and subjected to RT-PCR analyses.As shown in Fig.2B,Gas6treatment at10ng/ml for24h increased the SRA mRNA level.In contrast,Gas6had no e¡ect on the expression of other scavenger receptors including CD36and CD68in ISS10cells(data not shown).3.3.E¡ects of Gas6on uptake of AcLDLTo determine whether the upregulated expression of SRA by Gas6is correlated with an enhanced uptake of AcLDL, amounts of DiI-AcLDL internalized into ISS10were meas-ured.After treatment with Gas6for24h,con£uent mono-layers of ISS10were incubated with DiI-AcLDL.Fluores-cence microscopy was carried out to evaluate the cellular uptake of DiI-AcLDL.In Gas6-treated ISS10,signi¢cant amounts of DiI-labeled AcLDL were internalized(Fig.3). Fig.1.A:Axl gene expression in ISS10cells.Total RNA was iso-lated from ISS10cells and K562treated with PMA,then RT-PCR was performed as described in Section2.L-Actin was ampli¢ed as an internal ne1,DNA size marker(x X174);lane2, ISS10cells;lane3,K562treated with PMA.An identical experi-ment independently performed gave similar results.B:Gas6-induced DNA synthesis in ISS10cells.In24-well plates,con£uent ISS10 cells were rendered quiescent after incubation in DMEM for24h. ISS10cells were stimulated with the indicated amount of Gas6for 24h,and then the cells were pulsed with[3H]thymidine for4h. The data are presented as the mean cpm of triplicate culturesþS.E.M.These results demonstrate that increased SRA expression by Gas6was associated with enhanced AcLDL uptake in ISS10.3.4.OxLDL induced Gas6expressionA previous report indicated that human VSMCs express Gas6[1],and we have con¢rmed that ISS10also expressed Gas6by Western blot analysis.It was recently reported that modi¢ed LDL enhances SRA expression [18].To examine the e¡ects of the modi¢ed form of LDL on Gas6expression in ISS10cells,we incubated ISS10cells with various concentra-tions of OxLDL.As shown in Fig.4A,OxLDL stimulated Gas6expression in a dose-dependent manner in ISS10cells.In contrast,cyclophilin A expression was not a¡ected by OxLDL treatment in ISS10cells.Gas6was maximally induced by OxLDL after 12h incubation with OxLDL.On the other hand,OxLDL induced SRA expression in ISS10cells after 24h incubation (Fig.4B).4.DiscussionIn the current study,we have demonstrated an increased expression of SRA,a receptor for OxLDL,in a human smooth muscle cell line after Gas6treatment.We also re-vealed that the increase in type I and II scavenger receptor mRNA expression is correlated with an increase in scavenger receptor activity in human smooth muscle cells by Gas6treat-ment.Furthermore,we have shown that the expression of Gas6was increased in the presence of OxLDL in ISS10.Our results suggest important interactions between Gas6-Axl and SRA,which is the receptor for OxLDL.Thus,the future characterization of Gas6-Axl signaling should yield important discoveries regarding the mechanisms underlying the foam cell formation of human VSMCs.Whereas the scavenger receptor activity in di¡erentiated macrophages can be regulated in a narrow range by various growth factors and cytokines,that in VSMCs is regulated over a wide range [9].The regulation of scavenger receptor activity in VSMCs and macrophages,however,is fundamen-tally di¡erent.In macrophages,scavenger receptor expression is stimulated constitutively,and there is a high level of recep-tor activity.In smooth muscle cells,scavenger receptor expres-sion is weak in the absence of stimulation [7,8].Li et al.[8]demonstrated that after balloon injury,the aorta smooth muscle cells in the neointima of hypercholester-olemic rabbits express scavenger receptors,whereas smooth muscle cells in the media do not.These results clearly dem-onstrate that scavenger receptor expression is upregulated in smooth muscle cells in atherosclerotic lesions.The factors leading to scavenger receptor regulation in VSMCs in vivo are unknown.However,Melaragno et al.reported that the expression of Axl is increased in neointima VSMCs of rat carotid arteries after balloon injury and that Axl expression is selectively regulated by G protein-coupled receptor agonists in vitro [19].Wu et al.[20]have shown that scavenger recep-tor expression in human monocyte-derived macrophages is regulated via a signal transduction pathway involving ras,AP1(c-jun and junB),and ets domain proteins.In thepresentFig.2.E¡ect of Gas6on SRA expression in ISS10cells.A:West-ern blot analysis.Total cell protein extracted with 1%NP40from untreated ISS10cells (lanes 1and 2)and ISS10cells treated for 24h with IL-1L ,IFN-Q ,or Gas6was separated by SDS-PAGE,trans-ferred to a nitrocellulose membrane and blotted with anti-SRA anti-body.Each lane contained 10W g of ne 1,control;lane 2,IL-1L ;lane 3;INF-Q ;lane 4,Gas6.An identical experiment in-dependently performed gave similar results.B:RT-PCR analysis of SRA mRNA expression.Total RNA was isolated from ISS10cells with or without Gas6and RT-PCR was performed as described in Section 2.L -Actin was ampli¢ed as an internal ne M,DNA size marker (x X174);lane 1,Gas6-treated ISS10;lane 2,un-treated ISS10.An identical experiment independently performed gave similarresults.Fig.3.E¡ect of Gas6on uptake of DiI-AcLDL in ISS10cells.On day 1,ISS10cells were plated in complete medium.On day 2,the monolayers were incubated without (A)or with 10ng/ml Gas6(B)for 24h at 37³C.On day 3,the subcon£uent cells were re-fed with the medium containing DiI-AcLDL (1W g of protein/ml)and incu-bated for 4h at 37³C.The cells were photographed with a £uores-cence microscope with a rhodamine ¢lter package.An identical ex-periment independently performed gave similar results.study,we showed that Gas6stimulated the expression of scav-enger receptor in an Axl-expressing human smooth muscle cell line.Thus,Gas6may play an important role in foam cell formation in atherosclerotic lesions.Many studies also demonstrated that VSMCs express type I and II scavenger receptors that bind,internalize,and degrade modi¢ed LDL,suggesting that the scavenger receptor-medi-ated uptake of modi¢ed LDL by VSMCs also leads to lipid accumulation and foam cell formation in vivo as proposed in macrophages [7^9].Growth factors secreted by cells in devel-oping atherosclerotic lesions could stimulate scavenger recep-tor activity in VSMCs and contribute to lipid accumulation and foam cell formation [7].OxLDL,one of the atherogenic lipoproteins,induces the expression of several genes including scavenger receptors [21].The present study indicated that Gas6induced SRA expression and the time-course study(Fig.4B)showed that OxLDL stimulated Gas6expression before the induction of SRA expression.Taken together,the results suggest that Gas6induced by OxLDL stimulated SRA expression to take up OxLDL.Further investigation is needed to test this hypothesis.These results,showing Gas6upregulation of scavenger re-ceptor expression in a human smooth muscle cell line,suggest that Gas6may play an important role in foam cell formation in the progress of atherosclerosis.References[1]Nakano,T.,Higashino,K.,Kikuchi,N.,Kishino,J.,Nomura,K.,Fujita,H.,Ohara,O.and Arita,H.(1995)J.Biol.Chem.270,5702^5705.[2]Nakano,T.,Kishino,J.and Arita,H.(1996)FEBS Lett.387,75^77.[3]Schneider,C.,King,R.M.and Philipson,L.(1988)Cell 54,787^793.[4]Varnum,B.C.,Young,C.,Elliott,G.,Garcia,A.,Bartley,T.D.,Fridell,Y.W.,Hunt,R.W.,Trail,G.,Clogston,C.,Toso,R.J.,Yanagihara,D.,Bennett,L.,Sylber,M.,Merewether,L.A.,Tseng,A.,Escobar,E.,Liu,E.T.and Yamane,H.K.(1995)Nature 373,623^626.[5]McCloskey,P.,Fridell,Y.W.,Attar,E.,Villa,J.,Jin,Y.,Var-num,B.and Liu,E.T.(1997)J.Biol.Chem.272,23285^23291.[6]Fridell,Y.W.,Villa Jr.,J.,Attar,E.C.and Liu,E.T.(1998)J.Biol.Chem.273,7123^7126.[7]Gong,Q.and Pitas,R.E.(1995)J.Biol.Chem.270,21672^21678.[8]Li,H.,Freeman,M.W.and Libby,P.(1995)J.Clin.Invest.95,122^133.[9]Ross,R.(1993)Nature 362,801^809.[10]Steinberg,D.,Parthasarathy,S.,Carew,T.E.,Khoo,J.C.andWitztum,J.L.(1989)New Engl.J.Med.320,915^924.[11]Endemann,G.,Stanton,L.W.,Madden,K.S.,Bryant,C.M.,White,R.T.and Protter, A.A.(1993)J.Biol.Chem.268,11811^11816.[12]Ramprasad,M.P.,Fischer,W.,Witztum,J.L.,Sambrano,G.R.,Quehenberger,O.and Steinberg,D.(1995)A 92,9580^9584.[13]Kodama,T.,Freeman,M.,Rohrer,L.,Zabrecky,J.,Matsu-daira,P.and Krieger,M.(1990)Nature 343,531^535.[14]Murahashi,N.,Sasaguri,Y.,Ohuchida,M.,Kakita,N.andMorimatsu,M.(1992)Biotechnol.Appl.Biochem.16,152^160.[15]Mizobuchi,M.,Murao,K.,Takeda,R.and Kakimoto,Y.(1994)J.Neurochem.62,322^328.[16]Neubauer, A.,Fiebeler, A.,Graham, D.K.,O'Bryan,J.P.,Schmidt,C.A.,Barckow,P.,Serke,S.,Siegert,W.,Snodgrass,H.R.,Huhn,D.and Liu,E.T.(1994)Blood 84,1931^1941.[17]Murao,K.,Terpstra,V.,Green,S.R.,Kondratenko,N.,Stein-berg,D.and Quehenberger,O.(1997)J.Biol.Chem.272,17551^17557.[18]Yoshida,H.,Quehenberger,O.,Kondratenko,N.,Green,S.andSteinberg,D.(1998)Arterioscler.Thromb.Vasc.Biol.18,794^802.[19]Melaragno,M.G.,Wuthrich,D.A.,Poppa,V.,Gill,D.,Lindner,V.,Berk,B.C.and Corson,M.A.(1998)Circ.Res.83,697^704.[20]Wu,H.,Moulton,K.,Horvai,A.,Parik,S.and Glass,C.K.(1994)Mol.Cell.Biol.14,2129^2139.[21]De Vries,H.E.,Ronken,E.,Reinders,J.H.,Buchner,B.,VanBerkel,T.J.and Kuiper,J.(1998)FASEB J.12,111^118.Fig.4.E¡ect of OxLDL on Gas6expression in ISS10cells.ISS10cell monolayers were exposed to OxLDL at di¡erent concentrations or for di¡erent periods of time and cell lysates were analyzed by SDS-PAGE and Western blotting with anti Gas6,anti-SRA or anti-cyclophilin A antibody.A:Dose response of OxLDL on Gas6ex-pression.Cyclophilin A was used as an internal ne 1,control;lane 2,OxLDL 5W g/ml;lane 3,OxLDL 10W g/ml;lane 4,OxLDL 20W g/ml;lane 5,OxLDL 50W g/ml.B:Western blot analy-sis was performed to determine the time course of SRA and Gas6expression in ISS10cells after 50W g/ml OxLDL treatment.An iden-tical experiment independently performed gave similar results.。